

# APPENDIX

## 2013 Reporting Experience Including Trends (2007-2014)

---

Physician Quality Reporting System and  
Electronic Prescribing (eRx) Incentive Program

## APPENDIX TABLE OF CONTENTS

Data and methods.....	5
Data Sources .....	5
Unit of Analysis .....	5
Outcomes .....	6
Key Variables.....	13
2013 Physician Quality Reporting System Appendix Tables.....	15
2013 eRx Incentive Program Appendix Tables .....	257
Abbreviations .....	304

## LIST OF TABLES

Table A1. List of Individual Measure Numbers and Descriptions for PQRS (2013).....	15
Table A2. Distribution of PQRS Incentive Amounts by Specialty, excluding MOCP (2013).....	23
Table A3. Potential PQRS Incentives and Participation Information, excluding MOCP (2013).	26
Table A4. PQRS Participation and Incentive Eligibility by Reporting Mechanism/Option or Alternative Program (2013).....	28
Table A5. PQRS Participation and Incentive Eligibility by Eligible Professional Characteristics (2013).....	29
Table A6. Number of Eligible Professionals participating in PQRS by Specialty (2010 to 2013) .....	31
Table A7. PQRS Participation Information by Reporting Mechanism/Option or Alternative Program (2010 to 2013).....	33
Table A8. Trends in PQRS Participation by Specialty (2010 to 2013) .....	34
Table A9. Eligible Professionals who Participated in PQRS by Reporting Individual Measures through the Claims Reporting Mechanism, by Specialty (2010 to 2013) .....	37
Table A10. Eligible Professionals who Participated in PQRS by Reporting Measures Groups through the Claims Reporting Mechanism, by Specialty (2010 to 2013) .....	40
Table A11. Eligible Professionals who Participated in PQRS by Reporting Individual Measures through the Registry Mechanism, by Specialty (2010 to 2013) .....	43
Table A12. Eligible Professionals who Participated in PQRS by Reporting Measures Groups through the Registry Reporting Mechanism, by Specialty (2010 to 2013) .....	46
Table A13. Eligible Professionals who Participated in PQRS by Reporting through the EHR Reporting Mechanism, by Specialty (2010 to 2013) .....	49
Table A14. Eligible Professionals who Participated in PQRS, by Specialty and the Number of Beneficiaries on Whom They Reported (2013).....	52
Table A15. PQRS Participation and Incentive Eligibility, by State (2013).....	55
Table A16. Submission Information for Individual PQRS Measures submitted through the Claims Mechanism (2013).....	57
Table A17. Individual PQRS Measures Submitted through the Claims Mechanism where more than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2013).....	72
Table A18. Individual PQRS Measures Submitted through the Claims Mechanism Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2013).....	73
Table A19. Individual PQRS Measures Submitted through the Claims Mechanism Where More than 20% of Reported Instances were for a Patient Who Did Not Meet the Necessary Age Range (2013).....	74
Table A20. PQRS Incentive Eligibility Information by Reporting Mechanism/Option or Alternative Program (2010 to 2013).....	75
Table A21. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the Claims Mechanism, by Specialty (2010 to 2013) .....	76
Table A22. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Measures Groups through the Claims Mechanism, by Specialty (2010 to 2013).....	79
Table A23. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the Registry Mechanism, by Specialty (2010 to 2013).....	82
Table A24. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Measures Groups through the Registry Mechanism, by Specialty (2010 to 2013) .....	85

Table A25. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the EHR Mechanism, by Specialty (2010 to 2013) .....	88
Table A26. Eligible Professional Eligibility and Participation Information by PQRS Individual Measures (2010 to 2013) .....	91
Table A27. Reporting and Performance Information by PQRS Individual Measure (2010 to 2013) .....	117
Table A28. PQRS Individual Measure Reporting Consistency Across Program Years (2013). 142	
Table A29. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Four Years (2010 to 2013).....	160
Table A30. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Three Years (2011 to 2013)....	170
Table A31. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Two Years (2012 to 2013).....	180
Table A32. Percent of Eligible Professionals who Participated and had at Least a 90% Performance Rate by PQRS Individual Measure (2013).....	191
Table A33. Performance Information for PQRS Measures Reported by Practices Participating in the Small Group Practice Reporting Option (2013) .....	200
Table A34. Performance Information for PQRS Measures Reported by Practices Participating in the Medium Group Practice Web Interface Reporting Option (2013) .....	217
Table A35. Performance Information for PQRS Measures Reported by Practices Participating in the Medium Group Practice Registry Reporting Option (2013) .....	220
Table A36. Performance Information for PQRS Measures Reported by Practices Participating in the Large Group Practice Web Interface Reporting Option (2013) .....	237
Table A37. Performance Information for PQRS Measures Reported by Practices Participating in the Large Group Practice Registry Reporting Option (2013).....	240
Table A38. CAHPS Results for Practices Participating via the PQRS Web Interface for the Large Group Practice Reporting Option (2013). .....	250
Table A39. Performance Information for PQRS Measures Reported by Eligible Professionals Participating in Medicare ACOs participating under the Pioneer ACO Model (2013) .....	251
Table A40. Performance Information for PQRS Measures Reported by Eligible Professionals Participating in Medicare ACOs participating under the Shared Savings Program (2013).....	253
Table A41. PQRS Incentive Eligibility and Incentives Earned by Reporting Mechanism or Alternative Program (2013).....	256
Table A42. Distribution of Incentive Amounts by Specialty for the eRx Incentive Program (2013).....	257
Table A43. Potential Incentives and Participation Information by Specialty for the eRx Incentive Program (2013).....	260
Table A44. Eligible Professional Information by Specialty for the eRx Incentive Program (2012 to 2013).....	262
Table A45. Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program (2012 to 2013).....	265
Table A46. Eligible Professional Characteristics for the eRx Incentive Program (2013) .....	267
Table A47. Eligible Professional Information by State for the eRx Incentive Program (2013). 269	
Table A48. Eligible Professionals who Successfully met Reporting Criteria but did not Receive an Incentive Because they did not have at Least 10% of their MPFS Charges from	

Instances for the eRx Measure (i.e., 10% Limitation Threshold) for the eRx Incentive Program (2012 to 2013).....	271
Table A49. Eligible Professionals by Specialty Subject to the eRx Payment Adjustment (2012–2014).....	274
Table A50. Incentive Eligibility and Incentives Earned by Reporting Mechanism for the eRx Incentive Program (2013).....	277
Table A51. History of Available Reporting Mechanisms for each PQRS Measure, by Program Year (2007–2013).....	278
Table A52. Abbreviations.....	304

## DATA AND METHODS

This section describes the data and methods used in the “2013 Physician Quality Reporting System (PQRS) and Electronic Prescribing (eRx) Incentive Program Reporting Experience Including Trends (2007-2014)” report.

### Data Sources

The report used multiple sources of data: (1) Medicare Part B claims data; (2) data submitted by qualified registries; (3) data submitted by qualified Electronic Health Records (EHR) vendors; (4) PQRS measure data submitted through an online web interface by practices that were approved to participate in the PQRS Group Practice Reporting Option (GPRO) and by eligible professionals participating in Medicare Accountable Care Organizations (ACOs) through the Shared Savings Program (SSP ACO) and the Pioneer ACO Model; and (5) Clinician & Group Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS) data submitted by practices participating in the Large GPRO. In addition, the report uses Maintenance of Certification Program Incentive (MOCP) data reported by participating specialty boards for the 2013 program year. Data on the 2015 PQRS payment adjustment were from the PQRS Payment Adjustment file dated May 30, 2014. Data on the 2014 eRx payment adjustment were from the eRx Payment Adjustment File dated August 7, 2014.

Claims data encompassed services within the respective program years and must have been processed by the last Friday in February of the following year to be included in analyses. For example, the analysis of the 2013 program year—for both PQRS and the eRx Incentive Program—encompassed claims with service dates from January 1, 2013 through December 31, 2013 and processed no later than February 28, 2014. To provide preliminary information for the 2014 program year for PQRS, the available information encompassed only service dates from January 1, 2014 through June 27, 2014 from claims processed no later than June 27, 2014. Similar to claims data, data collected from the registry and EHR mechanisms as well as the GPRO web interface aligns with the program year and must have been received by CMS by the established deadline for the reporting option. No preliminary information was available for the 2014 program year from the registry and EHR mechanisms, or the web interface; that is, preliminary information for the 2014 program year included claims information only.

Information on physician specialty and location was obtained from the National Plan and Provider Enumeration System (NPPES), which is publicly available data and downloadable from the NPPES website.<sup>1</sup>

### Unit of Analysis

The most common unit of analysis for PQRS and the eRx Incentive Program was the individual eligible professional. The National Provider Identifier number (NPI) within a billing unit (i.e., the Taxpayer Identification Number [TIN]) defined an eligible professional; the NPI was the *performing* NPI.<sup>2</sup> All analyses regarding individual eligibility, participation, and incentive

---

<sup>1</sup> [http://nppes.viva-it.com/NPI\\_Files.html](http://nppes.viva-it.com/NPI_Files.html)

<sup>2</sup> There are multiple NPIs associated with a service (performing, referring, and ordering); the performing NPI identifies the eligible professional who actually performed the service.

eligibility were performed at the NPI level within a TIN (referred to as TIN/NPI). Consequently, a single eligible professional could be counted more than once if he/she worked for multiple practices (i.e., single NPI and more than one TIN).

An additional unit of analysis was at the group practice level, which was defined by a TIN. Practices that participated under the GPRO and SSP ACO were analyzed at the practice (i.e., TIN) level. In addition to summarizing group reporting information at the TIN level, this report also aggregates information from individual eligible professionals to the practice (TIN) level for descriptive purposes. For these descriptions, a practice was defined as eligible, participating, or incentive eligible if at least one eligible professional associated with that practice was eligible, participating, or incentive eligible.

This report also describes counts of individual eligible professionals who belong to a practice that participated under group reporting options (including those in practices participating via the GPRO and eligible professionals within SSP ACOs reporting PQRS data<sup>3</sup>). For example, unless otherwise noted, tables and figures that present counts of total eligible professionals also include the number of eligible professionals within practices participating under group reporting options. For the purposes of summarizing participation and incentive eligibility, all eligible professionals that are part of a practice that participates or is incentive eligible under a group reporting option are assumed to have participated or been incentive eligible. Eligible professionals that participated in PQRS as part of the Pioneer ACO model or by accepting the PQRS waiver as part of CPC practices are reported as individual participants in this report.

## Outcomes

The report summarizes the following outcomes:

1. *Program eligibility.* A professional was defined as eligible to participate individually in PQRS or the eRx Incentive Program if he/she had at least one Medicare Part B Physician Fee Schedule (MPFS) professional services claim that contained the denominator criteria of the applicable quality measure for any PQRS measure or the eRx measure, respectively, and was not part of a TIN electing group reporting for that program.

Eligible practices (TINs) that chose to report under the GPRO applied and met requirements for participation.<sup>4</sup> A practice could participate under the GPRO under PQRS and/or the eRx Incentive Program. Beginning in 2013, a practice could participate under the GPRO in the eRx Incentive Program alone; they were no longer required to participate in the PQRS GPRO. Eligible professionals were not eligible to participate individually in PQRS (or the eRx Incentive Program) if they participated as a group practice under the GPRO in the same program. All eligible professionals that were part of

---

<sup>3</sup> As part of their quality reporting requirements, practices within Medicare ACOs reporting PQRS data under the Medicare Shared Savings Program and Pioneer ACO models submitted data on 22 measures via the GPRO web interface.

<sup>4</sup> GPRO eligibility criteria varied by program year. In 2010, practices with at least 200 NPIs could participate in the GPRO option; in 2011, practices with 200+ NPIs could participate in “GPRO I” and those with 2-199 NPIs could participate in the GPRO II option; in 2012, practices with 25-99 NPIs could participate in the “Small GPRO” option, while practices with 100+ NPIs could participate in the “Large GPRO” option; and in 2013, Small GPRO (2-24 NPIs), Medium GPRO (25-99 NPIs), and Large GPRO (100+ NPIs) were available.

a practice self-nominating to participate via the GPRO or that were part of an SSP ACO were considered eligible under those reporting options only. Eligible professionals were considered eligible via the Pioneer ACO or CPC mechanism if they elected to participate via these programs.

2. *Program participation.*<sup>5</sup> Eligible professionals were defined as participating in PQRS or the eRx Incentive Program if they had a complete and valid submission of data on quality measures through claims or a valid submission from a qualified registry or EHR (via direct submission or the data submission vendor mechanism). To participate through the claims reporting mechanism, eligible professionals submitted the specified Quality Data Code(s) (QDC) for a given measure on a Medicare Part B professional services claim that met the denominator criteria for that measure. QDCs indicate that a specific quality action or outcome was or was not met, or that exclusion criteria for the measure were met. QDCs are entered on a line item on the claim, similar to procedure codes. A QDC for a given quality measure must be entered on a claim that also has all the required denominator criteria for that measure. For example, a measure could require a specific combination of diagnosis, procedure codes, and beneficiary age to be an ‘eligible instance’ for a certain measure; to report the measure validly, the eligible professional had to submit the required QDC(s) on line items for that claim. If an eligible professional submitted only one valid QDC for a measure that required two QDCs, that eligible professional does not count as participating.<sup>6</sup>

To report measures groups through the claims reporting mechanism, eligible professionals submitted a specified procedure code (referred to as an intent G-code) indicating intent to submit measures group information on one claim during the reporting period. In order to be considered participating, the eligible professional had then to report the specified QDCs for each applicable measure in the specific measures group. Alternatively, an eligible professional could submit one ‘composite’ G-code specified for that measures group indicating that all quality actions in the measures group had been performed for that patient.

To report measures through the registry and EHR reporting mechanisms, eligible professionals submitted performance data for each measure—such as number of eligible instances (denominator), instances of quality service performed (numerator), number of performance exclusions, reporting rates, and performance rates—in a file format specified by CMS.

A practice was defined as participating in the PQRS GPRO or SSP ACO if the practice submitted data for an assigned sample of patients through a web interface provided by

---

<sup>5</sup> In some places we have included results related to the SSP and the Pioneer ACO Model and CPC initiative given that eligible professionals within ACOs may report through those programs/models for purposes of earning a PQRS incentive. However, such eligible professionals participating in such initiatives outside the traditional PQRS are subject to reporting, participation, and program requirements specific to that program. Unless otherwise indicated, the program requirements discussed (i.e. reporting options, mechanisms, periods, criteria and measures, participation rules, etc.) generally pertain to the traditional PQRS.

<sup>6</sup> Please note, the program defined participation slightly differently in the 2007 and 2008 program years; an eligible professional was defined as participating in those years if they submitted at least one QDC for the measure.



CMS (or a registry for PQRS GPRO). A practice was defined as participating in PQRS as a Pioneer ACO if the TIN elected to participate in the Pioneer ACO model; note that some of these TINs are “split TINs” in which only some of the NPIs are participating in the Pioneer ACO model, in these cases, the non-ACO NPIs can only participate in PQRS through the usual individual participation mechanisms (i.e. claims, registry, or EHR). Eligible professionals were considered participating in PQRS via the CPC if they were eligible to participate in this program and had submitted a PQRS waiver.<sup>7</sup> A practice was defined as participating in the GPRO for the eRx Incentive Program if they had a valid submission of the eRx quality code through claims, or the required summary information through a registry or EHR.

3. *Incentive eligibility.*<sup>8</sup> An individually-participating eligible professional was defined as incentive eligible for the 2013 PQRS if they met the criteria for incentive eligibility through at least one individual reporting option. All options had a 12-month time period. The three basic criteria were:

- Percentage Method:

- Fifty percent of patients, individual measures option: An eligible professional must report at least 50 percent of eligible instances for at least three measures; this criterion applied to the individual measures option for the claims mechanism only. An eligible professional could qualify for an incentive by reporting at least 50 percent of eligible instances on one or two measures (i.e. less than three) if the Measure Applicability Validation (MAV) process was passed; the MAV process checked to ensure it was acceptable for an eligible professional to report fewer than three measures.<sup>9</sup>
- Eighty percent of patients, individual measures option: An eligible professional must report at least 80 percent of eligible instances for at least three measures; this criterion applied to the individual measures option for the registry and EHR reporting mechanisms. EHR data can be submitted via direct submission or via an approved data submission vendor.

---

<sup>7</sup> TIN/NPI that were on the CPC finder file but did not submit a PQRS waiver and submitted PQRS data via the claims, registry, or EHR submission mechanisms are counted under those mechanisms.

<sup>8</sup> In some places we have included results related to the SSP ACO and the Pioneer ACO Models and the CPC given that eligible professionals within these programs may earn a PQRS incentive. However, such eligible professionals participating in such initiatives outside the traditional PQRS are subject to reporting, participation, and program requirements specific to those programs. Unless otherwise indicated, the program requirements discussed below (i.e. reporting options, mechanisms, periods, criteria and measures, participation rules, etc.) generally pertain to the traditional PQRS.

<sup>9</sup> The MAV process determines whether eligible professionals could have reported additional clinically-related measures through two tests. First, the clinical relation test checks for any eligible instances on measures related to those reported. Second, the minimum threshold test checks for a certain number of eligible instances for those measures the eligible professional could have reported based on the clinical relation test. Eligible professionals who satisfied the reporting criteria for one or two individual measures but did not satisfy the MAV process did not earn an incentive because they could have reported additional measures. Conversely, eligible professionals who satisfied both the reporting criteria for one or two individual measures and the MAV process would qualify for an incentive.

- 20 Patient Method: An eligible professional must report at least one measures group for at least 20 patients; this criterion applied to the claims and registry measures group mechanisms. For claims-based measures groups, all 20 patients had to be Medicare Part B FFS patients; for registry-based measures groups, 11 out of 20 patients had to be Medicare Part B FFS.
- Align with EHR Incentive Program: For EHR only, an eligible professional must report on all three Medicare EHR Incentive Program core measures (or, if the denominator for one or more of the Medicare EHR Incentive Program core measures is zero, the eligible professional must report on up to three Medicare EHR Incentive Program alternate core measures) AND report on three additional measures available for the Medicare EHR Incentive Program. Eligible professionals could report PQRS measures via EHR to satisfy requirements for the PQRS/Medicare EHR Incentive Program Pilot. These results are included in the EHR direct submission and EHR DSV results in this report.

A group practice that participated under the GPRO or as an ACO was defined as incentive eligible if it met the 2013 satisfactory reporting criteria for the reporting mechanism. For practices participating via the web interface, those participating via the Large GPRO or an ACO were required to report on the first 411 patients from a preselected sample of Medicare patients for each of the 22 GPRO measures or on all eligible patients for a measure where fewer than 411 patients were available. The Medium GPRO option required a practice to report on the first 218 preselected sample of Medicare patients for each GPRO measure or on all eligible patients for a measure where fewer than 218 patients were available. Also beginning in 2013, practices participating via the Large GPRO and electing the web interface were required to submit survey results for the Clinician & Group Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS) survey, consisting of 12 patient experience of care summary survey measures. GPRO practices participating via registry—the only available mechanism for the Small GPRO—had to report on at least three measures for at least 80 percent of the practice’s Medicare Part B FFS patients; this mechanism was available to any practice participating under the GPRO, regardless of size.

An eligible professional was defined as incentive eligible for the 2013 eRx Incentive Program if: 1) they correctly reported the eRx quality measure in at least 25 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the eligible professional for the codes that appear in the eRx quality measure denominator were at least 10 percent of the total allowed Medicare Part B charges for all such covered professional services furnished by the eligible professional in the reporting period. A practice that participated in the Large GPRO option for the 2013 eRx Incentive Program was defined as incentive eligible if: 1) they correctly reported at least 2,500 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the practice for the codes that appear in the eRx quality measure denominator were at least 10 percent of the total allowed Medicare Part B charges (referred to as the 10 percent limitation threshold). A practice that participated in the Medium GPRO option for the 2013 eRx Incentive Program was defined as incentive eligible if: 1) they correctly reported at least 625 instances; and 2) they met the same 10 percent limitation threshold

as above. Finally, a practice that participated via the Small GPRO option was required to correctly report at least 75 instances and meet the 10 percent limitation threshold.

The above incentive eligibility criteria applied to the 2013 program year; criteria for preceding program years differed for some reporting options. When comparing results across years, it is important to note the incentive eligibility requirements can be different in different years. See Table 7 of the main text for a summary of the PQRS incentive eligibility criteria across the years.

Finally, eligible professionals who met incentive eligibility criteria for PQRS but had no Part B MPFS allowed charges on which to calculate an incentive payment had an incentive amount of \$0.00; these participants are not included in the counts of eligible professionals who were incentive eligible. Potentially, this was because an eligible professional or the vendor submitting data on behalf of the eligible professional provided an incorrect TIN or NPI.

4. *Incentive amounts.* Under PQRS and the eRx Incentive Program, eligible professionals (or group practices) who were incentive eligible qualified for an incentive payment equal to a percentage of their estimated Part B MPFS allowed charges for covered professional services furnished by the eligible professional (or group practice) during the reporting period. The applicable incentive percentage varied across program years. The applicable percentage for 2013 was one-half percent for both PQRS and the eRx Incentive Program. It was one-half percent for the 2012 PQRS and one percent for the 2012 eRx Incentive Program and the 2011 PQRS and eRx Incentive Programs, and two percent for both programs for the 2010 and 2009 program years. The applicable quality incentive percentage was 1.5 percent for PQRS in 2007 and 2008. Successful reporters in PQRS could earn an additional on-half percent of Part B MPFS allowed charges by meeting requirements for the MOCP program: 1) more frequently than is required to qualify for or maintain board certification, participate in a MOCP; and 2) more frequently than is required to qualify for or maintain board certification, successfully complete a qualified MOCP practice assessment.

For the eRx Incentive Program, counts of individually-participating incentive-eligible professionals and incentive dollar amounts for both eligible professionals and group practices participating under the GPRO shown in this report include those receiving an incentive through the Medicare EHR Incentive Program. These participants are not eligible to receive incentives through both the eRx and the Medicare EHR Incentive Program; therefore, eRx incentive payments were not made to these eligible professionals see the eRx Incentive Program section (Section IV) of the main body of this report for more details. All dollar amounts shown are those earned prior to a two percent reduction from sequestration.

5. *Measure performance*<sup>10</sup>. For PQRS, performance on a measure was calculated as the number of times the eligible professional reported that the recommended quality action for that measure was performed (numerator), divided by the number of instances they could have performed the quality action (denominator), multiplied by 100. For example,

---

<sup>10</sup> EHR performance rates of zero percent have been excluded from results.

under claims-based reporting options, the numerator was the number of times the eligible professional reported the measure-specific QDC indicating the quality action was met and the denominator was the number of eligible instances for that measure identified through claims. Instances that did not apply (i.e., reported as exclusions) were excluded from performance. The following hierarchy was used if an eligible professional participated through more than one reporting mechanisms: EHR, claims, and then registry. Applying the hierarchy ensured only one performance rate for each measure for an eligible professional; information could not be combined across reporting methods.

Due to differences in the methodology for calculating performance rates, the performance rates displayed in the 2013 Quality Resource Use Reports (QRURs) may differ from the rates displayed in the 2013 PQRS/eRx Experience Report in the following ways: (1) when an eligible professional (EP) reports via multiple reporting methods, the QRURs report the rate for the one which gives the highest rate/denominator, compared to the hierarchy described above; (2) this report excludes measures group measures from average performance rates while the QRURs include measures groups measures. For more information on the methodology used for the 2013 QRURs, please see the following link: <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2013-QRUR.html>.

Please note, multiple factors should be considered when interpreting performance trends. For example, there have been many changes within PQRS across program years that include changes in participation methods, measures, and the eligible professionals who participated and reported a particular measure. As a result, it is unclear the extent that any observed changes in performance were genuine or artifacts of the aforementioned changes.

6. *2014 eRx Payment Adjustment.* Section 1848(a)(5) of the Social Security Act requires payment adjustments under the eRx Incentive Program for eligible professionals who were not successful electronic prescribers. The 2014 eRx payment adjustment, a reduction of 2.0 percent, applies to the MPFS amounts for Medicare Part B services furnished by the eligible professional between January 1 and December 31, 2014, for those eligible professionals who are not successful electronic prescribers under the 2012 eRx Incentive program or did not report on the required number of claims for the period January 1 through June 30, 2013 and did not otherwise qualify for an exception from the payment adjustment. Certain types of individually-participating eligible professionals were not subject to the adjustment:

- Those that were not physicians (MD, DO, or podiatrist), nurse practitioners, or physician assistants as of June 30, 2013, based on primary taxonomy code in the National Plan and Provider Enumeration System (NPPES).
- Those that did not have at least 100 eligible claims containing an encounter code in the measure denominator during the period from January 1, 2013 to June 30, 2013.
- Those that did not meet the 10 percent limitation threshold were not subject to the adjustment.

To avoid the payment adjustment for 2014, eligible professionals who did not meet any of these automatic exclusion criteria had to report the G8553 code via claims on at least

10 Medicare billable services during the six-month period January 1, 2013 through June 30, 2013, or have been a successful 2012 electronic prescriber. Minimum reporting criteria to avoid the payment adjustment for practices reporting via GPRO were 2,500 instances for Large GPRO, 625 for Medium GPRO, and 75 instances for Small GPRO.

Alternatively, eligible professionals and practices could avoid the payment adjustment if one of the following applied:

- Reporting a G-code G8644 (to indicate a lack of prescribing privileges) at least one time on an eligible claim between January 1 and June 30, 2013.
- Requesting (by reporting the applicable G-code via claims between January 1, 2013 and June 30, 2013) and being granted a significant hardship exemption for the following reasons:
  - G8642: The eligible professional practices in a rural area without sufficient high-speed internet.
  - G8643: The eligible professional practices in an area without sufficient available pharmacies for electronic prescribing.
- For practices reporting under the GPRO, indicating a hardship or lack of prescribing privileges to CMS during self-nomination.
- Requesting (by June 30, 2013 through the Communication Support Page, or CSP) and being granted a significant hardship exemption for any of the following reasons:
  - Inability to prescribe electronically due to local, state, or federal law or regulation (e.g., controlled substances).
  - Limited prescribing activity, defined as an eligible professional generating fewer than 100 prescriptions during the 6-month reporting period.
  - Practicing in an area with limited high speed internet access.
  - Practicing in an area with limited available pharmacies for electronic prescribing.
- In addition, eligible professionals who achieved Meaningful Use in 2012 or the first half of 2013 and eligible professionals who demonstrated intent to participate in the EHR Incentive Program and adopted Certified EHR Technology by registering for the EHR Incentive Program by January 1, 2013 avoided the 2014 eRx payment adjustment.

The results in this report reflect that some eligible professionals had their 2014 eRx payment adjustment overturned based on informal review and re-analysis by CMS. These included eligible professionals participating individually and GPROs whose circumstances qualified them for exemption from the 2014 payment adjustment. Potential reasons for having an adjustment overturned via informal review included situations such as: incorrect national provider identifier (NPI) on the CSP hardship exemption, finder file discrepancies, use of an incorrect G-code, TINs registered for the EHR incentive program but were still assessed for the payment adjustment, EPs with an incorrect taxonomy in the NPPES and were incorrectly assessed for the adjustment, natural disasters and other

extenuating circumstances that interfered with reporting and deadlines, technical difficulties accessing the CSP, et cetera.

7. *2015 PQRS Payment Adjustment.* Beginning in 2015, eligible professionals who are eligible for PQRS but who do not meet the reporting requirements described below will be subject to a 1.5 percent payment reduction on all of their Part B MPFS charges. Eligible professionals who are part of a practice that self-nominated to participate via GPRO will be evaluated at the TIN level; all others will be evaluated individually.

To avoid the PQRS payment adjustment for 2015, individual participants had to meet at least one of the following criteria, for each TIN they report under:

- Meet the requirements for satisfactory reporting for incentive eligibility for the 2013 PQRS program, described above, or
- Report at least one valid measure via claims, registry, or EHR (direct submission or data submission vendor) or report at least one valid measures group via registry; or
- Elect to participate in the new administrative claims-based reporting option via the web portal between July 15, 2013 and October 15, 2013.

Practices reporting as a group could avoid the payment adjustment as follows:

- Meet the requirements for satisfactory GPRO reporting for incentive eligibility for the 2013 PQRS program, described above, or
- Report at least one valid measure via registry or the GPRO web interface (for practices with at least 25 eligible professionals), or for CPC practices, meet the electronic Clinical Quality Measure (eCQM) reporting requirements under that program; or
- Elect to participate in the new administrative claims-based reporting option via the web portal between July 15, 2013 and October 15, 2013.

Other avenues for avoiding the PQRS payment adjustment were related to not being eligible for PQRS: not having at least one eligible denominator claim, not meeting the specialty taxonomy criteria, or not having any MPFS charges in 2013. Individual eligible professionals or groups participating via GPRO, ACO, or CPC will be able to request an informal review of their negative payment determination between January 1, 2015 through February 28, 2015, for the 2013 PQRS program year; this report presents payment adjustment results prior to that informal review process.

## Key Variables

The analysis examined outcomes by several eligible professional and practice characteristics.

- *Specialty (TIN/NPI level only).* The specialty for eligible professionals was obtained from the NPPES. Specialty in the NPPES was self-designated by the professionals and could contain multiple specialties for the same professional. The primary specialty was used in cases where the professional designated it. If there was no

primary designation, the first specialty was selected to allow assigning of an eligible professional to a single specialty category. Some specialty codes were grouped for efficiency of data presentation.

- *Reporting Mechanism/Option (TIN and TIN/NPI levels).* There were eight individual reporting options and three group reporting options for the 2013 PQRS (GPRO registry reporting for all practice sizes, Medium GPRO web interface, and Large GPRO web interface). There were three individual reporting mechanisms (claims, registry, and EHR) and three group reporting options (Small, Medium, and Large GPRO) available to report data to earn an incentive in the 2013 eRx Incentive Program. Some analyses combined reporting options such as individual measures or measures group options).
- *State and Region.* The state for eligible professionals was obtained from NPPES. Region was based on CMS carrier regions on claims. In most tables, information on the Railroad Retirement Board (RRB) carrier is not provided. This is due to the RRB not being based on geographical location of the eligible professional.
- *Practice Size (TIN/NPI level only).* This variable was the number of eligible professionals within the practice who were defined as eligible based on data submitted through Medicare claims and therefore could have participated in PQRS or the eRx Incentive Program.
- *Beneficiary Volume (TIN and TIN/NPI levels).* This variable was a unique count of Medicare beneficiaries who were identified as having an eligible claim for at least one PQRS measure on which an eligible professional could have reported or who had at least one eligible claim on which an eligible professional could have reported the eRx measure for the eRx Incentive Program. A Health Insurance Claim (HIC) number identified beneficiaries. Beneficiary information was not available from the registry or EHR methods. Registry information was reported to CMS aggregated to individual eligible professionals and the patient identifier available in the EHR reporting method was not linkable to the claims-based HIC number.
- *Eligible Measures (TIN/NPI level only).* The number of measures the eligible professional could have reported (i.e., treated at least one beneficiary who qualified for the measure). Participation in registry-only measures was summed with claims-based eligibility counts to estimate the count of measures for which an eligible professional could have reported; eligibility information was not available for registry or EHR.

## 2013 PHYSICIAN QUALITY REPORTING SYSTEM APPENDIX TABLES

**Table A1. List of Individual Measure Numbers and Descriptions for PQRS (2013)**

Measure Number	Measure Description
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
6	Coronary Artery Disease (CAD): Antiplatelet Therapy
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older



Measure Number	Measure Description
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility
47	Advance Care Plan
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
53	Asthma: Pharmacologic Therapy for Persistent Asthma
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic
64	Asthma: Assessment of Asthma Control
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use
66	Appropriate Testing for Children with Pharyngitis
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
85	Hepatitis C: HCV Genotype Testing Prior to Treatment

Measure Number	Measure Description
86	Hepatitis C: Antiviral Treatment Prescribed
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
91	Acute Otitis Externa (AOE): Topical Therapy
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients
106	Major Depressive Disorder (MDD): Diagnostic Evaluation
107	Major Depressive Disorder (MDD): Suicide Risk Assessment
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
109	Osteoarthritis (OA): Function and Pain Assessment
110	Preventive Care and Screening: Influenza Immunization
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
112	Preventive Care and Screening: Screening Mammography
113	Preventive Care and Screening: Colorectal Cancer Screening
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)
122	Adult Kidney Disease: Blood Pressure Management
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Documentation of Current Medications in the Medical Record

Measure Number	Measure Description
131	Pain Assessment and Follow-Up
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
137	Melanoma: Continuity of Care – Recall System
138	Melanoma: Coordination of Care
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications
143	Oncology: Medical and Radiation – Pain Intensity Quantified
144	Oncology: Medical and Radiation – Plan of Care for Pain
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>a</sup>
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
154	Falls: Risk Assessment
155	Falls: Plan of Care
156	Oncology: Radiation Dose Limits to Normal Tissues
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy
163	Diabetes Mellitus: Foot Exam
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a</sup>
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a</sup>
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a</sup>
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a</sup>
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening

Measure Number	Measure Description
176	Rheumatoid Arthritis (RA): Tuberculosis Screening
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
178	Rheumatoid Arthritis (RA): Functional Status Assessment
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
180	Rheumatoid Arthritis (RA): Glucocorticoid Management
181	Elder Maltreatment Screen and Follow-Up Plan
182	Functional Outcome Assessment
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>
193	Perioperative Temperature Management
194	Oncology: Cancer Stage Documented
195	Radiology: Stenosis Measurement in Carotid Imaging Reports
197	Coronary Artery Disease (CAD): Lipid Control
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis
209	Functional Communication Measure - Spoken Language Comprehension
210	Functional Communication Measure - Attention
211	Functional Communication Measure - Memory
212	Functional Communication Measure - Motor Speech
213	Functional Communication Measure - Reading
214	Functional Communication Measure - Spoken Language Expression
215	Functional Communication Measure - Writing

Measure Number	Measure Description
216	Functional Communication Measure - Swallowing
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments
224	Melanoma: Overutilization of Imaging Studies in Melanoma
225	Radiology: Reminder System for Mammograms
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)
236	Hypertension (HTN): Controlling High Blood Pressure
237	Hypertension (HTN): Blood Pressure Measurement
238	Drugs to be Avoided in the Elderly <sup>a</sup>
239	Weight Assessment and Counseling for Children and Adolescents
240	Childhood Immunization Status
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control
242	Coronary Artery Disease (CAD): Symptom Management
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting
244	Hypertension: Blood Pressure Management
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence

Measure Number	Measure Description
249	Barrett's Esophagus
250	Radical Prostatectomy Pathology Reporting
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
252	Anticoagulation for Acute Pulmonary Embolus Patients
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion
263	Preoperative Diagnosis of Breast Cancer
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer
265	Biopsy Follow-Up
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
307	Prenatal Care: Anti-D Immune Globulin
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies
309	Cervical Cancer Screening
310	Chlamydia Screening for Women
311	Use of Appropriate Medications for Asthma

Measure Number	Measure Description
312	Low Back Pain: Use of Imaging Studies
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL
317	Preventive Care and Screening: Screening for High Blood Pressure
320	Endoscopy & Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality
322	Cardiac Stress imaging Not Meeting Appropriate use Criteria: Preoperative Evaluation in Low Risk Surgery Patients <sup>a</sup>
323	Cardiac Stress imaging Not Meeting Appropriate use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) <sup>a</sup>
324	Cardiac Stress Imaging Note Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients <sup>a</sup>
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy
327	Pediatric Kidney Disease: Adequacy of Volume Management
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level less than 10g/dL <sup>a</sup>

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A1: For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.

**Table A2. Distribution of PQRS Incentive Amounts by Specialty, excluding MOCP (2013)**

Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Total Incentive Amount After Sequestration	Percent of National Total Incentive Amount
<b>MD/DO</b>	<b>345,244</b>	<b>80.0%</b>	<b>47.3%</b>	<b>\$0.02</b>	<b>\$298</b>	<b>\$548</b>	<b>\$83,791</b>	<b>\$189,253,364</b>	<b>\$185,468,297</b>	<b>86.4%</b>
Allergy/Immunology	1,157	69.4%	29.9%	\$0.10	\$144	\$241	\$3,545	\$279,126	\$273,544	0.1%
Anesthesiology	27,319	80.6%	57.6%	\$0.05	\$182	\$219	\$8,712	\$5,977,882	\$5,858,324	2.7%
Cardiology	15,949	83.4%	56.7%	\$0.04	\$846	\$1,137	\$83,791	\$18,138,941	\$17,776,162	8.3%
Colon/Rectal Surgery	669	80.0%	49.3%	\$0.21	\$471	\$536	\$3,666	\$358,693	\$351,519	0.2%
Critical Care	1,169	77.7%	40.0%	\$0.33	\$345	\$513	\$18,416	\$600,003	\$588,003	0.3%
Dermatology	4,960	71.6%	41.7%	\$0.14	\$946	\$1,540	\$41,771	\$7,638,081	\$7,485,320	3.5%
Emergency Medicine	40,535	90.8%	67.4%	\$0.04	\$210	\$269	\$3,950	\$10,898,243	\$10,680,278	5.0%
Endocrinology	3,338	82.9%	53.7%	\$0.12	\$255	\$375	\$4,259	\$1,252,413	\$1,227,365	0.6%
Family Practice	46,963	80.2%	44.7%	\$0.02	\$216	\$327	\$12,857	\$15,351,432	\$15,044,403	7.0%
Gastroenterology	6,813	75.7%	48.9%	\$0.11	\$564	\$647	\$6,018	\$4,408,644	\$4,320,472	2.0%
General Practice	1,252	64.5%	20.6%	\$0.08	\$119	\$300	\$7,492	\$375,808	\$368,292	0.2%
General Surgery	10,038	77.5%	40.5%	\$0.05	\$366	\$472	\$16,049	\$4,741,822	\$4,646,986	2.2%
Geriatrics	2,071	78.6%	44.1%	\$0.05	\$351	\$555	\$9,502	\$1,149,659	\$1,126,665	0.5%
Hand Surgery	726	70.1%	37.7%	\$0.12	\$525	\$622	\$4,828	\$451,724	\$442,689	0.2%
Infectious Disease	2,735	82.0%	42.0%	\$0.05	\$201	\$410	\$5,438	\$1,121,047	\$1,098,626	0.5%
Internal Medicine	50,983	79.6%	46.3%	\$0.04	\$328	\$492	\$14,059	\$25,073,324	\$24,571,857	11.5%
Interventional Radiology	1,157	78.9%	56.4%	\$0.14	\$525	\$876	\$36,590	\$1,013,659	\$993,386	0.5%
Nephrology	5,279	82.5%	54.2%	\$0.04	\$1,103	\$1,303	\$26,366	\$6,877,058	\$6,739,517	3.1%
Neurology	7,042	80.9%	46.5%	\$0.13	\$277	\$436	\$6,544	\$3,073,059	\$3,011,598	1.4%
Neurosurgery	2,221	76.9%	43.0%	\$0.05	\$588	\$731	\$6,724	\$1,624,070	\$1,591,589	0.7%
Nuclear Medicine	374	88.8%	52.7%	\$0.24	\$336	\$682	\$6,013	\$255,095	\$249,993	0.1%
Obstetrics/ Gynecology	12,070	76.2%	34.8%	\$0.10	\$42	\$97	\$2,938	\$1,172,564	\$1,149,112	0.5%
Oncology/Hematology	6,722	82.9%	51.0%	\$0.07	\$430	\$826	\$13,632	\$5,552,003	\$5,440,963	2.5%
Ophthalmology	10,589	75.0%	51.7%	\$0.05	\$1,293	\$1,690	\$22,558	\$17,892,836	\$17,534,980	8.2%
Oral/Maxillofacial Surgery	85	90.4%	20.9%	\$0.07	\$48	\$115	\$834	\$9,768	\$9,572	0.0%
Orthopaedic Surgery	9,842	74.3%	42.1%	\$0.05	\$673	\$842	\$13,471	\$8,287,594	\$8,121,842	3.8%



Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Total Incentive Amount After Sequestration	Percent of National Total Incentive Amount
Other MD/DO	5,129	77.0%	39.1%	\$0.04	\$278	\$440	\$10,441	\$2,255,630	\$2,210,518	1.0%
Otolaryngology	3,871	71.3%	39.8%	\$0.05	\$466	\$583	\$5,887	\$2,257,821	\$2,212,664	1.0%
Pathology	7,436	87.5%	68.9%	\$0.05	\$310	\$384	\$27,904	\$2,854,325	\$2,797,238	1.3%
Pediatrics	3,948	76.5%	38.4%	\$0.02	\$2	\$36	\$2,580	\$142,018	\$139,178	0.1%
Physical Medicine	2,865	67.7%	30.9%	\$0.12	\$364	\$564	\$4,869	\$1,615,908	\$1,583,589	0.7%
Plastic Surgery	1,191	73.6%	25.0%	\$0.18	\$276	\$383	\$6,470	\$456,498	\$447,368	0.2%
Psychiatry	5,297	66.8%	16.4%	\$0.04	\$76	\$162	\$4,054	\$859,652	\$842,459	0.4%
Pulmonary Disease	5,691	80.9%	49.4%	\$0.04	\$596	\$814	\$8,889	\$4,631,382	\$4,538,755	2.1%
Radiation Oncology	2,428	77.5%	47.2%	\$0.19	\$840	\$1,937	\$26,034	\$4,703,458	\$4,609,389	2.1%
Radiology	23,315	79.4%	58.2%	\$0.04	\$480	\$638	\$19,726	\$14,866,706	\$14,569,372	6.8%
Rheumatology	2,726	83.0%	55.0%	\$0.04	\$413	\$629	\$10,967	\$1,714,437	\$1,680,148	0.8%
Thoracic/Cardiac Surgery	2,302	80.2%	54.5%	\$0.18	\$671	\$811	\$7,076	\$1,867,431	\$1,830,082	0.9%
Urology	5,212	78.4%	49.7%	\$0.08	\$848	\$959	\$12,052	\$4,995,785	\$4,895,870	2.3%
Vascular Surgery	1,775	78.6%	48.1%	\$0.14	\$927	\$1,385	\$25,099	\$2,457,763	\$2,408,608	1.1%
<b>Other Eligible Professionals</b>	<b>149,114</b>	<b>71.1%</b>	<b>28.6%</b>	<b>\$0.02</b>	<b>\$82</b>	<b>\$199</b>	<b>\$31,532</b>	<b>\$29,636,910</b>	<b>\$29,044,172</b>	<b>13.5%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	716	70.1%	2.2%	\$0.06	\$160	\$484	\$29,828	\$346,445	\$339,516	0.2%
Audiologist	1,982	58.6%	27.2%	\$0.06	\$27	\$42	\$573	\$83,421	\$81,753	0.0%
Certified Nurse Midwives	804	77.1%	39.5%	\$0.08	\$3	\$8	\$300	\$6,074	\$5,952	0.0%
Chiropractor	5,245	50.7%	11.2%	\$0.12	\$65	\$95	\$978	\$498,097	\$488,135	0.2%
Clinical Nurse Specialists	726	73.9%	26.4%	\$0.05	\$58	\$107	\$1,317	\$77,506	\$75,956	0.0%
Counselor/Psychologist	2,965	44.1%	8.8%	\$0.10	\$47	\$92	\$1,621	\$273,056	\$267,595	0.1%
Dentist	278	82.0%	9.0%	\$0.09	\$24	\$60	\$674	\$16,664	\$16,331	0.0%
Dietitian/Nutritionist	869	85.2%	27.5%	\$0.12	\$11	\$24	\$611	\$20,672	\$20,258	0.0%
Nurse Anesthetist	23,272	79.7%	44.7%	\$0.13	\$76	\$100	\$1,052	\$2,316,898	\$2,270,560	1.1%
Nurse Practitioner	29,905	78.6%	36.2%	\$0.02	\$52	\$109	\$3,033	\$3,265,784	\$3,200,468	1.5%

Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Total Incentive Amount After Sequestration	Percent of National Total Incentive Amount
Optometry	8,172	58.1%	23.5%	\$0.20	\$166	\$275	\$5,475	\$2,244,459	\$2,199,570	1.0%
Other Eligible Professional	15,438	72.4%	34.4%	\$0.04	\$274	\$636	\$31,532	\$9,816,984	\$9,620,645	4.5%
Physical/Occupational Therapy	22,476	69.2%	43.3%	\$0.10	\$159	\$233	\$6,537	\$5,244,942	\$5,140,043	2.4%
Physician Assistant	29,206	82.0%	43.4%	\$0.03	\$54	\$101	\$4,743	\$2,951,666	\$2,892,633	1.3%
Podiatrist	3,799	43.7%	20.8%	\$0.12	\$471	\$595	\$6,282	\$2,261,131	\$2,215,909	1.0%
Registered Nurse	1,299	78.8%	32.9%	\$0.05	\$64	\$96	\$3,930	\$124,120	\$121,638	0.1%
Social Worker	1,962	52.6%	5.8%	\$0.02	\$26	\$45	\$1,301	\$88,990	\$87,211	0.0%
<b>Unknown/Missing</b>	<b>261</b>	<b>60.7%</b>	<b>21.6%</b>	<b>\$0.04</b>	<b>\$41</b>	<b>\$154</b>	<b>\$5,917</b>	<b>\$40,074</b>	<b>\$39,273</b>	<b>0.0%</b>
<b>Total (Unduplicated)</b>	<b>494,619</b>	<b>77.1%</b>	<b>39.5%</b>	<b>\$0.02</b>	<b>\$200</b>	<b>\$443</b>	<b>\$83,791</b>	<b>\$218,930,348</b>	<b>\$214,551,741</b>	<b>100.0%</b>

*Notes for Table A2: Results include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative.*

**Table A3. Potential PQRS Incentives and Participation Information, excluding MOCP (2013)**

Specialty	Average Potential Incentive per Eligible Professional	Percent of Eligible Professionals who Participated
MD/DO	\$473	59.1%
Allergy/Immunology	\$278	43.1%
Anesthesiology	\$226	71.5%
Cardiology	\$1,043	67.9%
Colon/Rectal Surgery	\$501	61.6%
Critical Care	\$461	51.4%
Dermatology	\$1,235	58.2%
Emergency Medicine	\$231	74.2%
Endocrinology	\$378	64.7%
Family Practice	\$284	55.7%
Gastroenterology	\$630	64.6%
General Practice	\$252	31.9%
General Surgery	\$412	52.3%
Geriatrics	\$512	56.1%
Hand Surgery	\$579	53.8%
Infectious Disease	\$502	51.2%
Internal Medicine	\$444	58.2%
Interventional Radiologist	\$840	71.5%
Nephrology	\$1,118	65.6%
Neurology	\$432	57.5%
Neurosurgery	\$657	55.9%
Nuclear Medicine	\$644	59.3%
Obstetrics/Gynecology	\$88	45.7%
Oncology/Hematology	\$683	61.5%
Ophthalmology	\$1,298	68.9%
Oral/Maxillofacial Surgery	\$90	23.1%
Orthopaedic Surgery	\$728	56.6%
Other MD/DO	\$422	50.9%
Otolaryngology	\$539	55.9%
Pathology	\$397	78.7%
Pediatrics	\$30	50.1%
Physical Medicine	\$536	45.7%
Plastic Surgery	\$324	33.9%
Psychiatry	\$182	24.5%
Pulmonary Disease	\$754	61.1%
Radiation Oncology	\$1,681	60.9%
Radiologist	\$578	73.2%
Rheumatology	\$548	66.3%
Thoracic/Cardiac Surgery	\$717	67.9%
Urology	\$798	63.3%
Vascular Surgery	\$1,229	61.1%

Specialty	Average Potential Incentive per Eligible Professional	Percent of Eligible Professionals who Participated
Other Eligible Professionals	\$160	40.2%
Agencies/Hospitals/Nursing and Treatment Facilities	\$80	3.1%
Audiologist	\$41	46.4%
Certified Nurse Midwives	\$7	51.2%
Chiropractor	\$74	22.0%
Clinical Nurse Specialists	\$111	35.7%
Counselor/Psychologist	\$104	20.0%
Dentist	\$55	10.9%
Dietitian/Nutritionist	\$24	32.3%
Nurse Anesthetist	\$94	56.0%
Nurse Practitioner	\$102	46.1%
Optometry	\$159	40.5%
Other Eligible Professional	\$535	47.5%
Physical/Occupational Therapy	\$225	62.6%
Physician Assistant	\$94	53.0%
Podiatrist	\$549	47.7%
Registered Nurse	\$98	41.8%
Social Worker	\$49	10.9%
<b>Unknown/Missing</b>	<b>\$150</b>	<b>35.6%</b>
<b>Total (Unduplicated)</b>	<b>\$343</b>	<b>51.2%</b>

*Notes for Table A3: Results include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative.*

**Table A4. PQRS Participation and Incentive Eligibility by Reporting Mechanism/Option or Alternative Program (2013)**

Reporting Mechanism/Option or Alternative Program	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
<b>Individual Participants (TIN/NPI)</b>	<b>1,032,095</b>	<b>424,905</b>	<b>41.2%</b>	<b>284,971</b>	<b>67.1%</b>
Pioneer ACO	21,678	21,678	100.0%	15,007	69.2%
CPC	1,340	508	37.9%	426	83.9%
Claims	1,009,909	331,668	32.8%	204,905	61.8%
Individual Measures	1,009,909	329,102	32.6%	201,743	61.3%
Measures Groups	1,009,909	8,632	0.9%	3,910	45.3%
Registry	1,009,909	67,631	6.7%	50,742	75.0%
Individual Measures	1,009,909	51,473	5.1%	36,421	70.8%
Measures Groups	1,009,909	16,423	1.6%	14,505	88.3%
EHR	1,009,909	23,194	2.3%	21,152	91.2%
Direct Submission	1,009,909	5,149	0.5%	4,459	86.6%
Data Submission Vendor	1,009,909	18,046	1.8%	16,694	92.5%
<b>Group Reporting</b>	<b>221,500</b>	<b>216,749</b>	<b>97.9%</b>	<b>209,648</b>	<b>96.7%</b>
Small GPRO	2,568	1,933	75.3%	1,874	96.9%
Medium GPRO	8,276	7,029	84.9%	6,556	93.3%
Medium GPRO - Registry	8,276	4,857	58.7%	4,789	98.6%
Medium GPRO - Web Interface	8,276	2,172	26.2%	1,767	81.4%
Large GPRO	125,597	122,728	97.7%	117,124	95.4%
Large GPRO - Registry	125,597	40,275	32.1%	40,088	99.5%
Large GPRO - Web Interface	125,597	82,453	65.6%	77,036	93.4%
SSP ACO	85,059	85,059	100.0%	84,094	98.9%
<b>Total Eligible Professionals (Unduplicated)</b>	<b>1,253,595</b>	<b>641,654</b>	<b>51.2%</b>	<b>494,619</b>	<b>77.1%</b>

Notes for Table A4: (1) Eligible professional-level results in this table include EPs who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative. (2) Sums across participation methods do not equal totals due to participation in multiple methods.

**Table A5. PQRS Participation and Incentive Eligibility by Eligible Professional Characteristics (2013)**

Eligible Professional (EP) Characteristics	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
Geography (Regions)	--	--	--	--	--
1 – Boston	85,023	45,467	53.5%	38,384	84.4%
2 - New York	139,115	61,786	44.4%	44,984	72.8%
3 - Philadelphia	130,393	64,977	49.8%	49,712	76.5%
4 – Atlanta	228,389	120,636	52.8%	92,091	76.3%
5 - Chicago	227,761	131,631	57.8%	107,590	81.7%
6 – Dallas	129,217	58,774	45.5%	44,645	76.0%
7 - Kansas City	56,971	30,738	54.0%	25,392	82.6%
8 – Denver	42,710	21,737	50.9%	17,237	79.3%
9 - San Francisco	138,993	59,010	42.5%	45,862	77.7%
10 - Seattle	52,737	26,426	50.1%	21,231	80.3%
Unknown	23,689	23,354	98.6%	9,740	41.7%
# of Measures for which EP was Eligible	--	--	--	--	--
1 -5	273,796	102,591	37.5%	75,121	73.2%
6-15	225,514	89,546	39.7%	65,825	73.5%
16-30	79,046	13,855	17.5%	7,947	57.4%
>30	425,765	191,009	44.9%	120,448	63.1%
Unknown	27,974	27,904	99.7%	15,630	56.0%
Practice Size (# of NPIs)	--	--	--	--	--
Individual Participants	--	--	--	--	--
1	204,250	45,249	22.2%	20,762	45.9%
2-4	130,683	50,050	38.3%	27,905	55.8%
5-10	115,536	51,075	44.2%	32,612	63.9%
11-24	131,465	65,590	49.9%	47,157	71.9%
25-50	120,034	66,784	55.6%	50,195	75.2%
51-99	96,259	52,517	54.6%	38,779	73.8%
100-199	78,430	36,828	47.0%	26,642	72.3%
200+	155,438	56,812	36.5%	40,919	72.0%
Group Participants	--	--	--	--	--
1-24	21,252	20,660	97.2%	19,971	96.7%
25-50	9,441	9,221	97.7%	9,119	98.9%
51-99	14,467	13,450	93.0%	12,863	95.6%
100-199	27,653	25,781	93.2%	24,151	93.7%
200+	148,687	147,637	99.3%	143,544	97.2%
Total MPFS charges per EP	--	--	--	--	--
Individual Participants	--	--	--	--	--
less than or equal to \$2,500	212,443	40,346	19.0%	20,350	50.4%
\$2,501 - \$10,000	171,870	48,157	28.0%	32,833	68.2%
\$10,001 - \$40,000	260,746	108,862	41.8%	73,631	67.6%
\$40,001 - \$100,000	181,356	101,020	55.7%	70,879	70.2%
over \$100,000	205,680	126,520	61.5%	87,278	69.0%

Eligible Professional (EP) Characteristics	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
Group Participants	--	--	--	--	--
less than or equal to \$2,500	36,232	35,130	97.0%	33,589	95.6%
\$2,501 - \$10,000	33,699	32,851	97.5%	31,412	95.6%
\$10,001 - \$40,000	58,540	57,330	97.9%	55,293	96.4%
\$40,001 - \$100,000	48,912	48,014	98.2%	46,715	97.3%
over \$100,000	44,117	43,424	98.4%	42,639	98.2%
Beneficiary Volume	--	--	--	--	--
Individual Participants	--	--	--	--	--
1-25	306,016	61,007	19.9%	41,681	68.3%
26-100	261,611	94,388	36.1%	63,123	66.9%
101-200	164,609	77,838	47.3%	53,270	68.4%
201+	285,912	177,795	62.2%	126,367	71.1%
Unknown	13,947	13,877	99.5%	530	3.8%
Group Participants	--	--	--	--	--
1-25	46,677	45,335	97.1%	43,414	95.8%
26-100	51,937	50,795	97.8%	48,735	95.9%
101-200	42,652	41,872	98.2%	40,565	96.9%
201+	70,370	69,156	98.3%	67,651	97.8%
Unknown	9,864	9,591	97.2%	9,283	96.8%
<b>Specialty</b>	--	--	--	--	--
<b>MD/DO</b>	--	--	--	--	--
Primary Care	231,711	129,762	56.0%	103,146	79.5%
Surgery	69,708	37,790	54.2%	28,849	76.3%
Other Specialties	429,189	263,996	61.5%	213,249	80.8%
<b>Other Eligible Professionals</b>	--	--	--	--	--
Physicians	103,051	33,453	32.5%	17,494	52.3%
Physician Assistant	67,222	35,617	53.0%	29,206	82.0%
Nurses	143,405	70,933	49.5%	56,006	79.0%
Other Eligible Professionals	209,157	70,003	33.5%	46,654	66.6%
Unknown/Missing	152	100	65.8%	15	15.0%
<b>Total (Unduplicated)</b>	<b>1,253,595</b>	<b>641,654</b>	<b>51.2%</b>	<b>494,619</b>	<b>77.1%</b>

Notes for Table A5: (1) Eligible professional-level results in this table include EPs who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative. (2) Sums across participation methods do not equal totals due to participation in multiple methods. (3) EPs in the Unknown categories include Registry and EHR data where a match in claims was not found.

**Table A6. Number of Eligible Professionals participating in PQRS by Specialty (2010 to 2013)**

Specialty	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013
<b>MD/DO</b>	<b>642,615</b>	<b>665,234</b>	<b>706,758</b>	<b>730,608</b>
Allergy/Immunology	3,418	3,468	3,789	3,867
Anesthesiology	43,173	43,510	46,195	47,408
Cardiology	23,768	24,118	26,834	28,152
Colon/Rectal Surgery	1,069	1,110	1,251	1,357
Critical Care	2,422	2,488	2,687	2,926
Dermatology	10,234	10,466	11,457	11,907
Emergency Medicine	49,278	51,428	57,538	60,130
Endocrinology	6,087	6,278	5,960	6,218
Family Practice	93,052	98,388	101,941	105,151
Gastroenterology	12,265	13,210	13,499	13,937
General Practice	5,883	5,942	6,104	6,091
General Surgery	21,595	21,941	24,208	24,785
Geriatrics	4,055	4,080	4,545	4,700
Hand Surgery	1,530	1,594	1,795	1,924
Infectious Disease	5,084	5,313	6,116	6,512
Internal Medicine	100,777	102,364	105,943	110,178
Interventional Radiology	1,364	1,578	1,885	2,051
Nephrology	8,301	8,685	9,290	9,748
Neurology	15,544	13,433	14,564	15,149
Neurosurgery	4,452	4,476	4,955	5,169
Nuclear Medicine	703	683	705	710
Obstetrics/Gynecology	30,000	31,262	33,569	34,657
Oncology/Hematology	10,762	11,153	12,762	13,172
Ophthalmology	18,917	18,992	20,243	20,495
Oral/Maxillofacial Surgery	370	377	417	407
Orthopaedic Surgery	20,662	21,365	22,708	23,380
Other MD/DO	8,978	11,492	11,946	13,106
Otolaryngology	8,374	8,666	9,426	9,717
Pathology	9,109	10,814	10,223	10,799
Pediatrics	5,816	6,656	8,946	10,291
Physical Medicine	7,859	8,176	8,883	9,257
Plastic Surgery	4,630	4,694	4,752	4,770
Psychiatry	30,269	32,868	32,430	32,374
Pulmonary Disease	9,100	9,646	10,819	11,515
Radiation Oncology	4,448	4,498	5,054	5,147
Radiology	38,236	38,503	40,576	40,083
Rheumatology	4,116	4,291	4,786	4,956
Thoracic/Cardiac Surgery	4,526	4,601	4,089	4,225



Specialty	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013
Urology	9,233	9,422	10,283	10,496
Vascular Surgery	3,156	3,205	3,585	3,691
<b>Other Eligible Professionals</b>	<b>399,000</b>	<b>435,572</b>	<b>493,447</b>	<b>521,778</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	3,262	3,080	32,783	33,140
Audiologist	6,073	6,481	6,928	7,281
Certified Nurse Midwives	1,166	1,392	1,810	2,038
Chiropractor	47,494	47,819	48,531	46,972
Clinical Nurse Specialists	2,074	2,253	2,567	2,749
Counselor/ Psychologist	31,287	31,984	33,441	33,636
Dentist	3,281	3,232	3,173	3,103
Dietitian/Nutritionist	2,298	2,472	2,892	3,158
Nurse Anesthetist	42,437	45,448	48,857	52,111
Nurse Practitioner	50,645	64,210	70,615	82,560
Optometry	31,377	32,796	33,923	34,737
Other Eligible Professional	44,292	49,080	45,049	44,860
Physical/Occupational Therapy	39,769	44,085	48,292	51,916
Physician Assistant	43,059	48,766	59,312	67,222
Podiatrist	17,442	17,809	18,228	18,239
Registered Nurse	3,806	3,679	3,873	3,947
Social Worker	29,238	30,986	33,173	34,109
Unknown/Missing	980	967	1,157	1,209
<b>Total (Unduplicated)</b>	<b>1,042,595</b>	<b>1,101,773</b>	<b>1,201,362</b>	<b>1,253,595</b>

*Note for Table A6: Results include data for eligible professionals who belong to a group practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or Pioneer ACO Model, and eligible professionals participating through the CPC initiative.*

**Table A7. PQRS Participation Information by Reporting Mechanism/Option or Alternative Program (2010 to 2013)**

Reporting Mechanism/Option or Alternative Program	Eligible Professionals who Participated in 2010	Percent of Eligible Professionals in 2010	Eligible Professionals who Participated in 2011	Percent of Eligible Professionals in 2011	Eligible Professionals who Participated in 2012	Percent of Eligible Professionals in 2012	Eligible Professionals who Participated in 2013	Percent of Eligible Professionals in 2013
Pioneer ACO	N/A	N/A	N/A	N/A	49,856	100.0%	21,678	100.0%
CPC	N/A	N/A	N/A	N/A	N/A	N/A	508	37.9%
Claims Individual Measures	200,517	19.7%	229,282	21.6%	248,206	23.3%	329,102	32.6%
Claims Measures Groups	4,151	0.4%	4,472	0.4%	4,776	0.4%	8,632	0.9%
Registry Individual Measures	39,255	3.9%	50,215	4.7%	36,473	3.4%	51,473	5.1%
Registry Measures Groups	17,133	1.7%	12,894	1.2%	10,478	1.0%	16,423	1.6%
EHR	14	0.0%	560	0.1%	19,817	1.9%	23,194	2.3%
Group Practice Reporting Option (GPRO) I	24,931	100.0%	39,404	96.4%	N/A	N/A	N/A	N/A
Group Practice Reporting Option (GPRO) II	N/A	N/A	789	1.9%	N/A	N/A	N/A	N/A
GPRO (2 – 24 EPs)	N/A	N/A	N/A	N/A	N/A	N/A	1,933	75.3%
GPRO (25 – 99 EPs)	N/A	N/A	N/A	N/A	766	88.2%	7,029	84.9%
GPRO (100 or more EPs)	N/A	N/A	N/A	N/A	43,290	99.2%	122,728	97.7%
SSP ACO	N/A	N/A	N/A	N/A	40,085	99.9%	85,059	100.0%
<b>Total (Unduplicated)</b>	<b>269,076</b>	<b>25.8%</b>	<b>320,422</b>	<b>29.1%</b>	<b>435,878</b>	<b>36.3%</b>	<b>641,654</b>	<b>51.2%</b>

Notes for Table A7: (1) Sums across participation methods do not equal totals due to participation in multiple methods. (2) Results included the claims, registry, EHR, and Group Practice Reporting Option methods as well as participation through alternative programs. (3) In 2012, practices with 25 to 99 eligible professionals that reported under the GPRO were referred to as Small, but in 2013 these practices were referred to as Medium; in 2013, practices with 2 to 24 eligible professionals could participate under the GPRO and these were referred to as Small.

**Table A8. Trends in PQRS Participation by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>201,080</b>	<b>31.3%</b>	<b>229,484</b>	<b>34.5%</b>	<b>315,340</b>	<b>44.6%</b>	<b>431,548</b>	<b>59.1%</b>
Allergy/Immunology	376	11.0%	532	15.3%	1,023	27.0%	1,668	43.1%
Anesthesiology	21,205	49.1%	23,747	54.6%	28,318	61.3%	33,879	71.5%
Cardiology	8,729	36.7%	9,430	39.1%	14,354	53.5%	19,115	67.9%
Colon/Rectal Surgery	268	25.1%	313	28.2%	530	42.4%	836	61.6%
Critical Care	437	18.0%	535	21.5%	946	35.2%	1,504	51.4%
Dermatology	1,725	16.9%	2,310	22.1%	3,854	33.6%	6,926	58.2%
Emergency Medicine	32,327	65.6%	34,690	67.5%	39,132	68.0%	44,629	74.2%
Endocrinology	2,414	39.7%	2,820	44.9%	2,978	50.0%	4,025	64.7%
Family Practice	25,445	27.3%	30,259	30.8%	41,914	41.1%	58,572	55.7%
Gastroenterology	2,918	23.8%	4,240	32.1%	5,875	43.5%	9,003	64.6%
General Practice	493	8.4%	545	9.2%	1,045	17.1%	1,942	31.9%
General Surgery	3,819	17.7%	4,393	20.0%	8,665	35.8%	12,953	52.3%
Geriatrics	882	21.8%	978	24.0%	1,841	40.5%	2,636	56.1%
Hand Surgery	248	16.2%	290	18.2%	551	30.7%	1,036	53.8%
Infectious Disease	816	16.1%	999	18.8%	2,157	35.3%	3,336	51.2%
Internal Medicine	31,068	30.8%	32,286	31.5%	45,568	43.0%	64,089	58.2%
Interventional Radiology	537	39.4%	707	44.8%	1,096	58.1%	1,466	71.5%
Nephrology	2,699	32.5%	2,987	34.4%	4,413	47.5%	6,399	65.6%
Neurology	5,295	34.1%	3,450	25.7%	6,016	41.3%	8,706	57.5%
Neurosurgery	864	19.4%	959	21.4%	1,997	40.3%	2,889	55.9%
Nuclear Medicine	167	23.8%	173	25.3%	301	42.7%	421	59.3%
Obstetrics/Gynecology	3,726	12.4%	4,892	15.6%	9,722	29.0%	15,848	45.7%
Oncology/Hematology	3,258	30.3%	3,684	33.0%	6,163	48.3%	8,107	61.5%
Ophthalmology	8,144	43.1%	8,844	46.6%	11,135	55.0%	14,125	68.9%
Oral/Maxillofacial Surgery	14	3.8%	22	5.8%	70	16.8%	94	23.1%
Orthopaedic Surgery	4,746	23.0%	5,482	25.7%	8,278	36.5%	13,238	56.6%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Other MD/DO	1,438	16.0%	3,029	26.4%	3,807	31.9%	6,665	50.9%
Otolaryngology	1,477	17.6%	1,852	21.4%	3,429	36.4%	5,429	55.9%
Pathology	6,136	67.4%	8,007	74.0%	7,050	69.0%	8,500	78.7%
Pediatrics	628	10.8%	991	14.9%	3,026	33.8%	5,159	50.1%
Physical Medicine	789	10.0%	1,004	12.3%	2,248	25.3%	4,231	45.7%
Plastic Surgery	692	14.9%	760	16.2%	1,006	21.2%	1,618	33.9%
Psychiatry	825	2.7%	3,148	9.6%	3,989	12.3%	7,928	24.5%
Pulmonary Disease	1,958	21.5%	2,532	26.2%	4,759	44.0%	7,032	61.1%
Radiation Oncology	995	22.4%	1,291	28.7%	2,215	43.8%	3,134	60.9%
Radiology	15,796	41.3%	18,543	48.2%	24,065	59.3%	29,351	73.2%
Rheumatology	1,386	33.7%	1,586	37.0%	2,465	51.5%	3,284	66.3%
Thoracic/Cardiac Surgery	2,523	55.7%	2,703	58.7%	2,338	57.2%	2,869	67.9%
Urology	2,888	31.3%	3,432	36.4%	5,351	52.0%	6,649	63.3%
Vascular Surgery	929	29.4%	1,039	32.4%	1,650	46.0%	2,257	61.1%
<b>Other Eligible Professionals</b>	<b>67,863</b>	<b>17.0%</b>	<b>90,781</b>	<b>20.8%</b>	<b>120,256</b>	<b>24.4%</b>	<b>209,676</b>	<b>40.2%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	283	8.7%	338	11.0%	623	1.9%	1,022	3.1%
Audiologist	212	3.5%	259	4.0%	1,132	16.3%	3,382	46.4%
Certified Nurse Midwives	125	10.7%	182	13.1%	602	33.3%	1,043	51.2%
Chiropractor	563	1.2%	860	1.8%	1,626	3.4%	10,342	22.0%
Clinical Nurse Specialists	221	10.7%	265	11.8%	618	24.1%	982	35.7%
Counselor/Psychologist	534	1.7%	685	2.1%	1,980	5.9%	6,717	20.0%
Dentist	29	0.9%	50	1.5%	235	7.4%	339	10.9%
Dietitian/Nutritionist	187	8.1%	221	8.9%	671	23.2%	1,020	32.3%
Nurse Anesthetist	15,532	36.6%	18,510	40.7%	21,883	44.8%	29,202	56.0%
Nurse Practitioner	11,139	22.0%	18,798	29.3%	23,043	32.6%	38,057	46.1%
Optometry	7,459	23.8%	9,372	28.6%	10,852	32.0%	14,072	40.5%
Other Eligible Professional	9,991	22.6%	13,980	28.5%	14,697	32.6%	21,326	47.5%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Physical/Occupational Therapy	6,391	16.1%	8,378	19.0%	12,429	25.7%	32,476	62.6%
Physician Assistant	12,375	28.7%	15,098	31.0%	23,179	39.1%	35,617	53.0%
Podiatrist	1,823	10.5%	2,629	14.8%	4,211	23.1%	8,700	47.7%
Registered Nurse	777	20.4%	821	22.3%	1,232	31.8%	1,649	41.8%
Social Worker	222	0.8%	335	1.1%	1,243	3.7%	3,730	10.9%
Unknown/Missing	133	13.6%	157	16.2%	282	24.4%	430	35.6%
<b>Total (Unduplicated)</b>	<b>269,076</b>	<b>25.8%</b>	<b>320,422</b>	<b>29.1%</b>	<b>435,878</b>	<b>36.3%</b>	<b>641,654</b>	<b>51.2%</b>

*Notes for Table 8: Results include EPs who belong to a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or Pioneer ACO Model, and eligible professionals participating through the CPC initiative.*

**Table A9. Eligible Professionals who Participated in PQRS by Reporting Individual Measures through the Claims Reporting Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>145,047</b>	<b>23.3%</b>	<b>162,557</b>	<b>25.4%</b>	<b>171,222</b>	<b>28.3%</b>	<b>201,457</b>	<b>36.6%</b>
Allergy/Immunology	232	6.8%	341	9.8%	347	10.5%	684	22.7%
Anesthesiology	20,040	47.6%	23,070	53.7%	24,317	57.4%	26,914	66.4%
Cardiology	5,331	22.4%	5,159	21.4%	4,673	21.8%	5,549	29.4%
Colon/Rectal Surgery	213	19.9%	238	21.4%	246	23.5%	310	32.3%
Critical Care	353	14.6%	392	16.0%	399	17.8%	425	21.3%
Dermatology	538	5.3%	675	6.4%	771	7.7%	1,353	13.8%
Emergency Medicine	32,030	65.0%	33,976	66.6%	33,880	64.4%	34,292	68.5%
Endocrinology	866	17.2%	1,042	20.1%	1,139	24.2%	1,302	32.0%
Family Practice	14,778	16.1%	16,944	17.9%	18,745	21.3%	22,631	28.9%
Gastroenterology	1,820	15.2%	2,202	18.1%	2,544	22.6%	3,787	36.8%
General Practice	370	6.3%	433	7.3%	586	10.2%	755	14.8%
General Surgery	2,879	13.3%	3,198	14.6%	3,704	17.8%	4,595	25.1%
Geriatrics	569	14.0%	615	15.1%	676	18.2%	807	24.9%
Hand Surgery	186	12.2%	221	13.9%	235	14.9%	474	31.0%
Infectious Disease	452	8.9%	543	10.2%	684	13.6%	924	20.6%
Internal Medicine	14,427	15.6%	17,110	17.7%	17,477	20.3%	21,695	28.5%
Interventional Radiology	522	38.3%	657	41.6%	822	49.6%	947	60.4%
Nephrology	1,050	13.1%	1,106	13.2%	1,236	16.1%	1,862	25.9%
Neurology	1,484	12.1%	1,879	14.9%	2,142	18.5%	2,605	25.6%
Neurosurgery	634	14.2%	692	15.5%	900	21.6%	1,063	28.4%
Nuclear Medicine	138	19.6%	126	18.4%	147	25.3%	198	39.5%
Obstetrics/Gynecology	2,238	7.5%	2,697	8.8%	3,323	11.5%	4,754	18.4%
Oncology/Hematology	2,649	24.6%	2,770	24.9%	2,765	27.0%	3,007	33.0%
Ophthalmology	7,555	39.9%	8,087	42.6%	8,133	44.9%	9,889	56.6%
Oral/Maxillofacial Surgery	12	3.2%	13	3.4%	31	8.2%	33	9.5%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Orthopaedic Surgery	3,687	17.8%	3,851	18.3%	4,138	20.7%	5,969	32.5%
Other MD/DO	1,037	11.6%	1,327	13.0%	1,480	14.7%	2,303	24.3%
Otolaryngology	905	10.8%	1,117	12.9%	1,303	16.2%	2,173	29.3%
Pathology	4,733	61.3%	4,814	63.0%	5,144	61.7%	5,204	69.5%
Pediatrics	302	5.2%	414	6.5%	553	8.2%	645	10.4%
Physical Medicine	553	7.0%	686	8.4%	896	11.4%	1,727	22.8%
Plastic Surgery	246	5.7%	291	6.7%	327	7.7%	544	14.0%
Psychiatry	674	2.2%	738	2.4%	901	3.0%	2,611	9.5%
Pulmonary Disease	1,433	15.7%	1,778	18.4%	1,948	21.9%	2,474	31.0%
Radiation Oncology	755	17.0%	996	22.1%	1,047	24.7%	1,278	32.8%
Radiology	14,554	38.8%	17,012	45.4%	18,333	51.7%	19,980	64.0%
Rheumatology	789	19.2%	840	19.8%	899	23.2%	1,081	30.7%
Thoracic/Cardiac Surgery	1,037	29.3%	1,069	30.3%	977	29.5%	991	34.2%
Urology	2,252	24.4%	2,641	28.0%	2,508	29.6%	2,724	35.0%
Vascular Surgery	724	22.9%	797	24.9%	846	27.8%	898	33.1%
<b>Other Eligible Professionals</b>	<b>55,378</b>	<b>14.1%</b>	<b>66,610</b>	<b>15.9%</b>	<b>76,855</b>	<b>16.7%</b>	<b>127,488</b>	<b>27.8%</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	233	7.1%	279	9.1%	295	0.9%	422	1.3%
Audiologist	171	2.8%	232	3.6%	392	6.3%	2,168	35.0%
Certified Nurse Midwives	72	6.2%	105	7.5%	160	11.1%	186	14.7%
Chiropractor	546	1.1%	853	1.8%	1,493	3.1%	10,100	21.6%
Clinical Nurse Specialists	179	8.6%	195	8.7%	238	10.6%	342	15.5%
Counselor/Psychologist	461	1.5%	581	1.8%	598	1.9%	4,387	13.9%
Dentist	20	0.6%	29	0.9%	30	1.0%	35	1.2%
Dietitian/Nutritionist	136	5.9%	176	7.1%	137	5.8%	152	6.5%
Nurse Anesthetist	14,274	34.6%	17,130	38.8%	18,669	41.0%	23,484	50.8%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Nurse Practitioner	6,721	13.8%	8,115	14.3%	10,136	16.6%	13,100	21.1%
Optometry	6,949	22.4%	8,811	27.2%	9,969	30.0%	12,646	37.5%
Other Eligible Professional	7,595	17.4%	8,307	19.0%	8,596	21.0%	11,111	29.2%
Physical/Occupational Therapy	6,081	15.3%	7,310	16.8%	9,246	19.8%	24,308	49.6%
Physician Assistant	9,529	22.8%	11,093	23.7%	12,953	25.2%	15,383	30.4%
Podiatrist	1,499	8.6%	2,359	13.2%	2,828	16.5%	6,534	39.6%
Registered Nurse	707	18.6%	746	20.3%	787	22.5%	979	29.2%
Social Worker	205	0.7%	289	0.9%	328	1.0%	2,151	6.6%
Unknown/Missing	92	9.4%	115	11.9%	129	12.0%	157	15.2%
<b>Total (Unduplicated)</b>	<b>200,517</b>	<b>19.7%</b>	<b>229,282</b>	<b>21.6%</b>	<b>248,206</b>	<b>23.3%</b>	<b>329,102</b>	<b>32.6%</b>

*Notes for Table A9: Results include eligible professionals who reported individual measures through the claims reporting mechanism. Eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals who participated through the CPC initiative are excluded.*



**Table A10. Eligible Professionals who Participated in PQRS by Reporting Measures Groups through the Claims Reporting Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>3,487</b>	<b>0.6%</b>	<b>3,758</b>	<b>0.6%</b>	<b>3,861</b>	<b>0.6%</b>	<b>6,699</b>	<b>1.2%</b>
Allergy/Immunology	0	0.0%	6	0.2%	4	0.1%	23	0.8%
Anesthesiology	38	0.1%	58	0.1%	61	0.1%	121	0.3%
Cardiology	559	2.4%	635	2.6%	549	2.6%	764	4.1%
Colon/Rectal Surgery	16	1.5%	4	0.4%	6	0.6%	19	2.0%
Critical Care	5	0.2%	6	0.2%	7	0.3%	22	1.1%
Dermatology	12	0.1%	1	0.0%	1	0.0%	5	0.1%
Emergency Medicine	47	0.1%	7	0.0%	144	0.3%	17	0.0%
Endocrinology	50	1.0%	66	1.3%	72	1.5%	147	3.6%
Family Practice	759	0.8%	826	0.9%	880	1.0%	1,474	1.9%
Gastroenterology	18	0.2%	23	0.2%	25	0.2%	78	0.8%
General Practice	12	0.2%	18	0.3%	12	0.2%	35	0.7%
General Surgery	140	0.6%	125	0.6%	104	0.5%	240	1.3%
Geriatrics	36	0.9%	32	0.8%	27	0.7%	69	2.1%
Hand Surgery	4	0.3%	11	0.7%	12	0.8%	14	0.9%
Infectious Disease	2	0.0%	2	0.0%	3	0.1%	14	0.3%
Internal Medicine	895	1.0%	966	1.0%	823	1.0%	1,429	1.9%
Interventional Radiology	0	0.0%	0	0.0%	0	0.0%	1	0.1%
Nephrology	91	1.1%	84	1.0%	121	1.6%	264	3.7%
Neurology	10	0.1%	8	0.1%	7	0.1%	100	1.0%
Neurosurgery	71	1.6%	75	1.7%	75	1.8%	101	2.7%
Nuclear Medicine	1	0.1%	1	0.1%	1	0.2%	3	0.6%
Obstetrics/Gynecology	29	0.1%	49	0.2%	112	0.4%	134	0.5%
Oncology/Hematology	24	0.2%	14	0.1%	16	0.2%	37	0.4%
Ophthalmology	1	0.0%	1	0.0%	9	0.0%	18	0.1%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	1	0.3%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Orthopaedic Surgery	285	1.4%	349	1.7%	381	1.9%	602	3.3%
Other MD/DO	41	0.5%	48	0.5%	50	0.5%	105	1.1%
Otolaryngology	4	0.0%	2	0.0%	5	0.1%	30	0.4%
Pathology	0	0.0%	0	0.0%	1	0.0%	0	0.0%
Pediatrics	2	0.0%	4	0.1%	6	0.1%	8	0.1%
Physical Medicine	45	0.6%	63	0.8%	64	0.8%	139	1.8%
Plastic Surgery	0	0.0%	0	0.0%	1	0.0%	12	0.3%
Psychiatry	0	0.0%	0	0.0%	0	0.0%	30	0.1%
Pulmonary Disease	34	0.4%	38	0.4%	69	0.8%	205	2.6%
Radiation Oncology	0	0.0%	1	0.0%	0	0.0%	0	0.0%
Radiology	0	0.0%	0	0.0%	0	0.0%	1	0.0%
Rheumatology	204	5.0%	183	4.3%	188	4.8%	285	8.1%
Thoracic/Cardiac Surgery	9	0.3%	9	0.3%	13	0.4%	20	0.7%
Urology	30	0.3%	35	0.4%	6	0.1%	78	1.0%
Vascular Surgery	13	0.4%	8	0.2%	6	0.2%	54	2.0%
<b>Other Eligible Professionals</b>	<b>664</b>	<b>0.2%</b>	<b>713</b>	<b>0.2%</b>	<b>912</b>	<b>0.2%</b>	<b>1,929</b>	<b>0.4%</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	1	0.0%	3	0.1%	3	0.0%	5	0.0%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	0	0.0%	2	0.1%	2	0.1%	2	0.2%
Chiropractor	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Clinical Nurse Specialists	9	0.4%	8	0.4%	13	0.6%	12	0.5%
Counselor/Psychologist	0	0.0%	0	0.0%	0	0.0%	168	0.5%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	0	0.0%	3	0.1%	4	0.2%	12	0.5%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Nurse Practitioner	153	0.3%	183	0.3%	268	0.4%	512	0.8%
Optometry	0	0.0%	0	0.0%	5	0.0%	4	0.0%
Other Eligible Professional	222	0.5%	201	0.5%	202	0.5%	387	1.0%
Physical/Occupational Therapy	158	0.4%	179	0.4%	232	0.5%	387	0.8%
Physician Assistant	109	0.3%	121	0.3%	145	0.3%	323	0.6%
Podiatrist	7	0.0%	12	0.1%	35	0.2%	86	0.5%
Registered Nurse	5	0.1%	1	0.0%	3	0.1%	8	0.2%
Social Worker	0	0.0%	0	0.0%	0	0.0%	23	0.1%
Unknown/Missing	0	0.0%	1	0.1%	3	0.3%	4	0.4%
<b>Total (Unduplicated)</b>	<b>4,151</b>	<b>0.4%</b>	<b>4,472</b>	<b>0.4%</b>	<b>4,776</b>	<b>0.4%</b>	<b>8,632</b>	<b>0.9%</b>

*Notes for Table A10: Eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals that participated as part of a Medicare ACO participating under the Shared Savings Program or Pioneer ACO Model, and eligible professionals participating through the CPC Initiative are excluded.*

**Table A11. Eligible Professionals who Participated in PQRS by Reporting Individual Measures through the Registry Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>32,532</b>	<b>5.2%</b>	<b>41,587</b>	<b>6.5%</b>	<b>28,832</b>	<b>4.8%</b>	<b>35,792</b>	<b>6.5%</b>
Allergy/Immunology	105	3.1%	215	6.2%	120	3.6%	154	5.1%
Anesthesiology	172	0.4%	164	0.4%	194	0.5%	389	1.0%
Cardiology	2,199	9.3%	2,949	12.2%	1,531	7.1%	1,530	8.1%
Colon/Rectal Surgery	51	4.8%	93	8.4%	51	4.9%	77	8.0%
Critical Care	83	3.4%	115	4.7%	93	4.1%	128	6.4%
Dermatology	1,311	12.8%	1,834	17.5%	1,700	16.9%	3,617	36.9%
Emergency Medicine	475	1.0%	489	1.0%	319	0.6%	516	1.0%
Endocrinology	467	9.3%	650	12.6%	355	7.5%	316	7.8%
Family Practice	7,059	7.7%	8,663	9.1%	4,921	5.6%	4,566	5.8%
Gastroenterology	613	5.1%	1,008	8.3%	727	6.5%	1,100	10.7%
General Practice	80	1.4%	83	1.4%	66	1.1%	90	1.8%
General Surgery	881	4.1%	1,278	5.8%	1,092	5.3%	1,255	6.8%
Geriatrics	268	6.6%	319	7.8%	208	5.6%	181	5.6%
Hand Surgery	62	4.1%	71	4.5%	69	4.4%	100	6.5%
Infectious Disease	346	6.8%	478	9.0%	279	5.5%	286	6.4%
Internal Medicine	7,239	7.8%	8,901	9.2%	5,538	6.4%	5,942	7.8%
Interventional Radiology	50	3.7%	81	5.1%	66	4.0%	88	5.6%
Nephrology	397	5.0%	618	7.4%	476	6.2%	682	9.5%
Neurology	627	5.1%	829	6.6%	588	5.1%	645	6.3%
Neurosurgery	203	4.6%	249	5.6%	210	5.0%	249	6.6%
Nuclear Medicine	26	3.7%	51	7.5%	20	3.4%	18	3.6%
Obstetrics/Gynecology	1,276	4.3%	1,707	5.6%	886	3.1%	1,307	5.1%
Oncology/Hematology	655	6.1%	1,073	9.6%	662	6.5%	905	9.9%
Ophthalmology	1,061	5.6%	1,395	7.4%	1,301	7.2%	1,604	9.2%
Oral/Maxillofacial Surgery	2	0.5%	9	2.4%	1	0.3%	4	1.1%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Orthopaedic Surgery	842	4.1%	1,106	5.3%	1,015	5.1%	1,208	6.6%
Other MD/DO	372	4.1%	465	4.5%	487	4.8%	727	7.7%
Otolaryngology	490	5.9%	687	7.9%	514	6.4%	690	9.3%
Pathology	29	0.4%	24	0.3%	168	2.0%	226	3.0%
Pediatrics	348	6.0%	343	5.4%	214	3.2%	498	8.0%
Physical Medicine	182	2.3%	271	3.3%	207	2.6%	404	5.3%
Plastic Surgery	114	2.6%	147	3.4%	103	2.4%	161	4.1%
Psychiatry	184	0.6%	229	0.7%	194	0.7%	391	1.4%
Pulmonary Disease	471	5.2%	798	8.3%	467	5.3%	533	6.7%
Radiation Oncology	327	7.4%	387	8.6%	410	9.7%	578	14.8%
Radiology	1,710	4.6%	1,537	4.1%	1,541	4.3%	2,284	7.3%
Rheumatology	289	7.0%	389	9.2%	250	6.4%	265	7.5%
Thoracic/Cardiac Surgery	647	18.3%	755	21.4%	659	19.9%	594	20.5%
Urology	626	6.8%	875	9.3%	916	10.8%	1,239	15.9%
Vascular Surgery	193	6.1%	252	7.9%	214	7.0%	245	9.0%
<b>Other Eligible Professionals</b>	<b>6,699</b>	<b>1.7%</b>	<b>8,601</b>	<b>2.1%</b>	<b>7,581</b>	<b>1.6%</b>	<b>15,599</b>	<b>3.4%</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	42	1.3%	46	1.5%	47	0.1%	131	0.4%
Audiologist	60	1.0%	36	0.6%	20	0.3%	160	2.6%
Certified Nurse Midwives	53	4.5%	83	6.0%	43	3.0%	87	6.9%
Chiropractor	11	0.0%	9	0.0%	4	0.0%	37	0.1%
Clinical Nurse Specialists	47	2.3%	71	3.2%	31	1.4%	57	2.6%
Counselor/Psychologist	98	0.3%	124	0.4%	79	0.2%	179	0.6%
Dentist	11	0.3%	21	0.6%	22	0.7%	27	1.0%
Dietitian/Nutritionist	54	2.3%	49	2.0%	24	1.0%	37	1.6%
Nurse Anesthetist	17	0.0%	60	0.1%	107	0.2%	180	0.4%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Nurse Practitioner	2,237	4.6%	2,992	5.3%	1,961	3.2%	3,050	4.9%
Optometry	215	0.7%	268	0.8%	296	0.9%	532	1.6%
Other Eligible Professional	1,332	3.0%	1,524	3.5%	1,413	3.4%	2,599	6.8%
Physical/Occupational Therapy	446	1.1%	734	1.7%	1,765	3.8%	5,499	11.2%
Physician Assistant	1,714	4.1%	2,171	4.6%	1,499	2.9%	2,664	5.3%
Podiatrist	260	1.5%	273	1.5%	185	1.1%	224	1.4%
Registered Nurse	67	1.8%	74	2.0%	54	1.5%	66	2.0%
Social Worker	35	0.1%	66	0.2%	31	0.1%	70	0.2%
Unknown/Missing	24	2.4%	27	2.8%	60	5.6%	82	7.9%
<b>Total (Unduplicated)</b>	<b>39,255</b>	<b>3.9%</b>	<b>50,215</b>	<b>4.7%</b>	<b>36,473</b>	<b>3.4%</b>	<b>51,473</b>	<b>5.1%</b>

*Notes for Table A11: Results include eligible professionals who reported individual measures through the registry reporting mechanism. Eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating through the Shared Savings Program or the pioneer ACO Model, and eligible professionals participating through the CPC initiative have been excluded.*

**Table A12. Eligible Professionals who Participated in PQRS by Reporting Measures Groups through the Registry Reporting Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>15,006</b>	<b>2.4%</b>	<b>11,392</b>	<b>1.8%</b>	<b>9,192</b>	<b>1.5%</b>	<b>14,147</b>	<b>2.6%</b>
Allergy/Immunology	70	2.0%	10	0.3%	9	0.3%	32	1.1%
Anesthesiology	31	0.1%	30	0.1%	19	0.0%	65	0.2%
Cardiology	2,279	9.6%	2,039	8.5%	1,672	7.8%	1,658	8.8%
Colon/Rectal Surgery	31	2.9%	7	0.6%	3	0.3%	42	4.4%
Critical Care	26	1.1%	10	0.4%	10	0.4%	40	2.0%
Dermatology	48	0.5%	19	0.2%	8	0.1%	12	0.1%
Emergency Medicine	61	0.1%	74	0.1%	28	0.1%	32	0.1%
Endocrinology	182	3.6%	151	2.9%	113	2.4%	188	4.6%
Family Practice	4,042	4.4%	2,800	3.0%	1,923	2.2%	2,893	3.7%
Gastroenterology	340	2.8%	171	1.4%	132	1.2%	303	2.9%
General Practice	77	1.3%	53	0.9%	37	0.6%	64	1.3%
General Surgery	350	1.6%	176	0.8%	100	0.5%	434	2.4%
Geriatrics	150	3.7%	134	3.3%	97	2.6%	139	4.3%
Hand Surgery	24	1.6%	13	0.8%	12	0.8%	34	2.2%
Infectious Disease	89	1.8%	63	1.2%	51	1.0%	105	2.3%
Internal Medicine	3,045	3.3%	2,433	2.5%	1,882	2.2%	2,395	3.1%
Interventional Radiologist	1	0.1%	1	0.1%	1	0.1%	4	0.3%
Nephrology	1,164	14.6%	1,071	12.8%	1,105	14.4%	1,502	20.9%
Neurology	85	0.7%	63	0.5%	127	1.1%	293	2.9%
Neurosurgery	67	1.5%	38	0.8%	35	0.8%	97	2.6%
Nuclear Medicine	15	2.1%	11	1.6%	10	1.7%	4	0.8%
Obstetrics/Gynecology	226	0.8%	124	0.4%	81	0.3%	178	0.7%
Oncology/Hematology	336	3.1%	242	2.2%	211	2.1%	436	4.8%
Ophthalmology	191	1.0%	105	0.6%	110	0.6%	303	1.7%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Orthopaedic Surgery	571	2.8%	426	2.0%	376	1.9%	789	4.3%
Other MD/DO	98	1.1%	74	0.7%	69	0.7%	142	1.5%
Otolaryngology	233	2.8%	179	2.1%	139	1.7%	253	3.4%
Pathology	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	16	0.3%	7	0.1%	7	0.1%	17	0.3%
Physical Medicine	74	0.9%	46	0.6%	43	0.5%	191	2.5%
Plastic Surgery	18	0.4%	7	0.2%	2	0.0%	14	0.4%
Psychiatry	11	0.0%	4	0.0%	14	0.0%	53	0.2%
Pulmonary Disease	224	2.5%	146	1.5%	205	2.3%	440	5.5%
Radiation Oncology	26	0.6%	31	0.7%	21	0.5%	277	7.1%
Radiologist	2	0.0%	3	0.0%	1	0.0%	16	0.1%
Rheumatology	370	9.0%	367	8.7%	314	8.1%	411	11.7%
Thoracic/Cardiac Surgery	56	1.6%	41	1.2%	29	0.9%	48	1.7%
Urology	303	3.3%	172	1.8%	133	1.6%	117	1.5%
Vascular Surgery	74	2.3%	51	1.6%	63	2.1%	126	4.6%
<b>Other Eligible Professionals</b>	<b>2,108</b>	<b>0.5%</b>	<b>1,488</b>	<b>0.4%</b>	<b>1,279</b>	<b>0.3%</b>	<b>2,264</b>	<b>0.5%</b>
Agencies/ Hospitals/ Nursing and Treatment Facilities	22	0.7%	23	0.7%	13	0.0%	24	0.1%
Audiologist	0	0.0%	0	0.0%	0	0.0%	2	0.0%
Certified Nurse Midwives	4	0.3%	0	0.0%	1	0.1%	3	0.2%
Chiropractor	9	0.0%	0	0.0%	1	0.0%	31	0.1%
Clinical Nurse Specialists	7	0.3%	7	0.3%	5	0.2%	20	0.9%
Counselor/Psychologist	0	0.0%	1	0.0%	2	0.0%	14	0.0%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	5	0.2%	3	0.1%	2	0.1%	6	0.3%
Nurse Anesthetist	11	0.0%	0	0.0%	0	0.0%	16	0.0%



Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Nurse Practitioner	598	1.2%	503	0.9%	470	0.8%	657	1.1%
Optometry	63	0.2%	14	0.0%	4	0.0%	9	0.0%
Other Eligible Professional	866	2.0%	598	1.4%	490	1.2%	864	2.3%
Physical/Occupational Therapy	58	0.1%	30	0.1%	8	0.0%	100	0.2%
Physician Assistant	311	0.7%	240	0.5%	228	0.4%	442	0.9%
Podiatrist	144	0.8%	59	0.3%	48	0.3%	63	0.4%
Registered Nurse	10	0.3%	10	0.3%	7	0.2%	12	0.4%
Social Worker	0	0.0%	0	0.0%	0	0.0%	1	0.0%
Unknown/Missing	19	1.9%	14	1.4%	7	0.6%	12	1.2%
<b>Total (Unduplicated)</b>	<b>17,133</b>	<b>1.7%</b>	<b>12,894</b>	<b>1.2%</b>	<b>10,478</b>	<b>1.0%</b>	<b>16,423</b>	<b>1.6%</b>

*Notes for Table A12: Results include eligible professionals who reported measures groups through the registry reporting mechanism. Eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative have been excluded.*

**Table A13. Eligible Professionals who Participated in PQRS by Reporting through the EHR Reporting Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
<b>MD/DO</b>	<b>10</b>	<b>0.0%</b>	<b>440</b>	<b>0.1%</b>	<b>16,152</b>	<b>2.7%</b>	<b>18,388</b>	<b>3.3%</b>
Allergy/Immunology	0	0.0%	0	0.0%	65	2.0%	75	2.5%
Anesthesiology	0	0.0%	0	0.0%	82	0.2%	99	0.2%
Cardiology	0	0.0%	40	0.2%	1,560	7.3%	1,828	9.7%
Colon/Rectal Surgery	0	0.0%	0	0.0%	39	3.7%	57	5.9%
Critical Care	0	0.0%	0	0.0%	27	1.2%	39	2.0%
Dermatology	0	0.0%	5	0.0%	167	1.7%	131	1.3%
Emergency Medicine	0	0.0%	2	0.0%	194	0.4%	148	0.3%
Endocrinology	0	0.0%	1	0.0%	236	5.0%	231	5.7%
Family Practice	7	0.0%	174	0.2%	4,539	5.2%	4,929	6.3%
Gastroenterology	0	0.0%	7	0.1%	410	3.6%	591	5.7%
General Practice	1	0.0%	9	0.2%	69	1.2%	92	1.8%
General Surgery	0	0.0%	10	0.0%	660	3.2%	844	4.6%
Geriatrics	0	0.0%	2	0.0%	108	2.9%	155	4.8%
Hand Surgery	0	0.0%	2	0.1%	32	2.0%	85	5.6%
Infectious Disease	0	0.0%	5	0.1%	178	3.5%	136	3.0%
Internal Medicine	2	0.0%	78	0.1%	3,215	3.7%	3,218	4.2%
Interventional Radiology	0	0.0%	0	0.0%	11	0.7%	11	0.7%
Nephrology	0	0.0%	5	0.1%	183	2.4%	256	3.6%
Neurology	0	0.0%	11	0.1%	422	3.6%	475	4.7%
Neurosurgery	0	0.0%	0	0.0%	91	2.2%	108	2.9%
Nuclear Medicine	0	0.0%	0	0.0%	14	2.4%	17	3.4%
Obstetrics/Gynecology	0	0.0%	9	0.0%	1,003	3.5%	1,470	5.7%
Oncology/Hematology	0	0.0%	5	0.0%	260	2.5%	208	2.3%
Ophthalmology	0	0.0%	0	0.0%	89	0.5%	66	0.4%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	1	0.3%	1	0.3%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Orthopaedic Surgery	0	0.0%	24	0.1%	528	2.6%	938	5.1%
Other MD/DO	0	0.0%	3	0.0%	100	1.0%	140	1.5%
Otolaryngology	0	0.0%	7	0.1%	185	2.3%	235	3.2%
Pathology	0	0.0%	0	0.0%	6	0.1%	0	0.0%
Pediatrics	0	0.0%	2	0.0%	108	1.6%	92	1.5%
Physical Medicine	0	0.0%	3	0.0%	129	1.6%	262	3.5%
Plastic Surgery	0	0.0%	0	0.0%	76	1.8%	69	1.8%
Psychiatry	0	0.0%	0	0.0%	190	0.6%	166	0.6%
Pulmonary Disease	0	0.0%	9	0.1%	420	4.7%	422	5.3%
Radiation Oncology	0	0.0%	0	0.0%	35	0.8%	5	0.1%
Radiology	0	0.0%	0	0.0%	51	0.1%	6	0.0%
Rheumatology	0	0.0%	5	0.1%	165	4.3%	175	5.0%
Thoracic/Cardiac Surgery	0	0.0%	0	0.0%	101	3.1%	158	5.5%
Urology	0	0.0%	17	0.2%	317	3.7%	303	3.9%
Vascular Surgery	0	0.0%	5	0.2%	86	2.8%	147	5.4%
<b>Other Eligible Professionals</b>	<b>4</b>	<b>0.0%</b>	<b>119</b>	<b>0.0%</b>	<b>3,653</b>	<b>0.8%</b>	<b>4,801</b>	<b>1.0%</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	0	0.0%	1	0.0%	25	0.1%	35	0.1%
Audiologist	0	0.0%	0	0.0%	14	0.2%	11	0.2%
Certified Nurse Midwives	0	0.0%	1	0.1%	36	2.5%	36	2.8%
Chiropractor	0	0.0%	0	0.0%	7	0.0%	37	0.1%
Clinical Nurse Specialists	0	0.0%	1	0.0%	31	1.4%	34	1.5%
Counselor/Psychologist	0	0.0%	0	0.0%	45	0.1%	16	0.1%
Dentist	0	0.0%	0	0.0%	1	0.0%	5	0.2%
Dietitian/Nutritionist	0	0.0%	0	0.0%	9	0.4%	14	0.6%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nurse Practitioner	2	0.0%	41	0.1%	1,588	2.6%	2,060	3.3%
Optometry	0	0.0%	0	0.0%	24	0.1%	11	0.0%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012	Eligible Professionals Participating in 2013	Percent of Eligible Professionals Participating in 2013
Other Eligible Professional	1	0.0%	22	0.1%	534	1.3%	757	2.0%
Physical/Occupational Therapy	0	0.0%	0	0.0%	35	0.1%	73	0.1%
Physician Assistant	1	0.0%	39	0.1%	1,098	2.1%	1,319	2.6%
Podiatrist	0	0.0%	12	0.1%	150	0.9%	359	2.2%
Registered Nurse	0	0.0%	2	0.1%	27	0.8%	32	1.0%
Social Worker	0	0.0%	0	0.0%	29	0.1%	2	0.0%
Unknown/Missing	0	0.0%	1	0.1%	12	1.1%	5	0.5%
<b>Total (Unduplicated)</b>	<b>14</b>	<b>0.0%</b>	<b>560</b>	<b>0.1%</b>	<b>19,817</b>	<b>1.9%</b>	<b>23,194</b>	<b>2.3%</b>

*Notes for Table A13: Results include eligible professionals who reported measures groups through the registry reporting mechanism. Eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative have been excluded.*

**Table A14. Eligible Professionals who Participated in PQRS, by Specialty and the Number of Beneficiaries on Whom They Reported (2013)**

Specialty	Number of participating EPs with 25 or fewer patients	Participation rate for EPs with 25 or fewer patients	Number EPs with 26-100 patients	Participation rate for EPs with 26-100 patients	Number EPs with 101-200 patients	Participation rate for EPs with 101-200 patients	Number EPs with more than 200 patients	Participation rate for EPs with more than 200 patients	Total EPs	Overall participation rate
<b>MD/DO</b>	<b>53,502</b>	<b>34.9%</b>	<b>78,980</b>	<b>51.9%</b>	<b>80,014</b>	<b>62.4%</b>	<b>201,876</b>	<b>72.2%</b>	<b>431,548</b>	<b>59.1%</b>
Allergy/Immunology	241	29.3%	620	43.5%	453	48.3%	303	48.0%	1,668	43.1%
Anesthesiology	4,238	50.2%	7,687	68.9%	9,925	78.4%	11,844	79.2%	33,879	71.5%
Cardiology	971	31.3%	1,462	50.2%	1,801	59.0%	13,082	75.7%	19,115	67.9%
Colon/Rectal Surgery	59	36.0%	154	57.9%	276	67.6%	327	65.5%	836	61.6%
Critical Care	181	31.5%	353	47.7%	337	52.3%	565	62.8%	1,504	51.4%
Dermatology	367	27.2%	563	42.7%	711	50.7%	5,156	67.0%	6,926	58.2%
Emergency Medicine	5,016	44.1%	7,610	68.6%	6,516	77.8%	25,002	86.8%	44,629	74.2%
Endocrinology	350	42.4%	627	59.3%	736	65.1%	2,218	71.3%	4,025	64.7%
Family Practice	5,150	26.4%	11,211	47.4%	14,606	63.1%	25,780	69.6%	58,572	55.7%
Gastroenterology	489	32.8%	957	56.5%	1,389	62.9%	5,988	71.6%	9,003	64.6%
General Practice	547	24.7%	444	28.4%	311	33.9%	570	42.9%	1,942	31.9%
General Surgery	1,450	29.7%	3,126	46.9%	3,795	59.3%	4,032	64.2%	12,953	52.3%
Geriatrics	193	31.2%	417	47.9%	482	52.5%	1,456	66.1%	2,636	56.1%
Hand Surgery	38	18.7%	128	41.2%	213	52.3%	631	64.6%	1,036	53.8%
Infectious Disease	478	40.9%	889	51.8%	689	56.8%	1,200	51.4%	3,336	51.2%
Internal Medicine	5,231	29.6%	10,587	50.2%	12,731	60.4%	32,984	69.1%	64,089	58.2%
Interventional Radiologist	224	42.7%	245	67.1%	320	78.0%	612	89.1%	1,466	71.5%
Nephrology	306	28.6%	630	48.2%	822	61.6%	4,503	76.4%	6,399	65.6%
Neurology	969	35.0%	1,591	54.2%	1,665	60.7%	4,121	65.0%	8,706	57.5%
Neurosurgery	286	33.8%	604	51.8%	799	59.7%	1,118	64.5%	2,889	55.9%
Nuclear Medicine	69	34.5%	109	55.1%	83	70.9%	112	76.7%	421	59.3%
Obstetrics/Gynecology	4,908	37.3%	6,370	48.3%	2,370	48.7%	1,221	50.2%	15,848	45.7%
Oncology/Hematology	611	35.5%	1,336	52.7%	1,534	59.1%	4,478	72.6%	8,107	61.5%
Ophthalmology	791	30.7%	1,187	49.0%	1,074	58.0%	10,911	80.9%	14,125	68.9%
Oral/Maxillofacial Surgery	36	16.0%	31	23.5%	14	51.9%	5	38.5%	94	23.1%
Orthopaedic Surgery	867	26.7%	1,535	43.6%	2,369	56.1%	8,081	67.4%	13,238	56.6%
Other MD/DO	914	29.7%	1,451	50.5%	1,279	54.4%	2,798	61.1%	6,665	50.9%

Specialty	Number of participating EPs with 25 or fewer patients	Participation rate for EPs with 25 or fewer patients	Number EPs with 26-100 patients	Participation rate for EPs with 26-100 patients	Number EPs with 101-200 patients	Participation rate for EPs with 101-200 patients	Number EPs with more than 200 patients	Participation rate for EPs with more than 200 patients	Total EPs	Overall participation rate
Otolaryngology	405	28.0%	598	50.9%	812	54.8%	3,483	63.5%	5,429	55.9%
Pathology	4,222	70.2%	2,876	87.0%	132	78.6%	41	70.7%	8,500	78.7%
Pediatrics	2,761	38.0%	308	44.7%	191	61.6%	163	67.9%	5,159	50.1%
Physical Medicine	383	23.5%	827	38.4%	895	48.0%	2,007	57.6%	4,231	45.7%
Plastic Surgery	290	18.9%	693	35.9%	370	46.1%	219	48.5%	1,618	33.9%
Psychiatry	2,632	18.9%	2,624	24.9%	1,310	29.7%	993	31.4%	7,928	24.5%
Pulmonary Disease	454	32.2%	887	49.7%	1,025	59.0%	4,369	69.5%	7,032	61.1%
Radiation Oncology	438	39.1%	866	58.3%	1,034	69.1%	728	74.6%	3,134	60.9%
Radiologist	5,794	50.6%	5,396	73.0%	4,592	81.6%	11,683	85.6%	29,351	73.2%
Rheumatology	185	32.1%	437	57.0%	599	65.7%	2,002	75.8%	3,284	66.3%
Thoracic/Cardiac Surgery	400	47.3%	845	66.3%	862	75.9%	573	73.5%	2,869	67.9%
Urology	402	24.2%	447	48.3%	576	59.3%	5,046	74.6%	6,649	63.3%
Vascular Surgery	156	33.5%	252	45.1%	316	57.1%	1,471	71.8%	2,257	61.1%
<b>Other Eligible Professionals</b>	<b>52,730</b>	<b>26.5%</b>	<b>66,113</b>	<b>41.0%</b>	<b>39,642</b>	<b>50.3%</b>	<b>45,018</b>	<b>58.8%</b>	<b>209,676</b>	<b>40.2%</b>
Agencies/Hospitals/ Nursing and Treatment Facilities	231	3.0%	244	1.5%	167	2.6%	226	7.8%	1,022	3.1%
Audiologist	635	30.5%	1,157	49.8%	879	55.4%	694	54.6%	3,382	46.4%
Certified Nurse Midwives	819	47.3%	75	50.7%	11	61.1%	2	50.0%	1,043	51.2%
Chiropractor	3,048	15.4%	5,333	25.2%	1,563	32.0%	376	34.2%	10,342	22.0%
Clinical Nurse Specialists	244	24.5%	327	37.2%	187	40.0%	172	49.0%	982	35.7%
Counselor/Psychologist	3,932	15.6%	1,859	30.7%	442	33.9%	262	33.5%	6,717	20.0%
Dentist	167	8.0%	103	12.5%	23	20.7%	7	17.9%	339	10.9%
Dietitian/Nutritionist	578	27.0%	339	43.0%	82	46.9%	14	27.5%	1,020	32.3%
Nurse Anesthetist	5,580	42.6%	9,352	57.0%	9,471	64.7%	4,734	59.8%	29,202	56.0%
Nurse Practitioner	8,775	32.8%	11,030	43.8%	8,079	53.5%	8,317	60.8%	38,057	46.1%
Optometry	1,283	15.9%	3,125	31.8%	3,178	46.2%	6,463	65.1%	14,072	40.5%
Other Eligible Professional	3,239	28.0%	4,281	43.2%	3,486	50.1%	9,389	60.6%	21,326	47.5%

Specialty	Number of participating EPs with 25 or fewer patients	Participation rate for EPs with 25 or fewer patients	Number EPs with 26-100 patients	Participation rate for EPs with 26-100 patients	Number EPs with 101-200 patients	Participation rate for EPs with 101-200 patients	Number EPs with more than 200 patients	Participation rate for EPs with more than 200 patients	Total EPs	Overall participation rate
Physical/Occupational Therapy	12,604	53.1%	16,028	70.2%	2,434	67.3%	394	57.7%	32,476	62.6%
Physician Assistant	8,214	36.9%	10,604	53.4%	7,705	62.8%	7,666	67.6%	35,617	53.0%
Podiatrist	320	16.6%	809	31.0%	1,415	44.7%	6,042	58.0%	8,700	47.7%
Registered Nurse	344	27.3%	558	44.4%	451	52.1%	246	47.7%	1,649	41.8%
Social Worker	2,717	9.5%	889	17.1%	69	19.5%	14	26.9%	3,730	10.9%
Unknown/Missing	110	20.5%	90	31.8%	54	37.8%	57	45.2%	430	35.6%
<b>Total (Unduplicated)</b>	<b>106,342</b>	<b>30.2%</b>	<b>145,183</b>	<b>46.3%</b>	<b>119,710</b>	<b>57.8%</b>	<b>246,951</b>	<b>69.3%</b>	<b>641,654</b>	<b>51.2%</b>

*Notes for Table A14: Result include eligible professionals who belong to a practice that reported under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative. There were 23,468 eligible professionals for whom we could not obtain beneficiary counts; these are included in the Total EPs column as well as the Overall Participation Rate column.*

**Table A15. PQRS Participation and Incentive Eligibility, by State (2013)**

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received an Incentive	Incentive Eligibility Rate
Alaska	2,839	728	25.6%	501	68.8%
Alabama	16,201	8,238	50.8%	5,838	70.9%
Arkansas	9,455	4,780	50.6%	3,046	63.7%
Arizona	23,457	11,610	49.5%	8,769	75.5%
California	106,075	44,623	42.1%	34,047	76.3%
Colorado	19,777	9,227	46.7%	7,061	76.5%
Connecticut	18,706	9,325	49.9%	7,118	76.3%
District of Columbia	4,399	1,770	40.2%	1,479	83.6%
Delaware	4,250	2,329	54.8%	1,922	82.5%
Florida	72,942	38,629	53.0%	28,741	74.4%
Georgia	33,047	17,993	54.4%	14,095	78.3%
Hawaii	4,334	1,578	36.4%	1,026	65.0%
Iowa	12,589	7,292	57.9%	6,334	86.9%
Idaho	5,798	3,011	51.9%	2,342	77.8%
Illinois	52,683	28,909	54.9%	23,464	81.2%
Indiana	24,193	13,624	56.3%	10,732	78.8%
Kansas	12,302	5,442	44.2%	3,975	73.0%
Kentucky	17,593	9,396	53.4%	7,241	77.1%
Louisiana	17,496	8,986	51.4%	6,656	74.1%
Massachusetts	45,770	26,963	58.9%	21,799	80.8%
Maryland	25,822	11,123	43.1%	8,317	74.8%
Maine	8,517	4,531	53.2%	3,887	85.8%
Michigan	48,585	27,430	56.5%	21,806	79.5%
Minnesota	30,583	19,913	65.1%	15,860	79.6%
Missouri	24,841	14,250	57.4%	11,582	81.3%
Mississippi	9,564	4,120	43.1%	3,072	74.6%
Montana	4,324	2,037	47.1%	1,508	74.0%
North Carolina	39,497	21,920	55.5%	16,792	76.6%
North Dakota	3,954	2,254	57.0%	1,805	80.1%
Nebraska	8,113	4,442	54.8%	3,551	79.9%
New Hampshire	7,896	4,337	54.9%	2,999	69.1%
New Jersey	40,163	19,396	48.3%	14,756	76.1%
New Mexico	7,072	3,519	49.8%	2,959	84.1%
Nevada	7,370	3,314	45.0%	2,327	70.2%
New York	97,165	45,494	46.8%	31,964	70.3%
Ohio	49,959	27,936	55.9%	22,129	79.2%
Oklahoma	13,277	5,899	44.4%	4,423	75.0%
Oregon	15,781	7,196	45.6%	5,497	76.4%
Pennsylvania	61,753	30,950	50.1%	22,994	74.3%
Puerto Rico	7,030	1,264	18.0%	596	47.2%
Rhode Island	5,836	2,421	41.5%	1,626	67.2%
South Carolina	16,650	8,566	51.4%	6,765	79.0%



State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received an Incentive	Incentive Eligibility Rate
South Dakota	4,539	2,517	55.5%	2,069	82.2%
Tennessee	27,311	13,689	50.1%	10,439	76.3%
Texas	74,091	35,938	48.5%	27,333	76.1%
Utah	9,067	5,627	62.1%	4,468	79.4%
Virginia	28,931	16,678	57.6%	13,350	80.0%
Virgin Islands	202	39	19.3%	22	56.4%
Vermont	3,390	2,182	64.4%	1,940	88.9%
Washington	29,100	15,683	53.9%	12,937	82.5%
Wisconsin	27,834	17,747	63.8%	15,350	86.5%
West Virginia	7,659	3,487	45.5%	2,486	71.3%
Wyoming	2,193	707	32.2%	424	60.0%
Other	411	165	40.1%	139	84.2%
Unknown/ Missing	1,209	430	35.6%	261	60.7%
<b>Total (Unduplicated)</b>	<b>1,253,595</b>	<b>641,654</b>	<b>51.2%</b>	<b>494,619</b>	<b>77.1%</b>

*Notes for Table A15: Results include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, and eligible professionals participating through the CPC initiative.*

**Table A16. Submission Information for Individual PQRS Measures submitted through the Claims Mechanism (2013)**

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
1	Diabetes Mellitus: Hemoglobin A1c Poor Control	283,929	26,644	9.4%	17,230	64.7%	54.5%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	283,929	23,518	8.3%	15,512	66.0%	54.8%
3	Diabetes Mellitus: High Blood Pressure Control	283,929	16,679	5.9%	10,440	62.6%	51.1%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	182,859	11,321	6.2%	7,671	67.8%	63.3%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	233,400	2,948	1.3%	898	30.5%	27.3%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	44,998	15,900	35.3%	11,777	74.1%	73.9%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	73,136	16,062	22.0%	11,430	71.2%	75.2%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	46,852	11,477	24.5%	8,383	73.0%	71.9%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	46,852	7,049	15.0%	4,900	69.5%	67.7%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	93,883	5,730	6.1%	3,595	62.7%	55.1%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	83,061	5,604	6.7%	3,719	66.4%	61.6%
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	87,768	4,581	5.2%	3,005	65.6%	61.2%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	78,905	5,042	6.4%	3,544	70.3%	63.2%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	92,597	865	0.9%	619	71.6%	50.6%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	35,695	23,383	65.5%	22,512	96.3%	87.7%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	81,090	48,952	60.4%	43,411	88.7%	83.4%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	113,252	7,207	6.4%	5,565	77.2%	62.0%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	93,484	5,005	5.4%	3,673	73.4%	61.1%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	112,221	6,994	6.2%	6,441	92.1%	77.4%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	90,607	4,819	5.3%	3,546	73.6%	58.0%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	477,589	12,342	2.6%	6,178	50.1%	42.6%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	92,597	1,090	1.2%	770	70.6%	43.3%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	139,806	3,590	2.6%	2,136	59.5%	50.5%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	2,910	618	21.2%	540	87.4%	80.6%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	2,910	448	15.4%	386	86.2%	80.7%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	3,177	186	5.9%	150	80.6%	75.9%
46	Medication Reconciliation	392,279	6,302	1.6%	2,182	34.6%	30.0%
47	Advance Care Plan	583,272	16,278	2.8%	9,356	57.5%	47.4%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	485,760	10,923	2.2%	4,529	41.5%	36.0%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	101,775	2,476	2.4%	1,611	65.1%	61.9%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	101,775	2,932	2.9%	1,931	65.9%	62.3%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	180,939	4,779	2.6%	2,829	59.2%	48.3%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	180,939	3,165	1.7%	1,940	61.3%	42.3%
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	66,724	1,777	2.7%	1,519	85.5%	63.1%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	66,155	44,470	67.2%	42,537	95.7%	89.2%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	50,497	34,864	69.0%	33,443	95.9%	88.7%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	172,025	43,171	25.1%	41,133	95.3%	88.5%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	172,025	33,159	19.3%	31,391	94.7%	87.5%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	66,724	1,075	1.6%	921	85.7%	62.7%
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	137	1	0.7%	1	100.0%	100.0%
66	Appropriate Testing for Children with Pharyngitis	103	0	0.0%	0	0.0%	0.0%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	26,238	1,233	4.7%	987	80.0%	71.2%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	21,648	1,001	4.6%	785	78.4%	63.6%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	33,060	1,585	4.8%	1,318	83.2%	70.9%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	32,677	1,421	4.3%	1,192	83.9%	75.9%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported ≥1 Valid QDC	% of Eligible Professionals who Reported ≥1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	94,503	2,243	2.4%	1,498	66.8%	60.8%
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	54,323	1,483	2.7%	954	64.3%	55.4%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	75,504	18,631	24.7%	16,651	89.4%	78.6%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	36,068	581	1.6%	449	77.3%	50.9%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	36,068	505	1.4%	398	78.8%	51.5%
86	Hepatitis C: Antiviral Treatment Prescribed	36,068	500	1.4%	384	76.8%	50.8%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	36,068	325	0.9%	272	83.7%	57.8%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	60,266	1,179	2.0%	924	78.4%	53.2%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	25,883	242	0.9%	210	86.8%	66.0%
91	Acute Otitis Externa (AOE): Topical Therapy	85,708	3,698	4.3%	3,208	86.7%	52.6%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	85,708	3,056	3.6%	2,697	88.3%	53.2%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	6,031	4,540	75.3%	4,099	90.3%	80.4%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	5,618	3,999	71.2%	3,764	94.1%	86.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	7,977	522	6.5%	302	57.9%	48.9%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	3,396	498	14.7%	300	60.2%	53.1%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	111,056	950	0.9%	409	43.1%	25.7%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	111,056	2,271	2.0%	1,161	51.1%	35.4%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	128,854	2,401	1.9%	1,703	70.9%	50.6%



Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
109	Osteoarthritis (OA): Function and Pain Assessment	184,531	2,159	1.2%	687	31.8%	34.1%
110	Preventive Care and Screening: Influenza Immunization	546,553	28,891	5.3%	13,261	45.9%	38.6%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	529,322	29,698	5.6%	18,544	62.4%	53.7%
112	Preventive Care and Screening: Breast Cancer Screening	466,838	22,879	4.9%	14,467	63.2%	54.1%
113	Preventive Care and Screening: Colorectal Cancer Screening	510,861	23,033	4.5%	13,263	57.6%	50.2%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	76,680	635	0.8%	343	54.0%	32.5%
117	Diabetes Mellitus: Dilated Eye Exam	300,661	22,152	7.4%	13,480	60.9%	60.0%
119	Diabetes Mellitus: Medical Attention for Nephropathy	283,929	9,640	3.4%	5,207	54.0%	43.3%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	100,291	2,213	2.2%	1,015	45.9%	36.4%
122	Adult Kidney Disease: Blood Pressure Management	9,681	749	7.7%	353	47.1%	37.2%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level $> 12.0$ g/dL	107,515	1,236	1.1%	549	44.4%	32.2%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	296,771	9,492	3.2%	4,402	46.4%	35.1%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	296,771	6,084	2.1%	2,393	39.3%	36.9%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	636,201	43,376	6.8%	24,724	57.0%	50.6%
130	Documentation of Current Medications in the Medical Record	660,806	93,493	14.1%	48,329	51.7%	42.4%
131	Pain Assessment and Follow-Up	663,837	42,411	6.4%	25,982	61.3%	42.8%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	595,873	7,545	1.3%	2,196	29.1%	25.5%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	72,759	11,943	16.4%	7,925	66.4%	70.1%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	44,943	6,633	14.8%	4,255	64.1%	62.9%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	184,531	2,428	1.3%	916	37.7%	34.8%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	89,827	17,011	18.9%	14,599	85.8%	78.4%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	19,274	10,832	56.2%	9,886	91.3%	86.4%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	15,135	9,691	64.0%	8,857	91.4%	84.0%
154	Falls: Risk Assessment	565,934	25,413	4.5%	15,336	60.3%	44.0%
155	Falls: Plan of Care	16,473	12,650	76.8%	11,328	89.5%	83.2%
156	Oncology: Radiation Dose Limits to Normal Tissues	2,730	468	17.1%	359	76.7%	66.9%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	2,666	51	1.9%	36	70.6%	56.2%
163	Diabetes Mellitus: Foot Exam	283,929	13,296	4.7%	6,634	49.9%	42.6%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	3,803	234	6.2%	193	82.5%	71.6%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	591,180	16,724	2.8%	9,024	54.0%	46.1%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	128,854	912	0.7%	596	65.4%	34.4%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	128,854	989	0.8%	610	61.7%	37.4%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	128,854	1,298	1.0%	817	62.9%	41.4%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	128,854	813	0.6%	516	63.5%	33.7%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	128,854	876	0.7%	534	61.0%	32.9%
181	Elder Maltreatment Screen and Follow-Up Plan	550,715	1,950	0.4%	870	44.6%	41.6%
182	Functional Outcome Assessment	97,369	23,355	24.0%	13,387	57.3%	52.4%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	60,266	625	1.0%	470	75.2%	47.6%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	60,266	606	1.0%	454	74.9%	48.5%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	14,760	1,238	8.4%	877	70.8%	62.4%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	2,912	55	1.9%	40	72.7%	55.0%
193	Perioperative Temperature Management	88,754	40,228	45.3%	32,337	80.4%	73.2%
194	Oncology: Cancer Stage Documented	216,931	3,264	1.5%	1,650	50.6%	53.0%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	53,060	16,282	30.7%	14,258	87.6%	80.9%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	201,388	7,230	3.6%	5,048	69.8%	53.0%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	224,337	9,163	4.1%	5,836	63.7%	51.7%
225	Radiology: Reminder System for Mammograms	21,659	8,684	40.1%	7,545	86.9%	81.5%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	601,621	57,100	9.5%	34,746	60.9%	54.5%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	69,732	389	0.6%	272	69.9%	48.2%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	69,732	198	0.3%	118	59.6%	35.4%
236	Hypertension (HTN): Controlling High Blood Pressure	239,973	5,639	2.3%	2,240	39.7%	38.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	224,337	3,152	1.4%	1,280	40.6%	36.6%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	137,671	498	0.4%	279	56.0%	73.1%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	137,671	628	0.5%	326	51.9%	70.1%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	34,751	115	0.3%	92	80.0%	56.5%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	83,674	260	0.3%	152	58.5%	53.5%
249	Barrett's Esophagus	6,970	3,971	57.0%	3,546	89.3%	80.0%
250	Radical Prostatectomy Pathology Reporting	3,075	2,142	69.7%	2,067	96.5%	85.8%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	4,613	2,792	60.5%	2,455	87.9%	78.6%
252	Anticoagulation for Acute Pulmonary Embolus Patients	22,999	3,439	15.0%	3,389	98.5%	91.0%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	770	161	20.9%	161	100.0%	97.9%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	8	0	0.0%	0	0.0%	0.0%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	9,811	976	9.9%	587	60.1%	46.7%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	7,002	89	1.3%	50	56.2%	38.4%
263	Preoperative Diagnosis of Breast Cancer	7,420	119	1.6%	82	68.9%	53.7%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	73,131	648	0.9%	289	44.6%	42.4%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	73,131	432	0.6%	190	44.0%	40.7%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	17,026	122	0.7%	66	54.1%	40.2%
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	633,309	18,462	2.9%	13,315	72.1%	59.7%
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	18,287	619	3.4%	178	28.8%	30.0%
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	701,046	1,558	0.2%	397	25.5%	22.9%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	177,577	945	0.5%	254	26.9%	33.8%
327	Pediatric Kidney Disease: Adequacy of Volume Management	277	0	0.0%	0	0.0%	0.0%
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level $< 10\text{g/dL}$	335	1	0.3%	1	100.0%	50.0%

*Notes for Table A16: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC. (2) Results included the claims method only. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) Reporting at least 50% of eligible instances defined satisfactory reporting. (5) The reporting rate was the percent of eligible instances on which the eligible professional reported.*



**Table A17. Individual PQRS Measures Submitted through the Claims Mechanism where more than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2013)**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Diagnosis Code	Percent of QDCs without Necessary Diagnosis Code
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	17,805	12,330	69.3%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	8,810	5,998	68.1%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	4,509	2,942	65.2%
122	Adult Kidney Disease: Blood Pressure Management	252,796	159,710	63.2%
86	Hepatitis C: Antiviral Treatment Prescribed	4,755	2,896	60.9%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	78,585	45,840	58.3%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	2,606	1,509	57.9%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	5,679	3,210	56.5%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	5,136	2,880	56.1%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	7,356	3,489	47.4%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	364	145	39.8%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	27,659	9,270	33.5%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	363,268	120,999	33.3%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	15,688	4,746	30.3%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	24,211	7,204	29.8%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	3,074	642	20.9%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	2,995	618	20.6%

*Notes for Table A17: Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) Results included the claims method only. (3) Results were restricted to individual measures (i.e., excluded measures groups).*

**Table A18. Individual PQRS Measures Submitted through the Claims Mechanism Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2013)**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Procedure Code	Percent of QDCs without Necessary Procedure Code
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	13,665	5,281	38.6%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	17,790	6,382	35.9%
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	12,637	3,322	26.3%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	161,557	39,139	24.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	8,388	1,961	23.4%
156	Oncology: Radiation Dose Limits to Normal Tissues	3,662	784	21.4%

*Notes for Tables A18: Results do not include eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. Results include data submitted for individual measures through the claims mechanism (i.e. measures groups are excluded).*

**Table A19. Individual PQRS Measures Submitted through the Claims Mechanism Where More than 20% of Reported Instances were for a Patient Who Did Not Meet the Necessary Age Range (2013)**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Age Range Code	Percent of QDCs without Necessary Age Range Code
327	Pediatric Kidney Disease: Adequacy of Volume Management	44	44	100.0%
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	802	800	99.8%
66	Appropriate Testing for Children with Pharyngitis	219	218	99.5%
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL	187	176	94.1%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	39,544	35,632	90.1%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	14,093	12,373	87.8%
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	14,936	10,136	67.9%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	33	22	66.7%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	7,696	4,738	61.6%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	2,335	842	36.1%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	301,255	97,892	32.5%
117	Diabetes Mellitus: Dilated Eye Exam	1,144,520	354,109	30.9%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	1,158	275	23.7%
163	Diabetes Mellitus: Foot Exam	381,476	85,634	22.4%

*Notes for Table A19: Results do not include eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. Results included the claims mechanism only. Results were restricted to individual measures (i.e., excluded measures groups).*

**Table A20. PQRS Incentive Eligibility Information by Reporting Mechanism/Option or Alternative Program (2010 to 2013)**

Reporting Option/Mechanism or Alternative Program	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Pioneer ACO	N/A	N/A	N/A	N/A	49,729	99.7%	15,007	69.2%
CPC	N/A	N/A	N/A	N/A	N/A	N/A	426	83.9%
Claims Individual Measures	122,567	61.1%	176,706	77.1%	180,450	72.7%	201,743	61.3%
Claims Measures Groups	2,182	52.6%	2,877	64.3%	2,619	54.8%	3,910	45.3%
Registry Individual Measures	34,276	87.3%	44,333	88.3%	31,068	85.2%	36,421	70.8%
Registry Measures Groups	16,186	94.5%	11,909	92.4%	8,993	85.8%	14,505	88.3%
EHR	13	92.9%	503	89.8%	18,570	93.7%	21,152	91.2%
Group Practice Reporting Option (GPRO) I	24,931	100.0%	39,404	100.0%	N/A	N/A	N/A	N/A
Group Practice Reporting Option (GPRO) II	N/A	N/A	76	0.2%	N/A	N/A	N/A	N/A
GPRO (2 – 24 EPs)	N/A	N/A	N/A	N/A	N/A	N/A	1,874	96.9%
GPRO (25 – 99 EPs)	N/A	N/A	N/A	N/A	766	100.0%	6,556	93.3%
GPRO (100 or more EPs)	N/A	N/A	N/A	N/A	43,290	100.0%	117,124	95.4%
SSP ACO	N/A	N/A	N/A	N/A	39,694	99.0%	84,094	98.9%
<b>Total (Unduplicated)</b>	<b>194,278</b>	<b>72.2%</b>	<b>266,740</b>	<b>83.2%</b>	<b>367,240</b>	<b>84.3%</b>	<b>494,619</b>	<b>77.1%</b>

Notes for Table A20: (1) Participation in PQRS through Medicare ACOs participating under the Shared Savings Program or the Pioneer ACO Model were not options before program year 2012; participation through the CPC Initiative was not an option before program year 2013. (2) In 2012, practices with 25 to 99 eligible professionals that reported under the GPRO were referred to as Small, but in 2013 these practices were referred to as Medium; in 2013, practices with 2 to 24 eligible professionals could participate under the GPRO and these were referred to as Small.

**Table A21. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the Claims Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
<b>MD/DO</b>	<b>89,198</b>	<b>61.5%</b>	<b>125,300</b>	<b>77.1%</b>	<b>124,851</b>	<b>72.9%</b>	<b>126,393</b>	<b>62.7%</b>
Allergy/Immunology	115	49.6%	210	61.6%	205	59.1%	234	34.2%
Anesthesiology	12,743	63.6%	19,352	83.9%	19,464	80.0%	20,630	76.7%
Cardiology	2,600	48.8%	3,463	67.1%	3,058	65.4%	2,922	52.7%
Colon/Rectal Surgery	86	40.4%	152	63.9%	143	58.1%	153	49.4%
Critical Care	148	41.9%	295	75.3%	242	60.7%	201	47.3%
Dermatology	318	59.1%	457	67.7%	513	66.5%	325	24.0%
Emergency Medicine	27,411	85.6%	32,260	94.9%	30,970	91.4%	31,033	90.5%
Endocrinology	466	53.8%	709	68.0%	716	62.9%	620	47.6%
Family Practice	7,857	53.2%	11,424	67.4%	11,751	62.7%	11,792	52.1%
Gastroenterology	798	43.8%	1,375	62.4%	1,561	61.4%	1,723	45.5%
General Practice	206	55.7%	299	69.1%	372	63.5%	375	49.7%
General Surgery	1,393	48.4%	2,126	66.5%	2,300	62.1%	2,051	44.6%
Geriatrics	235	41.3%	351	57.1%	405	59.9%	340	42.1%
Hand Surgery	108	58.1%	154	69.7%	164	69.8%	184	38.8%
Infectious Disease	204	45.1%	345	63.5%	451	65.9%	445	48.2%
Internal Medicine	6,871	47.6%	11,341	66.3%	10,307	59.0%	10,697	49.3%
Interventional Radiologist	285	54.6%	513	78.1%	642	78.1%	667	70.4%
Nephrology	449	42.8%	627	56.7%	621	50.2%	647	34.7%
Neurology	703	47.4%	1,262	67.2%	1,290	60.2%	1,210	46.4%
Neurosurgery	379	59.8%	503	72.7%	529	58.8%	520	48.9%
Nuclear Medicine	97	70.3%	103	81.7%	117	79.6%	159	80.3%
Obstetrics/Gynecology	880	39.3%	1,629	60.4%	1,849	55.6%	1,785	37.5%
Oncology/Hematology	1,116	42.1%	1,888	68.2%	1,899	68.7%	1,702	56.6%
Ophthalmology	4,374	57.9%	6,109	75.5%	5,993	73.7%	6,336	64.1%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Oral/Maxillofacial Surgery	5	41.7%	7	53.8%	21	67.7%	25	75.8%
Orthopaedic Surgery	2,041	55.4%	2,470	64.1%	2,618	63.3%	2,635	44.1%
Other MD/DO	519	50.0%	968	72.9%	918	62.0%	1,193	51.8%
Otolaryngology	400	44.2%	720	64.5%	791	60.7%	773	35.6%
Pathology	3,348	70.7%	4,423	91.9%	4,217	82.0%	4,338	83.4%
Pediatrics	212	70.2%	348	84.1%	414	74.9%	373	57.8%
Physical Medicine	281	50.8%	462	67.3%	541	60.4%	602	34.9%
Plastic Surgery	137	55.7%	215	73.9%	207	63.3%	179	32.9%
Psychiatry	310	46.0%	511	69.2%	498	55.3%	474	18.2%
Pulmonary Disease	609	42.5%	1,148	64.6%	1,206	61.9%	1,174	47.5%
Radiation Oncology	283	37.5%	626	62.9%	631	60.3%	590	46.2%
Radiologist	8,899	61.1%	13,088	76.9%	14,098	76.9%	14,562	72.9%
Rheumatology	311	39.4%	507	60.4%	537	59.7%	485	44.9%
Thoracic/Cardiac Surgery	615	59.3%	755	70.6%	576	59.0%	504	50.9%
Urology	996	44.2%	1,564	59.2%	1,481	59.1%	1,278	46.9%
Vascular Surgery	390	53.9%	541	67.9%	535	63.2%	457	50.9%
<b>Other Eligible Professionals</b>	<b>33,312</b>	<b>60.2%</b>	<b>51,309</b>	<b>77.0%</b>	<b>55,505</b>	<b>72.2%</b>	<b>75,249</b>	<b>59.0%</b>
Agencies/ Hospitals/ Nursing and Treatment Facilities	129	55.4%	207	74.2%	185	62.7%	238	56.4%
Audiologist	107	62.6%	135	58.2%	104	26.5%	904	41.7%
Certified Nurse Midwives	45	62.5%	88	83.8%	119	74.4%	77	41.4%
Chiropractor	208	38.1%	516	60.5%	511	34.2%	5,053	50.0%
Clinical Nurse Specialists	92	51.4%	153	78.5%	165	69.3%	150	43.9%
Counselor/Psychologist	235	51.0%	436	75.0%	335	56.0%	964	22.0%
Dentist	9	45.0%	23	79.3%	24	80.0%	14	40.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Dietitian/Nutritionist	88	64.7%	134	76.1%	78	56.9%	61	40.1%
Nurse Anesthetist	9,539	66.8%	14,006	81.8%	15,032	80.5%	17,864	76.1%
Nurse Practitioner	4,352	64.8%	6,314	77.8%	7,395	73.0%	7,330	56.0%
Optometry	2,864	41.2%	5,868	66.6%	5,924	59.4%	6,742	53.3%
Other Eligible Professional	4,486	59.1%	6,308	75.9%	6,189	72.0%	6,188	55.7%
Physical/Occupational Therapy	3,105	51.1%	5,637	77.1%	6,657	72.0%	15,939	65.6%
Physician Assistant	7,097	74.5%	9,569	86.3%	10,698	82.6%	10,856	70.6%
Podiatrist	349	23.3%	1,098	46.5%	1,278	45.2%	1,672	25.6%
Registered Nurse	476	67.3%	594	79.6%	619	78.7%	686	70.1%
Social Worker	131	63.9%	223	77.2%	192	58.5%	511	23.8%
Unknown/Missing	57	62.0%	97	84.3%	94	72.9%	101	64.3%
<b>Total (Unduplicated)</b>	<b>122,567</b>	<b>61.1%</b>	<b>176,706</b>	<b>77.1%</b>	<b>180,450</b>	<b>72.7%</b>	<b>201,743</b>	<b>61.3%</b>

*Notes for Table A21: Results do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Plan or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative.*

**Table A22. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Measures Groups through the Claims Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
<b>MD/DO</b>	<b>1,950</b>	<b>55.9%</b>	<b>2,518</b>	<b>67.0%</b>	<b>2,241</b>	<b>58.0%</b>	<b>3,340</b>	<b>49.9%</b>
Allergy/Immunology	0	0.0%	2	33.3%	4	100.0%	8	34.8%
Anesthesiology	25	65.8%	41	70.7%	43	70.5%	57	47.1%
Cardiology	431	77.1%	504	79.4%	439	80.0%	548	71.7%
Colon/Rectal Surgery	0	0.0%	1	25.0%	1	16.7%	4	21.1%
Critical Care	4	80.0%	6	100.0%	4	57.1%	5	22.7%
Dermatology	5	41.7%	1	100.0%	0	0.0%	5	100.0%
Emergency Medicine	19	40.4%	2	28.6%	58	40.3%	5	29.4%
Endocrinology	33	66.0%	50	75.8%	41	56.9%	88	59.9%
Family Practice	308	40.6%	487	59.0%	466	53.0%	651	44.2%
Gastroenterology	9	50.0%	16	69.6%	17	68.0%	49	62.8%
General Practice	6	50.0%	10	55.6%	10	83.3%	12	34.3%
General Surgery	37	26.4%	49	39.2%	31	29.8%	69	28.8%
Geriatrics	10	27.8%	17	53.1%	22	81.5%	32	46.4%
Hand Surgery	2	50.0%	4	36.4%	2	16.7%	0	0.0%
Infectious Disease	0	0.0%	2	100.0%	1	33.3%	6	42.9%
Internal Medicine	545	60.9%	687	71.1%	509	61.8%	749	52.4%
Interventional Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nephrology	48	52.7%	37	44.0%	29	24.0%	133	50.4%
Neurology	5	50.0%	3	37.5%	3	42.9%	32	32.0%
Neurosurgery	36	50.7%	41	54.7%	34	45.3%	39	38.6%
Nuclear Medicine	0	0.0%	1	100.0%	0	0.0%	2	66.7%
Obstetrics/Gynecology	13	44.8%	26	53.1%	46	41.1%	50	37.3%
Oncology/Hematology	6	25.0%	9	64.3%	12	75.0%	26	70.3%
Ophthalmology	0	0.0%	1	100.0%	1	11.1%	0	0.0%



Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	1	100.0%
Orthopaedic Surgery	171	60.0%	247	70.8%	226	59.3%	269	44.7%
Other MD/DO	21	51.2%	25	52.1%	33	66.0%	54	51.4%
Otolaryngology	1	25.0%	1	50.0%	1	20.0%	9	30.0%
Pathology	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	1	50.0%	2	50.0%	3	50.0%	3	37.5%
Physical Medicine	24	53.3%	32	50.8%	36	56.3%	55	39.6%
Plastic Surgery	0	0.0%	0	0.0%	0	0.0%	2	16.7%
Psychiatry	0	0.0%	0	0.0%	0	0.0%	6	20.0%
Pulmonary Disease	19	55.9%	32	84.2%	31	44.9%	119	58.0%
Radiation Oncology	0	0.0%	1	100.0%	0	0.0%	0	0.0%
Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rheumatology	138	67.6%	140	76.5%	123	65.4%	199	69.8%
Thoracic/Cardiac Surgery	3	33.3%	6	66.7%	8	61.5%	5	25.0%
Urology	23	76.7%	33	94.3%	6	100.0%	28	35.9%
Vascular Surgery	7	53.8%	2	25.0%	1	16.7%	20	37.0%
<b>Other Eligible Professionals</b>	<b>232</b>	<b>34.9%</b>	<b>358</b>	<b>50.2%</b>	<b>377</b>	<b>41.3%</b>	<b>569</b>	<b>29.5%</b>
Agencies/ Hospitals/ Nursing and Treatment Facilities	1	100.0%	3	100.0%	1	33.3%	2	40.0%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	0	0.0%	0	0.0%	1	50.0%	0	0.0%
Chiropractor	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Clinical Nurse Specialists	4	44.4%	5	62.5%	6	46.2%	5	41.7%
Counselor/Psychologist	0	0.0%	0	0.0%	0	0.0%	30	17.9%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	0	0.0%	1	33.3%	2	50.0%	0	0.0%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Nurse Practitioner	51	33.3%	108	59.0%	125	46.6%	165	32.2%
Optometry	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Other Eligible Professional	120	54.1%	125	62.2%	110	54.5%	175	45.2%
Physical/Occupational Therapy	13	8.2%	50	27.9%	65	28.0%	66	17.1%
Physician Assistant	38	34.9%	59	48.8%	53	36.6%	117	36.2%
Podiatrist	2	28.6%	6	50.0%	12	34.3%	3	3.5%
Registered Nurse	3	60.0%	1	100.0%	2	66.7%	2	25.0%
Social Worker	0	0.0%	0	0.0%	0	0.0%	4	17.4%
Unknown/Missing	0	0.0%	1	100.0%	1	33.3%	1	25.0%
<b>Total (Unduplicated)</b>	<b>2,182</b>	<b>52.6%</b>	<b>2,877</b>	<b>64.3%</b>	<b>2,619</b>	<b>54.8%</b>	<b>3,910</b>	<b>45.3%</b>

*Notes for Table A22: Results do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. Results include eligible professionals who earned an incentive through measures groups submitted through the claims reporting mechanism.*

**Table A23. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the Registry Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
<b>MD/DO</b>	<b>28,961</b>	<b>89.0%</b>	<b>37,544</b>	<b>90.3%</b>	<b>25,459</b>	<b>88.3%</b>	<b>26,326</b>	<b>73.6%</b>
Allergy/Immunology	96	91.4%	196	91.2%	114	95.0%	125	81.2%
Anesthesiology	136	79.1%	133	81.1%	131	67.5%	165	42.4%
Cardiology	2,090	95.0%	2,798	94.9%	1,409	92.0%	1,225	80.1%
Colon/Rectal Surgery	48	94.1%	91	97.8%	46	90.2%	60	77.9%
Critical Care	66	79.5%	86	74.8%	67	72.0%	69	53.9%
Dermatology	1,194	91.1%	1,739	94.8%	1,659	97.6%	2,522	69.7%
Emergency Medicine	434	91.4%	465	95.1%	285	89.3%	231	44.8%
Endocrinology	446	95.5%	602	92.6%	318	89.6%	264	83.5%
Family Practice	6,549	92.8%	8,120	93.7%	4,465	90.7%	3,813	83.5%
Gastroenterology	550	89.7%	917	91.0%	659	90.6%	862	78.4%
General Practice	72	90.0%	72	86.7%	61	92.4%	65	72.2%
General Surgery	804	91.3%	1,190	93.1%	969	88.7%	1,006	80.2%
Geriatrics	232	86.6%	267	83.7%	175	84.1%	133	73.5%
Hand Surgery	58	93.5%	66	93.0%	59	85.5%	70	70.0%
Infectious Disease	312	90.2%	428	89.5%	257	92.1%	227	79.4%
Internal Medicine	6,452	89.1%	7,873	88.5%	4,593	82.9%	4,428	74.5%
Interventional Radiologist	41	82.0%	74	91.4%	61	92.4%	44	50.0%
Nephrology	360	90.7%	532	86.1%	437	91.8%	577	84.6%
Neurology	529	84.4%	734	88.5%	497	84.5%	448	69.5%
Neurosurgery	189	93.1%	227	91.2%	193	91.9%	183	73.5%
Nuclear Medicine	14	53.8%	38	74.5%	16	80.0%	6	33.3%
Obstetrics/Gynecology	1,102	86.4%	1,486	87.1%	720	81.3%	900	68.9%
Oncology/Hematology	598	91.3%	959	89.4%	630	95.2%	751	83.0%
Ophthalmology	988	93.1%	1,263	90.5%	1,241	95.4%	1,360	84.8%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Oral/Maxillofacial Surgery	1	50.0%	6	66.7%	1	100.0%	3	75.0%
Orthopaedic Surgery	780	92.6%	1,008	91.1%	906	89.3%	918	76.0%
Other MD/DO	304	81.7%	387	83.2%	343	70.4%	469	64.5%
Otolaryngology	450	91.8%	618	90.0%	457	88.9%	495	71.7%
Pathology	7	24.1%	11	45.8%	149	88.7%	127	56.2%
Pediatrics	145	41.7%	133	38.8%	69	32.2%	105	21.1%
Physical Medicine	158	86.8%	226	83.4%	190	91.8%	271	67.1%
Plastic Surgery	105	92.1%	137	93.2%	92	89.3%	126	78.3%
Psychiatry	128	69.6%	129	56.3%	136	70.1%	193	49.4%
Pulmonary Disease	435	92.4%	721	90.4%	406	86.9%	425	79.7%
Radiation Oncology	303	92.7%	349	90.2%	386	94.1%	478	82.7%
Radiologist	1,215	71.1%	1,416	92.1%	1,458	94.6%	1,243	54.4%
Rheumatology	260	90.0%	336	86.4%	208	83.2%	233	87.9%
Thoracic/Cardiac Surgery	550	85.0%	632	83.7%	552	83.8%	445	74.9%
Urology	587	93.8%	851	97.3%	860	93.9%	1,082	87.3%
Vascular Surgery	173	89.6%	228	90.5%	184	86.0%	179	73.1%
<b>Other Eligible Professionals</b>	<b>5,313</b>	<b>79.3%</b>	<b>6,786</b>	<b>78.9%</b>	<b>5,600</b>	<b>73.9%</b>	<b>10,088</b>	<b>64.7%</b>
Agencies/ Hospitals/ Nursing and Treatment Facilities	27	64.3%	27	58.7%	29	61.7%	54	41.2%
Audiologist	23	38.3%	13	36.1%	13	65.0%	30	18.8%
Certified Nurse Midwives	31	58.5%	47	56.6%	26	60.5%	29	33.3%
Chiropractor	7	63.6%	7	77.8%	3	75.0%	11	29.7%
Clinical Nurse Specialists	44	93.6%	53	74.6%	22	71.0%	31	54.4%
Counselor/Psychologist	40	40.8%	36	29.0%	10	12.7%	31	17.3%
Dentist	7	63.6%	6	28.6%	10	45.5%	12	44.4%
Dietitian/Nutritionist	44	81.5%	44	89.8%	22	91.7%	15	40.5%
Nurse Anesthetist	11	64.7%	10	16.7%	2	1.9%	9	5.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Nurse Practitioner	1,821	81.4%	2,419	80.8%	1,430	72.9%	1,912	62.7%
Optometry	205	95.3%	251	93.7%	269	90.9%	475	89.3%
Other Eligible Professional	1,045	78.5%	1,311	86.0%	1,131	80.0%	1,753	67.4%
Physical/Occupational Therapy	305	68.4%	448	61.0%	1,297	73.5%	3,824	69.5%
Physician Assistant	1,403	81.9%	1,801	83.0%	1,150	76.7%	1,658	62.2%
Podiatrist	244	93.8%	258	94.5%	155	83.8%	180	80.4%
Registered Nurse	42	62.7%	47	63.5%	23	42.6%	41	62.1%
Social Worker	14	40.0%	8	12.1%	8	25.8%	23	32.9%
Unknown/Missing	2	8.3%	3	11.1%	9	15.0%	7	8.5%
<b>Total (Unduplicated)</b>	<b>34,276</b>	<b>87.3%</b>	<b>44,333</b>	<b>88.3%</b>	<b>31,068</b>	<b>85.2%</b>	<b>36,421</b>	<b>70.8%</b>

*Notes for Table A23: Results do not include eligible professionals who were part of a practice that participated under the QPRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. Results included the registry reporting mechanism for individual measures only.*

**Table A24. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Measures Groups through the Registry Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
<b>MD/DO</b>	<b>14,305</b>	<b>95.3%</b>	<b>10,565</b>	<b>92.7%</b>	<b>7,873</b>	<b>85.7%</b>	<b>12,660</b>	<b>89.5%</b>
Allergy/Immunology	69	98.6%	10	100.0%	7	77.8%	25	78.1%
Anesthesiology	28	90.3%	28	93.3%	17	89.5%	43	66.2%
Cardiology	2,184	95.8%	1,925	94.4%	1,574	94.1%	1,291	77.9%
Colon/Rectal Surgery	24	77.4%	7	100.0%	3	100.0%	37	88.1%
Critical Care	25	96.2%	10	100.0%	9	90.0%	39	97.5%
Dermatology	46	95.8%	17	89.5%	8	100.0%	5	41.7%
Emergency Medicine	59	96.7%	70	94.6%	28	100.0%	24	75.0%
Endocrinology	179	98.4%	138	91.4%	88	77.9%	170	90.4%
Family Practice	3,880	96.0%	2,639	94.3%	1,763	91.7%	2,691	93.0%
Gastroenterology	319	93.8%	162	94.7%	120	90.9%	277	91.4%
General Practice	72	93.5%	49	92.5%	35	94.6%	56	87.5%
General Surgery	327	93.4%	160	90.9%	90	90.0%	372	85.7%
Geriatrics	142	94.7%	101	75.4%	89	91.8%	121	87.1%
Hand Surgery	20	83.3%	13	100.0%	12	100.0%	29	85.3%
Infectious Disease	83	93.3%	57	90.5%	49	96.1%	99	94.3%
Internal Medicine	2,938	96.5%	2,239	92.0%	1,634	86.8%	2,119	88.5%
Interventional Radiologist	1	100.0%	0	0.0%	1	100.0%	3	75.0%
Nephrology	1,125	96.6%	1,030	96.2%	516	46.7%	1,419	94.5%
Neurology	81	95.3%	58	92.1%	116	91.3%	271	92.5%
Neurosurgery	62	92.5%	33	86.8%	33	94.3%	85	87.6%
Nuclear Medicine	14	93.3%	11	100.0%	2	20.0%	4	100.0%
Obstetrics/Gynecology	212	93.8%	116	93.5%	66	81.5%	114	64.0%
Oncology/Hematology	292	86.9%	234	96.7%	203	96.2%	409	93.8%
Ophthalmology	162	84.8%	82	78.1%	95	86.4%	283	93.4%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Orthopaedic Surgery	556	97.4%	388	91.1%	328	87.2%	744	94.3%
Other MD/DO	90	91.8%	65	87.8%	63	91.3%	117	82.4%
Otolaryngology	222	95.3%	177	98.9%	135	97.1%	235	92.9%
Pathology	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	15	93.8%	7	100.0%	7	100.0%	12	70.6%
Physical Medicine	72	97.3%	42	91.3%	42	97.7%	170	89.0%
Plastic Surgery	16	88.9%	7	100.0%	2	100.0%	11	78.6%
Psychiatry	5	45.5%	4	100.0%	11	78.6%	43	81.1%
Pulmonary Disease	213	95.1%	140	95.9%	198	96.6%	424	96.4%
Radiation Oncology	14	53.8%	19	61.3%	20	95.2%	259	93.5%
Radiologist	2	100.0%	0	0.0%	1	100.0%	13	81.3%
Rheumatology	350	94.6%	304	82.8%	298	94.9%	392	95.4%
Thoracic/Cardiac Surgery	53	94.6%	13	31.7%	27	93.1%	43	89.6%
Urology	283	93.4%	164	95.3%	126	94.7%	103	88.0%
Vascular Surgery	70	94.6%	46	90.2%	57	90.5%	108	85.7%
<b>Other Eligible Professionals</b>	<b>1,877</b>	<b>89.0%</b>	<b>1,342</b>	<b>90.2%</b>	<b>1,119</b>	<b>87.5%</b>	<b>1,843</b>	<b>81.4%</b>
Agencies/ Hospitals/ Nursing and Treatment Facilities	9	40.9%	5	21.7%	4	30.8%	9	37.5%
Audiologist	0	0.0%	0	0.0%	0	0.0%	2	100.0%
Certified Nurse Midwives	4	100.0%	0	0.0%	1	100.0%	3	100.0%
Chiropractor	0	0.0%	0	0.0%	1	100.0%	22	71.0%
Clinical Nurse Specialists	7	100.0%	7	100.0%	4	80.0%	15	75.0%
Counselor/Psychologist	0	0.0%	0	0.0%	1	50.0%	6	42.9%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	5	100.0%	3	100.0%	1	50.0%	6	100.0%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	5	31.3%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Nurse Practitioner	539	90.1%	460	91.5%	430	91.5%	524	79.8%
Optometry	50	79.4%	11	78.6%	3	75.0%	5	55.6%
Other Eligible Professional	807	93.2%	557	93.1%	413	84.3%	763	88.3%
Physical/Occupational Therapy	32	55.2%	29	96.7%	7	87.5%	49	49.0%
Physician Assistant	280	90.0%	210	87.5%	203	89.0%	383	86.7%
Podiatrist	135	93.8%	50	84.7%	44	91.7%	43	68.3%
Registered Nurse	9	90.0%	10	100.0%	7	100.0%	8	66.7%
Social Worker	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Unknown/Missing	4	21.1%	2	14.3%	1	14.3%	2	16.7%
<b>Total (Unduplicated)</b>	<b>16,186</b>	<b>94.5%</b>	<b>11,909</b>	<b>92.4%</b>	<b>8,993</b>	<b>85.8%</b>	<b>14,505</b>	<b>88.3%</b>

*Notes for Tables A24: Results do not include eligible professionals who are part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. Results include eligible professionals who earned an incentive through the reporting of measures groups through the registry reporting mechanism only.*



**Table A25. Eligible Professionals who Qualified for a PQRS Incentive by Reporting Individual Measures through the EHR Mechanism, by Specialty (2010 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
<b>MD/DO</b>	<b>9</b>	<b>90.0%</b>	<b>412</b>	<b>93.6%</b>	<b>15,357</b>	<b>95.1%</b>	<b>16,952</b>	<b>92.2%</b>
Allergy/Immunology	0	0.0%	0	0.0%	57	87.7%	61	81.3%
Anesthesiology	0	0.0%	0	0.0%	79	96.3%	89	89.9%
Cardiology	0	0.0%	40	100.0%	1,496	95.9%	1,748	95.6%
Colon/Rectal Surgery	0	0.0%	0	0.0%	39	100.0%	55	96.5%
Critical Care	0	0.0%	0	0.0%	26	96.3%	38	97.4%
Dermatology	0	0.0%	5	100.0%	164	98.2%	127	96.9%
Emergency Medicine	0	0.0%	2	100.0%	185	95.4%	137	92.6%
Endocrinology	0	0.0%	1	100.0%	222	94.1%	226	97.8%
Family Practice	7	100.0%	159	91.4%	4,294	94.6%	4,479	90.9%
Gastroenterology	0	0.0%	7	100.0%	373	91.0%	537	90.9%
General Practice	0	0.0%	8	88.9%	65	94.2%	82	89.1%
General Surgery	0	0.0%	10	100.0%	615	93.2%	768	91.0%
Geriatrics	0	0.0%	2	100.0%	101	93.5%	143	92.3%
Hand Surgery	0	0.0%	2	100.0%	32	100.0%	77	90.6%
Infectious Disease	0	0.0%	4	80.0%	170	95.5%	127	93.4%
Internal Medicine	2	100.0%	68	87.2%	3,072	95.6%	3,005	93.4%
Interventional Radiologist	0	0.0%	0	0.0%	11	100.0%	10	90.9%
Nephrology	0	0.0%	5	100.0%	176	96.2%	251	98.0%
Neurology	0	0.0%	11	100.0%	409	96.9%	454	95.6%
Neurosurgery	0	0.0%	0	0.0%	86	94.5%	94	87.0%
Nuclear Medicine	0	0.0%	0	0.0%	14	100.0%	17	100.0%
Obstetrics/Gynecology	0	0.0%	9	100.0%	951	94.8%	1,360	92.5%
Oncology/Hematology	0	0.0%	5	100.0%	246	94.6%	195	93.8%
Ophthalmology	0	0.0%	0	0.0%	86	96.6%	59	89.4%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	1	100.0%	1	100.0%
Orthopaedic Surgery	0	0.0%	24	100.0%	508	96.2%	853	90.9%
Other MD/DO	0	0.0%	2	66.7%	97	97.0%	125	89.3%
Otolaryngology	0	0.0%	7	100.0%	185	100.0%	204	86.8%
Pathology	0	0.0%	0	0.0%	6	100.0%	0	0.0%
Pediatrics	0	0.0%	2	100.0%	93	86.1%	77	83.7%
Physical Medicine	0	0.0%	3	100.0%	127	98.4%	201	76.7%
Plastic Surgery	0	0.0%	0	0.0%	70	92.1%	60	87.0%
Psychiatry	0	0.0%	0	0.0%	186	97.9%	153	92.2%
Pulmonary Disease	0	0.0%	9	100.0%	380	90.5%	397	94.1%
Radiation Oncology	0	0.0%	0	0.0%	34	97.1%	5	100.0%
Radiologist	0	0.0%	0	0.0%	50	98.0%	5	83.3%
Rheumatology	0	0.0%	5	100.0%	158	95.8%	169	96.6%
Thoracic/Cardiac Surgery	0	0.0%	0	0.0%	95	94.1%	147	93.0%
Urology	0	0.0%	17	100.0%	312	98.4%	286	94.4%
Vascular Surgery	0	0.0%	5	100.0%	86	100.0%	130	88.4%
<b>Other Eligible Professionals</b>	<b>4</b>	<b>100.0%</b>	<b>91</b>	<b>76.5%</b>	<b>3,206</b>	<b>87.8%</b>	<b>4,198</b>	<b>87.4%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	0	0.0%	1	100.0%	17	68.0%	20	57.1%
Audiologist	0	0.0%	0	0.0%	13	92.9%	9	81.8%
Certified Nurse Midwives	0	0.0%	0	0.0%	29	80.6%	32	88.9%
Chiropractor	0	0.0%	0	0.0%	6	85.7%	20	54.1%
Clinical Nurse Specialists	0	0.0%	0	0.0%	24	77.4%	31	91.2%
Counselor/Psychologist	0	0.0%	0	0.0%	27	60.0%	16	100.0%
Dentist	0	0.0%	0	0.0%	1	100.0%	4	80.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%	7	77.8%	12	85.7%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligibility Rate in 2013
Nurse Practitioner	2	100.0%	26	63.4%	1,384	87.2%	1,794	87.1%
Optometry	0	0.0%	0	0.0%	24	100.0%	10	90.9%
Other Eligible Professional	1	100.0%	21	95.5%	455	85.2%	665	87.8%
Physical/Occupational Therapy	0	0.0%	0	0.0%	35	100.0%	69	94.5%
Physician Assistant	1	100.0%	29	74.4%	1,000	91.1%	1,160	87.9%
Podiatrist	0	0.0%	12	100.0%	135	90.0%	325	90.5%
Registered Nurse	0	0.0%	2	100.0%	22	81.5%	29	90.6%
Social Worker	0	0.0%	0	0.0%	27	93.1%	2	100.0%
Unknown/Missing	0	0.0%	0	0.0%	7	58.3%	2	40.0%
<b>Total (Unduplicated)</b>	<b>13</b>	<b>92.9%</b>	<b>503</b>	<b>89.8%</b>	<b>18,570</b>	<b>93.7%</b>	<b>21,152</b>	<b>91.2%</b>

*Notes for Table A25: Results do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative.*

**Table A26. Eligible Professional Eligibility and Participation Information by PQRS Individual Measures (2010 to 2013)**

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	326,948	334,030	315,343	286,354	10.1%	11.2%	13.7%	12.3%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	326,622	333,895	315,106	286,462	9.4%	10.5%	12.9%	11.2%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	326,697	334,305	315,412	286,913	9.1%	10.8%	13.4%	9.7%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	3,720	4,413	3,747	3,499	94.8%	94.3%	95.1%	95.7%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	248,770	257,372	209,602	184,812	7.2%	8.3%	10.1%	9.3%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	4,172	5,961	7,455	4,199	95.9%	96.0%	97.0%	99.0%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	2,164	2,566	1,161	1,511	96.2%	92.7%	96.6%	88.6%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	255,966	264,734	253,407	233,720	0.5%	0.8%	1.4%	1.8%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	44,213	45,691	48,642	45,265	25.7%	29.4%	31.0%	38.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	72,987	76,420	75,489	73,325	16.3%	18.5%	19.2%	23.4%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	45,963	48,175	50,322	46,956	19.3%	21.3%	27.7%	26.4%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	45,974	48,165	47,360	46,888	10.7%	12.7%	13.4%	16.5%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	97,559	96,538	87,861	94,044	9.6%	5.9%	6.4%	6.8%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	69,190	69,020	64,075	83,288	9.9%	9.8%	9.0%	7.5%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	89,935	88,932	81,114	87,920	5.9%	5.8%	5.9%	5.8%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	76,925	76,521	70,036	79,018	7.7%	7.7%	7.5%	6.8%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	101,443	224,361	204,349	92,751	0.9%	0.4%	0.4%	1.6%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	31,663	38,884	38,008	35,726	52.3%	49.9%	59.1%	65.6%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	81,075	83,398	82,850	81,107	43.8%	49.0%	52.6%	60.5%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	97,567	101,837	128,218	113,796	3.4%	4.0%	4.6%	8.5%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	101,842	103,182	108,471	93,583	4.4%	5.4%	4.2%	5.7%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	851	960	770	494	80.7%	100.0%	99.9%	94.1%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	72,590	74,997	125,699	112,450	2.4%	3.0%	4.9%	6.7%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	81,074	84,064	104,109	90,677	4.5%	5.3%	4.0%	5.6%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	532,868	538,622	505,070	478,774	2.3%	2.6%	6.1%	4.6%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	101,542	224,400	204,369	92,609	1.4%	0.8%	0.8%	1.2%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	180,391	179,379	159,993	140,092	3.2%	3.2%	2.1%	3.4%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	4,032	3,845	3,405	3,032	37.6%	38.1%	36.9%	35.1%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	4,031	3,845	3,406	3,032	30.6%	30.8%	31.0%	29.7%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	4,373	4,154	3,706	3,314	28.7%	29.6%	22.4%	21.1%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	498,294	501,894	467,598	392,303	0.2%	0.3%	0.3%	1.6%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
47	Advance Care Plan	630,017	654,277	618,360	584,942	1.6%	2.2%	5.3%	4.7%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	539,520	546,207	512,380	485,824	1.3%	1.5%	4.5%	2.5%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	125,304	126,078	114,324	101,783	2.0%	2.3%	2.0%	2.6%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	125,325	125,992	114,283	101,798	2.0%	2.3%	2.0%	3.1%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	215,296	217,821	199,930	180,964	1.7%	1.8%	1.7%	2.7%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	215,197	217,697	199,904	180,953	1.2%	1.1%	1.1%	1.8%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	50,360	83,305	76,207	66,770	2.3%	2.0%	1.2%	2.9%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	69,637	72,175	70,847	66,645	57.0%	59.5%	61.9%	67.7%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	54,135	55,279	54,180	50,767	62.0%	64.9%	50.6%	69.4%



Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	203,053	207,255	191,853	172,044	17.1%	18.0%	21.8%	25.2%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	203,047	207,245	191,857	172,038	12.4%	13.2%	16.4%	19.3%
64	Asthma: Assessment of Asthma Control	50,034	83,237	78,089	66,940	0.8%	1.2%	5.0%	2.4%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	174	226	1,043	180	4.0%	15.0%	84.3%	24.4%
66	Appropriate Testing for Children with Pharyngitis	134	189	129	130	0.7%	25.4%	0.0%	20.0%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	28,262	30,109	28,819	26,255	5.7%	4.7%	4.4%	5.7%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	22,972	24,512	23,705	21,696	5.7%	4.7%	4.2%	6.5%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	35,484	37,308	35,615	33,087	5.8%	5.1%	4.5%	6.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	35,264	37,516	35,758	32,689	5.1%	4.7%	4.3%	5.3%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	131,106	134,396	104,973	94,531	1.6%	1.5%	1.8%	2.7%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	89,303	93,124	72,676	54,364	1.9%	1.9%	2.1%	3.2%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	89,791	89,550	84,284	75,775	16.3%	19.0%	21.0%	25.5%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	13	31	0	15	100.0%	9.7%	0.0%	100.0%
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	10	28	1	6	100.0%	0.0%	100.0%	50.0%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	246	252	151	132	81.3%	57.5%	23.8%	23.5%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	36,074	39,469	38,884	36,081	1.3%	0.9%	1.1%	1.7%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	36,074	39,468	38,884	36,081	1.3%	0.8%	0.9%	1.5%
86	Hepatitis C: Antiviral Treatment Prescribed	36,078	39,511	38,884	36,083	1.2%	1.0%	0.9%	1.5%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	36,072	39,462	38,883	36,077	0.8%	0.5%	0.6%	1.0%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	67,336	70,676	66,971	60,279	0.8%	1.1%	1.1%	2.0%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	25,973	28,327	28,149	25,885	0.8%	0.4%	0.3%	1.0%
91	Acute Otitis Externa (AOE): Topical Therapy	87,135	105,733	97,645	85,716	0.9%	1.5%	2.6%	4.6%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	87,128	105,720	97,645	85,712	0.6%	1.0%	2.1%	3.7%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	7,295	7,125	6,747	6,057	62.4%	64.5%	68.1%	76.0%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	6,855	6,734	6,341	5,638	63.2%	66.1%	59.6%	72.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	7,926	7,911	9,006	7,988	6.7%	7.8%	6.4%	8.2%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,057	4,128	3,775	3,413	12.7%	14.7%	15.4%	18.7%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	108,497	115,853	114,474	111,215	0.6%	0.7%	0.8%	1.3%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	108,499	115,856	114,474	111,202	0.7%	0.8%	1.0%	2.5%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	146,599	151,136	140,859	129,006	0.9%	1.1%	1.1%	2.2%
109	Osteoarthritis (OA): Function and Pain Assessment	213,659	218,885	203,717	184,557	0.8%	0.7%	0.8%	1.3%
110	Preventive Care and Screening: Influenza Immunization	575,237	587,537	571,267	548,387	3.1%	4.7%	7.3%	8.1%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	569,825	590,388	557,747	531,635	3.1%	4.7%	8.1%	9.5%
112	Preventive Care and Screening: Screening Mammography	515,671	523,430	491,753	468,779	2.8%	3.6%	7.2%	8.6%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
113	Preventive Care and Screening: Colorectal Cancer Screening	558,467	569,384	536,579	512,926	2.7%	3.7%	7.2%	8.2%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	98,605	100,215	89,194	76,691	0.4%	0.4%	0.4%	0.9%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	340,041	347,761	331,107	302,236	4.3%	5.2%	10.4%	9.3%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	1,751	2,266	719	1,473	100.0%	96.6%	95.0%	97.9%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	325,839	332,508	314,862	286,177	3.1%	3.7%	8.0%	6.1%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	53,494	61,611	103,028	100,424	4.4%	3.7%	1.2%	2.9%
122	Adult Kidney Disease: Blood Pressure Management	53,335	61,449	9,839	9,870	4.3%	3.4%	6.8%	11.5%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	52,359	60,684	113,152	107,531	1.2%	0.9%	0.4%	1.5%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	338,908	345,501	323,402	297,036	1.0%	1.4%	1.5%	3.6%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	338,907	345,497	323,070	297,031	0.7%	1.0%	0.9%	2.4%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	704,404	722,617	682,207	639,568	1.3%	2.7%	5.9%	10.7%
130	Documentation of Current Medications in the Medical Record	691,221	710,120	705,256	663,342	3.4%	6.2%	8.1%	16.8%
131	Pain Assessment and Follow-Up	170,678	177,520	705,787	664,919	3.6%	4.5%	1.8%	7.4%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	117,265	120,628	644,900	595,868	0.5%	0.6%	0.4%	1.3%
137	Melanoma: Continuity of Care – Recall System	1,595	1,902	2,036	3,861	99.2%	97.2%	97.9%	98.0%
138	Melanoma: Coordination of Care	1,246	1,809	1,889	3,296	99.1%	97.5%	97.8%	97.2%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	72,524	75,907	75,085	72,871	10.0%	12.5%	13.9%	17.5%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	44,154	45,600	47,772	44,956	8.7%	11.6%	12.4%	15.1%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	213,553	218,874	203,908	184,810	0.7%	0.9%	1.4%	2.2%
143	Oncology: Medical and Radiation – Pain Intensity Quantified	61	54	79	190	100.0%	100.0%	88.6%	51.1%
144	Oncology: Medical and Radiation – Plan of Care for Pain	18	46	50	55	100.0%	100.0%	100.0%	94.5%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	125,169	108,364	97,696	90,020	8.7%	12.3%	15.3%	19.5%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>a</sup>	27,027	23,526	21,310	19,286	28.4%	39.7%	45.1%	57.8%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	19,252	18,169	16,745	15,185	33.2%	44.4%	51.5%	65.4%
154	Falls: Risk Assessment	607,979	622,542	589,962	566,477	1.4%	1.7%	2.2%	5.2%
155	Falls: Plan of Care	6,688	8,268	9,453	18,290	60.9%	70.7%	74.8%	78.9%
156	Oncology: Radiation Dose Limits to Normal Tissues	3,661	3,557	3,352	2,747	11.6%	15.2%	16.0%	21.3%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	3,105	2,984	3,120	2,671	1.5%	2.0%	1.5%	1.9%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	96	112	82	74	100.0%	99.1%	100.0%	83.8%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	87	74	40	35	100.0%	94.6%	97.5%	91.4%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	61	70	64	53	100.0%	95.7%	98.4%	100.0%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	68	85	60	72	100.0%	96.5%	98.3%	98.6%
163	Diabetes Mellitus: Foot Exam	324,827	331,724	314,625	285,616	1.7%	2.6%	7.9%	6.6%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a</sup>	16	5	8	4	100.0%	80.0%	87.5%	50.0%



Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a</sup>	19	5	5	4	100.0%	80.0%	40.0%	25.0%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a</sup>	11	2	5	4	100.0%	50.0%	80.0%	50.0%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a</sup>	7	2	5	4	100.0%	50.0%	80.0%	50.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>	16	7	9	7	100.0%	85.7%	66.7%	57.1%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	16	10	9	16	100.0%	90.0%	55.6%	81.3%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	15	2	5	13	100.0%	50.0%	20.0%	76.9%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	14	2	5	13	100.0%	50.0%	20.0%	76.9%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	4,823	4,807	4,363	3,809	3.7%	4.8%	5.6%	6.4%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	662,216	675,446	641,652	592,534	0.7%	1.2%	4.2%	4.3%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	146,538	150,934	140,815	128,875	0.3%	0.3%	0.4%	0.8%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	146,538	150,932	140,816	128,858	0.4%	0.3%	0.4%	0.8%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	146,537	150,932	140,816	128,858	0.4%	0.3%	0.5%	1.0%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	146,537	150,932	140,813	128,858	0.3%	0.2%	0.3%	0.6%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	146,537	150,942	140,814	128,858	0.4%	0.3%	0.4%	0.7%
181	Elder Maltreatment Screen and Follow-Up Plan	66,877	69,780	589,553	550,705	0.1%	0.1%	0.0%	0.4%
182	Functional Outcome Assessment	47,621	47,966	98,125	98,021	0.6%	1.2%	3.6%	27.0%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	67,361	70,698	66,966	60,294	0.7%	0.9%	0.8%	1.3%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	67,359	70,695	66,968	60,294	0.6%	0.8%	0.7%	1.2%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	17,192	17,475	16,363	14,765	4.8%	5.8%	6.2%	9.1%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	15	13	9	50	100.0%	100.0%	88.9%	98.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	3,444	3,330	3,102	2,920	0.1%	0.1%	0.1%	2.4%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	170	242	205	163	100.0%	94.6%	88.8%	90.8%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	149	226	148	118	99.3%	91.2%	83.8%	87.3%
193	Perioperative Temperature Management	85,758	89,505	90,070	88,760	17.2%	26.6%	31.9%	45.5%
194	Oncology: Cancer Stage Documented	164,235	167,770	155,882	216,983	0.7%	1.2%	1.3%	1.8%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	65,456	64,773	59,471	53,084	16.9%	19.9%	24.6%	31.5%
197	Coronary Artery Disease (CAD): Lipid Control	1,778	4,329	11,545	4,596	100.0%	100.0%	99.8%	99.3%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	927	1,246	699	1,197	100.0%	99.3%	99.9%	99.2%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	814	1,738	4,156	19	100.0%	100.0%	100.0%	100.0%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	264,191	272,354	253,905	204,545	1.7%	2.9%	6.7%	8.1%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	264,152	272,232	254,048	227,024	1.7%	3.0%	7.2%	7.9%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	50	30	22	40	100.0%	83.3%	100.0%	100.0%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	70	30	21	14	100.0%	86.7%	100.0%	92.9%
209	Functional Communication Measure - Spoken Language Comprehension	10	23	13	10	100.0%	100.0%	100.0%	100.0%
210	Functional Communication Measure - Attention	6	15	10	6	100.0%	100.0%	100.0%	100.0%
211	Functional Communication Measure - Memory	10	21	9	12	100.0%	100.0%	100.0%	100.0%
212	Functional Communication Measure - Motor Speech	6	14	9	11	100.0%	100.0%	100.0%	100.0%
213	Functional Communication Measure - Reading	4	8	5	1	100.0%	100.0%	100.0%	100.0%
214	Functional Communication Measure - Spoken Language Expression	12	25	13	21	100.0%	100.0%	100.0%	100.0%
215	Functional Communication Measure - Writing	0	0	0	0	N/A	N/A	N/A	N/A
216	Functional Communication Measure - Swallowing	10	21	10	19	100.0%	100.0%	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	N/A	153	459	784	N/A	100.0%	100.0%	100.0%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	N/A	146	444	757	N/A	100.0%	100.0%	100.0%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	N/A	129	423	710	N/A	100.0%	100.0%	100.0%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	N/A	172	504	832	N/A	100.0%	100.0%	100.0%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	N/A	165	498	823	N/A	100.0%	100.0%	100.0%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	N/A	91	230	481	N/A	100.0%	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	N/A	155	442	751	N/A	100.0%	100.0%	100.0%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	N/A	1,806	1,957	3,544	N/A	97.6%	97.8%	98.5%
225	Radiology: Reminder System for Mammograms	N/A	26,858	24,176	21,678	N/A	20.3%	26.6%	41.7%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	682,002	648,514	604,015	N/A	5.6%	9.7%	13.7%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	N/A	213	192	1,022	N/A	30.0%	21.4%	83.0%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	86,880	79,262	69,917	N/A	0.3%	0.2%	0.9%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	86,846	79,261	69,733	N/A	0.1%	0.1%	0.3%
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	N/A	1	2	1	N/A	0.0%	50.0%	0.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	N/A	1	2	2	N/A	0.0%	50.0%	50.0%
236	Hypertension (HTN): Controlling High Blood Pressure	N/A	0	11,249	243,035	N/A	0.0%	100.0%	8.2%
237	Hypertension (HTN): Blood Pressure Measurement	N/A	227	12,114	4,519	N/A	100.0%	100.0%	100.0%
238	Drugs to be Avoided in the Elderly <sup>a</sup>	N/A	552	18,568	6,155	N/A	100.0%	100.0%	100.0%
239	Weight Assessment and Counseling for Children and Adolescents	N/A	52	115	36	N/A	100.0%	100.0%	100.0%
240	Childhood Immunization Status	N/A	11	5	1	N/A	100.0%	100.0%	100.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	253,286	225,460	N/A	N/A	5.3%	3.4%
242	Coronary Artery Disease (CAD): Symptom Management	N/A	N/A	510	26	N/A	N/A	100.0%	100.0%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	N/A	N/A	0	0	N/A	N/A	N/A	N/A
244	Hypertension: Blood Pressure Management	N/A	N/A	81	505	N/A	N/A	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	N/A	N/A	152,193	137,674	N/A	N/A	0.2%	0.4%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	N/A	N/A	152,193	137,674	N/A	N/A	0.2%	0.5%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	37,316	34,752	N/A	N/A	0.1%	0.3%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	87,976	83,675	N/A	N/A	0.1%	0.3%
249	Barrett's Esophagus	N/A	N/A	7,590	7,014	N/A	N/A	48.1%	58.0%
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	3,516	3,083	N/A	N/A	61.3%	70.4%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	4,987	4,614	N/A	N/A	52.8%	60.9%
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	25,106	22,999	N/A	N/A	7.8%	15.0%



Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	840	770	N/A	N/A	11.2%	20.9%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	10	8	N/A	N/A	20.0%	0.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	N/A	N/A	0	4	N/A	N/A	0.0%	100.0%
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	N/A	N/A	25	60	N/A	N/A	84.0%	96.7%
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	N/A	N/A	15	19	N/A	N/A	100.0%	84.2%
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	N/A	N/A	23	54	N/A	N/A	91.3%	87.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	N/A	N/A	28	70	N/A	N/A	100.0%	94.3%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	10,224	9,816	N/A	N/A	0.9%	10.4%
262	Image Confirmation of Successful Excision of Image–Localized Breast Lesion	N/A	N/A	8,243	7,021	N/A	N/A	2.1%	3.6%
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	8,747	7,441	N/A	N/A	2.1%	3.9%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	N/A	N/A	139	170	N/A	N/A	100.0%	100.0%
265	Biopsy Follow-Up	N/A	N/A	389	1,281	N/A	N/A	100.0%	98.9%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	78,554	73,131	N/A	N/A	0.4%	0.9%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	78,554	73,131	N/A	N/A	0.3%	0.6%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	18,471	17,026	N/A	N/A	0.3%	0.7%
303	Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery	N/A	N/A	0	5	N/A	N/A	0.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	N/A	N/A	12	4	N/A	N/A	100.0%	75.0%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	N/A	N/A	1,694	70	N/A	N/A	100.0%	100.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	N/A	N/A	0	0	N/A	N/A	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin	N/A	N/A	0	0	N/A	N/A	N/A	N/A
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	N/A	N/A	19,184	6,480	N/A	N/A	100.0%	100.0%
309	Cervical Cancer Screening	N/A	N/A	17,128	5,939	N/A	N/A	100.0%	100.0%
310	Chlamydia Screening for Women	N/A	N/A	688	281	N/A	N/A	100.0%	100.0%
311	Use of Appropriate Medications for Asthma	N/A	N/A	2,972	1,645	N/A	N/A	100.0%	100.0%
312	Low Back Pain: Use of Imaging Studies	N/A	N/A	3,106	1,144	N/A	N/A	100.0%	100.0%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	N/A	N/A	14,688	633	N/A	N/A	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	N/A	N/A	17,369	5,221	N/A	N/A	100.0%	100.0%
317	Preventive Care and Screening: Screening for High Blood Pressure	N/A	N/A	663,267	634,348	N/A	N/A	3.1%	4.0%
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	N/A	N/A	N/A	18,289	N/A	N/A	N/A	3.6%
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	N/A	N/A	N/A	701,240	N/A	N/A	N/A	0.4%
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients <sup>a</sup>	N/A	N/A	N/A	9	N/A	N/A	N/A	100.0%
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) <sup>a</sup>	N/A	N/A	N/A	9	N/A	N/A	N/A	100.0%

Measure Number	Measure Description	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals in 2013	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012	Reporting Rate in 2013
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients <sup>a</sup>	N/A	N/A	N/A	9	N/A	N/A	N/A	100.0%
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	N/A	N/A	N/A	5	N/A	N/A	N/A	100.0%
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	N/A	N/A	N/A	177,578	N/A	N/A	N/A	0.5%
327	Pediatric Kidney Disease: Adequacy of Volume Management	N/A	N/A	N/A	277	N/A	N/A	N/A	0.0%
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL <sup>a</sup>	N/A	N/A	N/A	336	N/A	N/A	N/A	0.6%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A26: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) These results are restricted to individual measures (i.e., excluded measures groups). (3) We only have eligibility information in claims; participation in non-claims measures (e.g., registry only measures) was used as a proxy for eligibility, which results in artificial 100% participation rates. (4) We applied the following hierarchy if an eligible professional participated in multiple methods: EHR, Claims 12-month, Registry 12-month, and Registry 6-month. For example, if an eligible professional participated in both claims and registry methods, the information from claims was used. (5) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.

**Table A27. Reporting and Performance Information by PQRS Individual Measure (2010 to 2013)**

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	80.6%	82.0%	82.7%	70.9%	21.9%	23.3%	21.4%	28.1%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	80.6%	82.4%	83.5%	72.7%	57.0%	55.6%	50.8%	48.3%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	79.9%	81.9%	83.4%	74.4%	58.6%	71.3%	69.7%	73.1%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	91.0%	98.0%	98.5%	99.8%	85.6%	79.7%	82.2%	83.5%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	77.1%	80.6%	88.5%	75.5%	85.3%	85.2%	69.9%	85.8%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	95.6%	97.2%	98.7%	98.9%	71.4%	82.1%	69.9%	74.2%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	91.7%	97.0%	96.9%	98.7%	82.7%	75.8%	86.8%	77.6%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	62.9%	67.8%	68.9%	54.7%	68.6%	71.4%	54.8%	63.2%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	74.5%	74.4%	73.5%	71.5%	95.2%	95.5%	95.4%	95.4%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	70.0%	70.9%	70.0%	68.4%	95.7%	94.2%	94.4%	92.5%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	68.9%	70.1%	77.8%	70.1%	97.0%	96.3%	96.0%	94.9%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	65.8%	66.9%	67.4%	67.9%	91.5%	93.1%	92.0%	91.2%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	73.9%	73.7%	76.1%	62.2%	92.6%	93.9%	95.5%	93.1%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	73.4%	74.6%	74.2%	64.8%	89.4%	92.3%	92.9%	90.7%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	71.9%	72.1%	72.5%	64.5%	93.4%	95.0%	95.5%	93.9%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	72.7%	74.5%	73.9%	66.3%	91.2%	94.4%	94.4%	92.0%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	68.8%	54.0%	57.2%	81.2%	50.6%	62.4%	62.8%	43.2%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	91.4%	88.9%	88.8%	91.4%	83.5%	85.3%	85.7%	88.1%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	78.5%	82.1%	83.8%	83.2%	92.0%	93.3%	93.8%	94.5%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	77.8%	80.3%	71.0%	80.0%	78.6%	82.8%	81.5%	84.7%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	65.4%	70.5%	68.3%	72.4%	82.8%	84.6%	83.1%	87.1%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	85.3%	90.6%	93.1%	99.9%	79.4%	83.5%	90.5%	93.4%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	74.6%	77.9%	77.5%	89.5%	84.3%	90.6%	72.6%	79.7%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	63.1%	68.9%	65.9%	72.5%	69.7%	72.8%	79.0%	86.6%



Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	71.4%	69.6%	83.8%	74.0%	55.1%	61.2%	37.3%	40.9%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	76.2%	56.3%	40.8%	69.4%	46.8%	70.6%	66.1%	41.4%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	79.6%	76.1%	62.2%	68.4%	72.5%	70.2%	77.1%	67.6%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	90.1%	90.6%	92.7%	89.0%	97.9%	98.3%	99.2%	98.6%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	90.8%	91.8%	93.6%	90.0%	92.0%	94.0%	95.9%	93.8%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	87.7%	87.4%	93.5%	93.2%	99.4%	99.0%	98.9%	99.5%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	65.7%	49.2%	22.3%	39.7%	91.3%	95.9%	96.4%	96.3%
47	Advance Care Plan	68.2%	67.3%	85.2%	75.8%	50.7%	54.6%	58.1%	53.0%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	54.8%	52.5%	82.9%	47.9%	66.5%	76.0%	68.0%	78.2%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	71.4%	70.3%	66.4%	65.0%	82.5%	85.2%	88.4%	91.6%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	70.3%	67.7%	63.3%	65.0%	82.7%	89.8%	96.7%	94.5%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	74.0%	66.9%	58.9%	57.3%	56.0%	68.3%	69.4%	53.4%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	74.2%	62.9%	54.3%	57.2%	89.7%	73.4%	98.5%	97.0%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	94.3%	87.3%	78.1%	82.0%	81.7%	69.1%	92.9%	89.4%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	87.7%	88.8%	88.7%	90.4%	95.1%	95.0%	95.1%	95.6%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	90.6%	91.3%	78.7%	90.8%	96.4%	96.6%	96.9%	96.9%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	89.2%	90.5%	87.2%	90.6%	95.0%	95.7%	96.8%	97.2%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	86.5%	89.4%	83.9%	90.4%	92.4%	93.2%	94.6%	94.7%
64	Asthma: Assessment of Asthma Control	89.3%	83.1%	97.7%	86.3%	48.6%	40.6%	41.6%	18.8%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	100.0%	99.0%	100.0%	98.9%	85.7%	93.9%	60.0%	81.4%
66	Appropriate Testing for Children with Pharyngitis	100.0%	99.3%	0.0%	100.0%	100.0%	100.0%	0.0%	74.7%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	73.7%	74.0%	74.2%	77.1%	88.8%	94.6%	95.6%	87.0%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	69.3%	71.1%	71.6%	78.9%	94.7%	97.7%	95.3%	83.1%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	75.9%	76.4%	76.3%	80.1%	81.7%	89.5%	90.4%	88.3%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	77.9%	78.4%	80.2%	80.6%	88.3%	95.3%	95.4%	96.3%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	69.0%	64.6%	65.8%	65.1%	90.6%	94.0%	91.6%	92.4%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	67.6%	66.1%	66.4%	65.6%	93.2%	93.7%	94.3%	92.3%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	80.4%	82.9%	83.4%	83.8%	77.4%	81.3%	82.6%	82.8%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	100.0%	100.0%	0.0%	100.0%	6.7%	94.4%	0.0%	98.8%
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	100.0%	0.0%	100.0%	100.0%	10.0%	0.0%	93.5%	98.2%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	98.7%	97.7%	92.5%	100.0%	34.8%	23.9%	95.1%	98.9%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	79.6%	68.3%	63.9%	73.8%	86.1%	89.9%	94.7%	90.8%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	77.7%	65.9%	68.5%	75.6%	88.4%	93.5%	96.2%	91.6%
86	Hepatitis C: Antiviral Treatment Prescribed	84.0%	77.0%	62.6%	74.4%	41.2%	45.8%	70.2%	57.4%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	80.2%	67.0%	61.8%	79.5%	78.5%	85.8%	93.1%	86.4%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	75.8%	75.2%	62.3%	72.9%	59.4%	60.3%	82.7%	69.9%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	83.1%	64.0%	59.5%	80.9%	70.2%	91.5%	82.4%	89.1%
91	Acute Otitis Externa (AOE): Topical Therapy	82.7%	85.1%	86.1%	85.2%	73.8%	83.7%	83.9%	85.0%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	81.3%	85.8%	87.8%	86.9%	63.3%	78.2%	73.9%	79.4%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	80.7%	82.3%	84.4%	82.8%	97.5%	96.8%	97.4%	97.7%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	87.4%	87.6%	86.0%	88.4%	98.5%	98.0%	97.8%	98.1%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	72.8%	69.6%	66.6%	64.3%	71.6%	90.5%	92.5%	88.5%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	72.6%	67.6%	70.0%	66.1%	79.6%	93.5%	91.1%	95.4%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	69.6%	74.9%	73.7%	62.8%	77.3%	78.4%	72.3%	69.1%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	72.0%	73.8%	70.0%	58.0%	80.8%	82.3%	77.0%	76.7%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	70.2%	76.1%	65.3%	71.9%	79.9%	70.2%	74.9%	73.0%
109	Osteoarthritis (OA): Function and Pain Assessment	63.9%	40.0%	38.4%	38.4%	51.7%	80.1%	84.1%	84.1%
110	Preventive Care and Screening: Influenza Immunization	72.2%	76.9%	77.6%	65.6%	51.2%	50.4%	43.9%	46.8%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	75.8%	80.8%	82.8%	76.8%	54.5%	58.1%	53.4%	48.6%
112	Preventive Care and Screening: Screening Mammography	76.6%	78.0%	84.6%	78.0%	53.5%	58.2%	55.0%	44.0%
113	Preventive Care and Screening: Colorectal Cancer Screening	73.0%	76.4%	83.4%	76.1%	52.0%	53.9%	49.8%	39.8%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	81.7%	67.6%	52.4%	56.1%	42.3%	44.1%	42.3%	53.6%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	66.9%	65.8%	80.9%	66.7%	79.7%	80.3%	85.9%	72.9%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	90.3%	97.1%	93.9%	98.2%	67.2%	63.5%	64.0%	70.0%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	78.5%	77.5%	88.0%	74.2%	74.0%	78.7%	81.0%	81.7%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	89.3%	87.1%	61.9%	59.2%	40.0%	45.3%	66.6%	59.6%
122	Adult Kidney Disease: Blood Pressure Management	84.3%	80.1%	63.9%	66.4%	58.2%	65.6%	87.2%	82.1%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	54.1%	53.6%	43.3%	59.4%	94.8%	95.0%	20.9%	17.2%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	59.5%	55.0%	51.6%	51.5%	74.2%	86.6%	84.1%	76.6%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	54.7%	53.3%	42.1%	48.8%	66.9%	69.2%	88.7%	68.1%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	55.0%	65.5%	76.9%	71.3%	60.2%	59.9%	57.5%	57.8%
130	Documentation of Current Medications in the Medical Record	69.2%	70.5%	68.9%	57.6%	74.7%	85.7%	85.6%	88.0%
131	Pain Assessment and Follow-Up	73.5%	73.6%	63.2%	63.2%	97.3%	94.8%	86.9%	85.7%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	73.0%	79.5%	31.2%	32.4%	84.2%	82.6%	65.2%	71.0%
137	Melanoma: Continuity of Care – Recall System	99.9%	99.8%	99.9%	99.9%	78.2%	96.0%	97.3%	97.2%
138	Melanoma: Coordination of Care	99.9%	99.5%	100.0%	99.9%	87.7%	94.0%	93.8%	93.7%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	63.0%	64.9%	65.3%	64.5%	92.1%	91.3%	91.6%	90.8%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	58.6%	60.8%	60.4%	61.2%	94.2%	95.8%	95.8%	97.2%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	61.1%	44.1%	59.7%	63.5%	61.6%	82.7%	69.1%	75.2%
143	Oncology: Medical and Radiation – Pain Intensity Quantified	99.9%	99.1%	99.0%	83.1%	31.8%	79.2%	81.6%	82.7%
144	Oncology: Medical and Radiation – Plan of Care for Pain	100.0%	100.0%	99.6%	100.0%	90.0%	91.2%	92.1%	93.5%



Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	77.7%	78.3%	81.6%	80.5%	48.1%	54.1%	57.6%	65.1%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>a</sup>	83.3%	85.5%	86.2%	87.0%	1.1%	1.5%	0.9%	0.9%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	82.3%	83.9%	84.5%	86.4%	54.8%	56.2%	59.0%	66.9%
154	Falls: Risk Assessment	62.7%	61.3%	59.2%	62.6%	91.9%	81.9%	85.5%	81.9%
155	Falls: Plan of Care	87.0%	86.8%	85.5%	86.0%	88.0%	87.2%	91.2%	91.1%
156	Oncology: Radiation Dose Limits to Normal Tissues	73.9%	72.9%	76.1%	76.4%	93.2%	95.8%	96.6%	97.7%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	80.9%	73.9%	64.4%	67.7%	81.6%	88.0%	92.6%	92.8%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	99.6%	98.2%	99.5%	99.7%	83.9%	92.2%	95.8%	96.6%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	99.6%	99.2%	98.9%	89.7%	75.8%	75.8%	80.1%	76.7%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	97.7%	98.9%	98.6%	98.3%	97.2%	96.4%	99.3%	99.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	98.5%	98.9%	98.7%	99.0%	75.5%	88.3%	95.1%	76.7%
163	Diabetes Mellitus: Foot Exam	59.0%	62.9%	85.2%	64.7%	72.1%	77.0%	67.3%	57.4%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a</sup>	100.0%	100.0%	100.0%	100.0%	93.9%	10.0%	9.6%	0.0%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a</sup>	99.8%	100.0%	70.0%	100.0%	78.9%	7.5%	8.3%	0.0%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a</sup>	99.7%	100.0%	100.0%	100.0%	63.6%	33.3%	4.2%	0.0%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a</sup>	100.0%	100.0%	100.0%	100.0%	100.0%	60.0%	5.0%	0.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>	100.0%	100.0%	86.7%	100.0%	94.1%	3.3%	2.3%	2.9%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	91.3%	100.0%	100.0%	100.0%	37.5%	97.2%	100.0%	96.9%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	88.3%	100.0%	100.0%	100.0%	33.2%	57.1%	100.0%	99.7%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	93.1%	100.0%	100.0%	100.0%	28.4%	71.4%	100.0%	80.6%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	71.2%	76.6%	79.1%	76.8%	94.6%	95.9%	95.8%	94.8%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	50.3%	58.2%	86.8%	69.5%	63.2%	86.6%	74.5%	75.5%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	56.9%	52.4%	51.2%	69.2%	85.7%	75.7%	81.1%	66.2%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	59.7%	50.3%	47.3%	62.6%	61.6%	91.3%	92.4%	90.4%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	60.9%	49.8%	50.1%	63.7%	62.2%	89.8%	92.8%	87.7%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	59.9%	43.1%	44.5%	64.5%	55.5%	88.0%	89.6%	86.9%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	60.8%	58.8%	45.9%	62.8%	95.9%	96.0%	99.9%	99.7%
181	Elder Maltreatment Screen and Follow-Up Plan	74.0%	69.7%	14.8%	42.5%	55.3%	96.7%	90.8%	36.2%
182	Functional Outcome Assessment	50.2%	54.7%	52.9%	59.5%	76.6%	78.7%	80.9%	94.9%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	83.3%	78.7%	66.5%	74.0%	47.3%	54.6%	62.7%	42.5%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	83.4%	78.7%	65.1%	73.3%	51.6%	61.6%	67.4%	45.3%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	73.5%	72.3%	71.1%	67.0%	92.5%	96.1%	97.3%	96.8%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	100.0%	100.0%	100.0%	99.5%	83.3%	100.0%	100.0%	94.9%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	74.4%	66.7%	70.8%	79.1%	100.0%	78.6%	100.0%	85.2%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	98.5%	99.2%	100.0%	100.0%	90.6%	94.8%	92.0%	95.1%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	100.0%	99.1%	100.0%	99.9%	3.4%	4.4%	5.2%	23.4%
193	Perioperative Temperature Management	67.0%	73.0%	77.9%	75.9%	85.3%	87.9%	90.4%	90.8%
194	Oncology: Cancer Stage Documented	71.6%	68.8%	68.2%	57.3%	85.6%	86.3%	93.2%	73.6%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	75.3%	79.9%	82.7%	82.6%	59.5%	61.7%	66.1%	76.2%
197	Coronary Artery Disease (CAD): Lipid Control	97.9%	99.8%	99.7%	99.9%	75.3%	82.2%	42.7%	21.5%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	99.1%	99.6%	98.3%	99.7%	45.6%	61.1%	38.3%	34.2%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	100.0%	100.0%	100.0%	100.0%	72.1%	52.4%	63.4%	83.3%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	86.1%	82.4%	89.5%	85.2%	76.1%	77.7%	70.8%	68.4%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	83.7%	79.9%	88.9%	81.1%	74.7%	79.6%	63.2%	68.7%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	96.4%	94.5%	90.1%	98.8%	32.4%	79.0%	68.3%	17.0%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	96.2%	95.5%	96.1%	100.0%	50.3%	79.3%	52.3%	77.5%
209	Functional Communication Measure - Spoken Language Comprehension	80.8%	100.0%	100.0%	100.0%	58.8%	70.8%	73.6%	36.7%
210	Functional Communication Measure - Attention	88.9%	100.0%	100.0%	100.0%	58.3%	56.6%	79.3%	25.0%
211	Functional Communication Measure - Memory	83.0%	100.0%	100.0%	100.0%	55.5%	69.0%	73.0%	45.8%
212	Functional Communication Measure - Motor Speech	81.5%	100.0%	100.0%	100.0%	66.7%	77.4%	92.5%	63.6%
213	Functional Communication Measure - Reading	87.5%	100.0%	100.0%	100.0%	58.3%	95.0%	100.0%	100.0%
214	Functional Communication Measure - Spoken Language Expression	77.6%	100.0%	100.0%	100.0%	45.8%	77.4%	63.1%	70.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
215	Functional Communication Measure - Writing	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
216	Functional Communication Measure - Swallowing	84.7%	100.0%	100.0%	100.0%	73.6%	72.7%	58.3%	55.3%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	N/A	100.0%	100.0%	100.0%	N/A	71.7%	71.5%	78.9%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	N/A	100.0%	100.0%	100.0%	N/A	68.8%	60.6%	75.2%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	N/A	100.0%	100.0%	100.0%	N/A	61.2%	48.9%	72.0%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	N/A	100.0%	100.0%	100.0%	N/A	67.0%	57.4%	71.7%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	N/A	100.0%	100.0%	100.0%	N/A	68.9%	59.3%	75.2%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	N/A	100.0%	100.0%	100.0%	N/A	69.7%	56.6%	68.9%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	N/A	100.0%	100.0%	100.0%	N/A	63.7%	52.7%	66.6%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	N/A	100.0%	99.9%	99.8%	N/A	95.0%	99.2%	99.0%
225	Radiology: Reminder System for Mammograms	N/A	74.5%	80.4%	83.2%	N/A	68.5%	74.6%	81.6%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	65.4%	75.4%	70.4%	N/A	81.6%	84.1%	89.7%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	N/A	99.8%	94.9%	99.8%	N/A	93.3%	95.5%	69.1%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	65.1%	61.0%	79.7%	N/A	85.0%	92.6%	90.6%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	59.8%	58.0%	59.0%	N/A	80.7%	75.4%	74.8%
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	N/A	0.0%	100.0%	0.0%	N/A	0.0%	100.0%	0.0%
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	N/A	0.0%	100.0%	100.0%	N/A	0.0%	100.0%	100.0%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
236	Hypertension (HTN): Controlling High Blood Pressure	N/A	0.0%	100.0%	83.1%	N/A	0.0%	66.8%	68.5%
237	Hypertension (HTN): Blood Pressure Measurement	N/A	100.0%	100.0%	100.0%	N/A	0.0%	95.8%	95.9%
238	Drugs to be Avoided in the Elderly <sup>a</sup>	N/A	100.0%	100.0%	100.0%	N/A	3.5%	8.1%	9.0%
239	Weight Assessment and Counseling for Children and Adolescents	N/A	100.0%	100.0%	100.0%	N/A	57.1%	0.0%	0.0%
240	Childhood Immunization Status	N/A	100.0%	100.0%	100.0%	N/A	0.0%	0.0%	0.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	89.4%	75.2%	N/A	N/A	49.7%	35.9%
242	Coronary Artery Disease (CAD): Symptom Management	N/A	N/A	100.0%	89.2%	N/A	N/A	0.0%	99.9%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
244	Hypertension: Blood Pressure Management	N/A	N/A	100.0%	100.0%	N/A	N/A	61.9%	61.2%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	N/A	N/A	30.5%	57.4%	N/A	N/A	87.4%	88.7%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	N/A	N/A	28.9%	54.2%	N/A	N/A	77.6%	84.1%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	78.1%	75.5%	N/A	N/A	95.9%	92.9%



Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	60.9%	58.5%	N/A	N/A	88.0%	83.8%
249	Barrett's Esophagus	N/A	N/A	81.2%	83.5%	N/A	N/A	98.8%	98.8%
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	89.1%	91.3%	N/A	N/A	99.1%	99.1%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	79.0%	81.3%	N/A	N/A	97.5%	98.3%
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	88.0%	94.5%	N/A	N/A	84.8%	90.7%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	99.5%	98.9%	N/A	N/A	74.7%	94.1%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	100.0%	0.0%	N/A	N/A	100.0%	0.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	N/A	N/A	0.0%	100.0%	N/A	N/A	0.0%	100.0%
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	N/A	N/A	55.1%	85.4%	N/A	N/A	81.3%	78.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	N/A	N/A	83.2%	90.6%	N/A	N/A	54.4%	36.5%
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	N/A	N/A	80.4%	80.5%	N/A	N/A	74.0%	78.7%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	N/A	N/A	90.7%	93.0%	N/A	N/A	85.5%	82.6%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	43.4%	58.5%	N/A	N/A	81.4%	87.6%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	N/A	N/A	88.1%	82.4%	N/A	N/A	97.1%	97.5%
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	85.7%	84.5%	N/A	N/A	98.4%	97.2%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	N/A	N/A	100.0%	100.0%	N/A	N/A	95.1%	94.5%
265	Biopsy Follow-Up	N/A	N/A	99.7%	99.8%	N/A	N/A	92.5%	93.2%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	44.7%	45.4%	N/A	N/A	95.4%	95.2%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	44.3%	45.1%	N/A	N/A	95.2%	91.4%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	52.4%	52.6%	N/A	N/A	89.8%	88.5%
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	N/A	N/A	0.0%	100.0%	N/A	N/A	0.0%	99.9%
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	N/A	N/A	100.0%	100.0%	N/A	N/A	100.0%	95.0%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	N/A	N/A	100.0%	100.0%	N/A	N/A	0.0%	0.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	N/A	N/A	100.0%	100.0%	N/A	N/A	9.2%	12.5%
309	Cervical Cancer Screening	N/A	N/A	100.0%	100.0%	N/A	N/A	41.7%	24.1%
310	Chlamydia Screening for Women	N/A	N/A	100.0%	100.0%	N/A	N/A	93.7%	84.2%
311	Use of Appropriate Medications for Asthma	N/A	N/A	100.0%	100.0%	N/A	N/A	89.1%	81.4%
312	Low Back Pain: Use of Imaging Studies	N/A	N/A	100.0%	100.0%	N/A	N/A	38.0%	53.8%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	N/A	N/A	100.0%	100.0%	N/A	N/A	58.2%	59.8%
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	N/A	N/A	100.0%	100.0%	N/A	N/A	52.8%	22.5%
317	Preventive Care and Screening: Screening for High Blood Pressure	N/A	N/A	76.5%	77.8%	N/A	N/A	87.2%	72.9%
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	N/A	N/A	N/A	37.5%	N/A	N/A	N/A	87.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Percent of Instances Reported in 2013	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012	Average Performance Rate in 2013
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	N/A	N/A	N/A	61.7%	N/A	N/A	N/A	97.9%
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	3.0%
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	8.5%
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	22.8%
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	100.0%
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	N/A	N/A	N/A	32.7%	N/A	N/A	N/A	96.7%
327	Pediatric Kidney Disease: Adequacy of Volume Management	N/A	N/A	N/A	0.0%	N/A	N/A	N/A	0.0%
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL <sup>a</sup>	N/A	N/A	N/A	75.0%	N/A	N/A	N/A	67.3%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A27: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) These results are restricted to individual measures (i.e., excluded measures groups). (3) We applied the following hierarchy if an EP participated in multiple methods: EHR, Claims 12-month, Registry 12-month, and Registry 6-month. For example, if an EP participated in both claims and registry methods, the information from claims was used. (4) The percent of instances reported was calculated as the count of reported instances (numerator) divided by the count of eligible instances (denominator) from the method selected according to the hierarchy. (5) The performance rate was calculated as the count of reported instances where performance was met (numerator) divided by the total number of reported instances that excluded reported exclusions (i.e., performance denominator). (6) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.

**Table A28. PQRS Individual Measure Reporting Consistency Across Program Years (2013)**

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
1	Diabetes Mellitus: Hemoglobin A1c Poor Control	1,317	2,756	6,149	17,927	2.2	1.8
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	1,175	2,167	5,720	16,428	2.2	1.8
3	Diabetes Mellitus: High Blood Pressure Control	785	2,145	4,986	15,111	2.0	1.6
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	102	117	485	2,338	1.4	0.9
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	584	1,079	3,270	9,410	1.9	1.6
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	29	90	651	3,149	1.3	0.6
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	47	43	118	954	1.4	1.0
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	65	190	738	2,921	1.5	1.0
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	1,219	1,799	2,192	4,568	3.5	2.3
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	1,333	1,772	1,984	4,501	3.6	2.3
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	758	1,201	1,468	3,281	3.5	2.3

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	414	744	953	2,253	3.1	2.2
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	356	408	649	2,595	2.8	2.2
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	441	476	632	2,244	3.2	2.3
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	367	377	552	1,815	3.1	2.3
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	458	454	570	1,762	3.3	2.3
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	37	61	100	1,101	1.8	1.6
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	1,260	2,041	4,876	8,413	2.6	1.9
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	4,379	5,750	7,544	13,233	3.4	2.2
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	370	583	1,934	6,102	1.6	1.1
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	337	408	1,063	2,991	1.8	1.2



Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	33	35	97	272	1.6	0.9
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	87	206	2,923	4,035	1.6	0.8
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	271	366	1,051	2,899	1.7	1.2
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	650	956	5,872	12,682	1.7	1.1
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	29	54	196	685	1.7	1.4
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	208	260	678	2,851	1.9	1.5
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	115	107	118	221	3.9	2.2
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	87	101	112	199	3.6	2.2
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	67	67	91	170	3.4	2.1
46	Medication Reconciliation	31	142	403	5,649	1.1	0.4
47	Advance Care Plan	1,057	1,658	6,084	17,428	1.6	1.1
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	652	919	2,396	6,633	1.9	1.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	183	256	365	1,163	2.4	1.8
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	210	281	402	1,600	2.2	1.7
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	224	334	969	2,682	1.9	1.5
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	63	118	470	2,327	1.5	1.2
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	17	136	205	1,382	1.3	0.8
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	2,823	4,822	8,405	14,577	3.1	2.2
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	1,868	2,841	4,987	12,943	2.9	2.2
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	2,688	3,678	10,184	13,969	2.9	2.1
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	1,874	2,629	8,167	11,946	2.7	2.0
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	11	47	223	1,229	1.3	0.6
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	0	1	9	30	1.3	0.5
66	Appropriate Testing for Children with Pharyngitis	0	0	0	26	1.0	0.0
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	125	124	153	557	3.1	2.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	76	84	131	660	2.5	2.0
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	111	163	176	816	2.9	2.2
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	109	185	156	597	3.3	2.3
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	134	174	325	1,197	2.5	2.1
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	139	116	180	772	2.6	2.1
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	2,769	2,066	2,576	6,089	2.9	1.8
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	0	0	0	14	1.0	0.0
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	0	0	0	3	1.0	0.0
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	0	1	0	29	1.1	0.4
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	38	33	81	404	1.7	1.3
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	36	30	73	350	1.8	1.3
86	Hepatitis C: Antiviral Treatment Prescribed	32	42	72	347	1.7	1.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	36	20	51	215	1.8	1.3
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	60	65	170	817	1.6	1.1
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	11	16	13	195	1.4	1.0
91	Acute Otitis Externa (AOE): Topical Therapy	60	123	676	2,884	1.3	0.7
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	51	98	522	2,400	1.3	0.7
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	307	315	543	810	4.0	2.1
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	261	269	442	750	3.9	2.1
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	39	68	82	315	2.2	1.6
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	41	64	80	281	2.3	1.7
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	27	27	141	1,206	1.3	0.8
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	50	50	210	2,311	1.3	0.9
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	98	113	421	1,783	1.7	1.3

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
109	Osteoarthritis (OA): Function and Pain Assessment	97	191	403	1,294	1.9	1.4
110	Preventive Care and Screening: Influenza Immunization	1,165	3,370	10,125	26,402	1.6	1.0
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	1,305	3,669	11,926	30,266	1.6	1.0
112	Preventive Care and Screening: Breast Cancer Screening	720	2,259	8,727	26,506	1.5	0.9
113	Preventive Care and Screening: Colorectal Cancer Screening	991	2,750	9,220	26,565	1.6	1.0
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	18	26	78	503	1.3	0.7
117	Diabetes Mellitus: Dilated Eye Exam	1,718	2,946	5,090	11,651	2.5	1.7
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	23	52	225	1,043	1.4	0.8
119	Diabetes Mellitus: Medical Attention for Nephropathy	422	1,235	3,713	10,356	1.6	1.1
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	55	92	327	2,217	1.4	0.9
122	Adult Kidney Disease: Blood Pressure Management	26	88	189	616	1.8	1.3
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	39	65	87	1,219	1.5	1.1
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	636	885	1,096	7,047	1.7	1.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	381	634	736	4,788	1.7	1.2
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	1,044	3,928	12,656	48,259	1.4	0.8
130	Documentation of Current Medications in the Medical Record	3,513	9,249	17,294	75,293	1.6	1.0
131	Pain Assessment and Follow-Up	777	1,773	5,252	38,060	1.4	1.0
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	128	120	1,208	6,020	1.3	0.7
137	Melanoma: Continuity of Care - Recall System	222	322	374	1,744	2.1	1.5
138	Melanoma: Coordination of Care	347	359	372	1,501	2.1	1.4
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	1,420	1,898	1,938	3,671	2.8	1.6
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	758	1,142	1,156	1,933	2.7	1.5
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	181	350	909	2,359	1.7	1.1
143	Oncology: Medical and Radiation - Pain Intensity Quantified	1	14	8	68	1.5	1.0
144	Oncology: Medical and Radiation - Plan of Care for Pain	0	13	4	33	1.6	0.9
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	2,455	2,250	2,762	5,335	2.8	1.6

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	1,620	1,665	1,505	2,901	3.0	1.6
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	1,505	1,510	1,464	2,642	2.9	1.6
154	Falls: Risk Assessment	875	1,902	4,032	19,529	1.7	1.2
155	Falls: Plan of Care	504	1,173	1,943	9,265	1.7	1.2
156	Oncology: Radiation Dose Limits to Normal Tissues	53	80	81	228	2.5	1.6
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	0	6	6	25	1.7	1.1
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	5	9	2	20	3.1	1.7
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	1	2	2	8	3.5	1.8
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	4	8	1	15	3.1	1.7
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	4	7	2	32	2.7	1.8
163	Diabetes Mellitus: Foot Exam	680	1,622	3,720	11,631	1.6	1.0
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	0	0	2	0	2.0	0.0
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	0	0	0	0	0.0	0.0
166	Coronary Artery Bypass Graft (CABG): Stroke	0	0	0	0	0.0	0.0
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	0	0	2	0	2.0	0.0

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	0	3	1	0	2.8	0.5
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	0	3	1	9	1.5	0.9
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	0	0	1	9	1.1	0.3
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	0	0	1	9	1.1	0.3
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	37	17	37	106	2.5	1.6
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	724	1,484	3,333	19,347	1.4	0.8
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	63	45	145	688	1.6	1.1
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	74	57	163	623	1.7	1.1
178	Rheumatoid Arthritis (RA): Functional Status Assessment	71	58	213	873	1.6	1.1
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	55	38	133	530	1.6	1.1
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	59	53	155	543	1.7	1.1
181	Elder Maltreatment Screen and Follow-Up Plan	1	3	110	1,825	1.1	0.3
182	Functional Outcome Assessment	91	236	2,440	23,512	1.1	0.4
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	36	56	118	465	1.7	1.1



Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	26	45	119	465	1.7	1.2
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	129	182	173	558	2.5	1.6
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	0	0	48	1.1	0.4
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	0	0	2	69	1.0	0.2
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	18	36	31	53	2.1	1.1
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	11	15	13	38	2.0	1.1
193	Perioperative Temperature Management	8,484	6,639	7,292	17,016	2.2	1.2
194	Oncology: Cancer Stage Documented	493	405	469	2,514	1.7	1.1
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	6,716	1,951	2,781	4,674	2.7	1.3
197	Coronary Artery Disease (CAD): Lipid Control	26	86	775	3,576	1.2	0.5
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	28	37	308	785	1.4	0.7
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	2	1	5	11	1.7	1.0
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	385	938	3,859	11,142	1.4	0.7

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	516	1,101	4,859	11,227	1.5	0.7
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	0	0	6	34	1.2	0.4
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	0	0	6	7	1.5	0.5
209	Functional Communication Measure - Spoken Language Comprehension	0	3	0	6	1.7	1.0
210	Functional Communication Measure - Attention	0	1	2	2	1.8	0.8
211	Functional Communication Measure - Memory	1	1	0	9	1.5	1.0
212	Functional Communication Measure - Motor Speech	0	1	1	8	1.3	0.7
213	Functional Communication Measure - Reading	0	0	1	0	2.0	0.0
214	Functional Communication Measure - Spoken Language Expression	1	3	1	15	1.5	0.9
215	Functional Communication Measure - Writing	0	0	0	0	N/A	N/A
216	Functional Communication Measure - Swallowing	1	3	1	12	1.6	1.0
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	N/A	95	300	389	1.6	0.7
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	N/A	93	277	386	1.6	0.7
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	N/A	75	251	380	1.6	0.7

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	N/A	107	323	394	1.7	0.7
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	N/A	101	323	397	1.6	0.7
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	N/A	39	100	338	1.4	0.6
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	N/A	94	244	412	1.6	0.7
224	Melanoma: Overutilization of Imaging Studies in Melanoma	N/A	1,039	443	1,836	1.8	0.9
225	Radiology: Reminder System for Mammograms	N/A	3,671	1,647	3,562	2.0	0.9
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	12,515	20,063	48,436	1.6	0.7
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	N/A	5	9	832	1.0	0.2
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	28	63	543	1.2	0.5
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	13	23	157	1.3	0.6
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	N/A	0	0	0	N/A	N/A

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	N/A	0	0	1	1.0	0.0
236	Hypertension (HTN): Controlling High Blood Pressure	N/A	0	3,000	16,943	1.2	0.4
237	Hypertension (HTN): Blood Pressure Measurement	N/A	22	1,570	2,920	1.4	0.5
238	Drugs to be Avoided in the Elderly	N/A	92	1,517	4,540	1.3	0.5
239	Weight Assessment and Counseling for Children and Adolescents	N/A	0	2	34	1.1	0.2
240	Childhood Immunization Status	N/A	0	0	1	1.0	0.0
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	2,819	4,816	1.4	0.5
242	Coronary Artery Disease (CAD): Symptom Management	N/A	N/A	1	25	1.0	0.2
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	N/A	N/A	0	0	N/A	N/A
244	Hypertension: Blood Pressure Management	N/A	N/A	2	503	1.0	0.1
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	N/A	N/A	183	371	1.3	0.5
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	N/A	N/A	215	476	1.3	0.5
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	7	110	1.1	0.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	34	231	1.1	0.3
249	Barrett's Esophagus	N/A	N/A	2,768	1,298	1.7	0.5
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	1,313	856	1.6	0.5
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	1,979	829	1.7	0.5
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	973	2,466	1.3	0.5
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	12	149	1.1	0.3
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	0	0	N/A	N/A
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	N/A	N/A	0	4	1.0	0.0
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	N/A	N/A	10	48	1.2	0.4
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	N/A	N/A	6	10	1.4	0.5
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	N/A	N/A	8	39	1.2	0.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	N/A	N/A	15	51	1.2	0.4
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	67	953	1.1	0.2
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	N/A	N/A	102	151	1.4	0.5
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	108	180	1.4	0.5
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	N/A	N/A	78	92	1.5	0.5
265	Biopsy Follow-Up	N/A	N/A	194	1,073	1.2	0.4
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	168	495	1.3	0.4
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	119	326	1.3	0.4
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	36	91	1.3	0.5
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	N/A	N/A	0	5	1.0	0.0
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	N/A	N/A	0	3	1.0	0.0
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	N/A	N/A	15	55	1.2	0.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	N/A	N/A	0	0	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin	N/A	N/A	0	0	N/A	N/A
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	N/A	N/A	2,042	4,438	1.3	0.5
309	Cervical Cancer Screening	N/A	N/A	1,723	4,216	1.3	0.5
310	Chlamydia Screening for Women	N/A	N/A	52	229	1.2	0.4
311	Use of Appropriate Medications for Asthma	N/A	N/A	180	1,465	1.1	0.3
312	Low Back Pain: Use of Imaging Studies	N/A	N/A	127	1,017	1.1	0.3
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	N/A	N/A	141	492	1.2	0.4
316	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL.	N/A	N/A	2,047	3,174	1.4	0.5
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	N/A	N/A	7,906	17,438	1.3	0.5
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	N/A	N/A	N/A	667	1.0	0.0
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	N/A	N/A	N/A	3,034	1.0	0.0

Measure Number	Measure Description	Participating EPs Reporting Individually 2010 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2012 to 2013 <sup>a</sup>	Participating EPs Reporting Individually 2013 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	N/A	N/A	N/A	9	1.0	0.0
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	N/A	N/A	N/A	9	1.0	0.0
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients	N/A	N/A	N/A	9	1.0	0.0
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	N/A	N/A	N/A	5	1.0	0.0
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	N/A	N/A	N/A	962	1.0	0.0
327	Pediatric Kidney Disease: Adequacy of Volume Management	N/A	N/A	N/A	0	N/A	N/A
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL	N/A	N/A	N/A	2	1.0	0.0
Total	--	25,378	35,298	60,744	180,585	N/A	N/A

<sup>a</sup> This section describes continuous participation. Therefore, if an eligible professional participated in multiple years, but not continuously (e.g., 2010 and 2012, but not 2011) they were not included in this section.

<sup>b</sup> This section describes all eligible professionals who participated in the measure in program year 2013.

Notes for Table A28: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative; (2) These results are restricted to individual measures (i.e., excluded measures groups).



**Table A29. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Four Years (2010 to 2013)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	5,616	20.8%	18.2%	19.2%	20.9%	-0.1%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	5,236	57.7%	59.1%	59.2%	57.9%	0.1%
3	Diabetes Mellitus: High Blood Pressure Control	3,365	57.9%	74.3%	74.8%	74.5%	8.8%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	150	91.6%	93.4%	86.8%	91.3%	-0.1%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	2,103	90.4%	92.4%	85.5%	90.5%	0.0%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	56	89.4%	97.6%	94.4%	93.5%	1.5%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	84	91.1%	89.8%	96.1%	88.3%	-1.0%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	192	96.7%	96.2%	95.6%	95.9%	-0.3%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	6,813	96.4%	96.7%	96.8%	96.7%	0.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	7,101	97.2%	97.3%	97.1%	96.4%	-0.3%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	4,550	98.1%	98.0%	97.8%	97.8%	-0.1%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	2,214	92.7%	92.9%	92.5%	92.7%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	1,728	96.5%	96.6%	96.5%	96.2%	-0.1%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	2,272	94.9%	95.2%	95.4%	95.4%	0.2%
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	1,732	96.3%	96.1%	96.5%	95.9%	-0.1%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2,019	96.5%	96.6%	96.4%	96.0%	-0.2%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	185	64.1%	64.7%	61.8%	54.2%	-5.5%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	4,983	83.9%	85.4%	85.6%	87.4%	1.4%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	19,874	92.4%	93.4%	94.1%	94.9%	0.9%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	679	83.4%	84.3%	88.9%	94.0%	4.1%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	568	82.8%	84.9%	84.3%	90.1%	2.9%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	33	69.7%	74.6%	96.2%	98.1%	12.1%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	188	92.7%	90.2%	88.9%	94.0%	0.4%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	458	71.6%	76.5%	81.0%	88.4%	7.3%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	1,564	68.7%	69.3%	69.0%	69.0%	0.2%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	102	55.7%	58.1%	53.0%	50.2%	-3.4%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	631	87.0%	88.3%	86.9%	84.5%	-1.0%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	509	99.1%	99.1%	99.2%	99.0%	0.0%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	387	94.1%	95.7%	96.2%	96.5%	0.9%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	286	99.6%	99.7%	99.0%	99.7%	0.0%
46	Medication Reconciliation	31	93.9%	92.7%	97.1%	98.9%	1.8%
47	Advance Care Plan	1,877	59.0%	61.6%	59.4%	60.1%	0.6%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	1,477	88.1%	89.6%	89.7%	90.5%	0.9%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	555	96.7%	96.8%	97.5%	97.5%	0.3%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	567	96.9%	97.8%	97.8%	98.3%	0.5%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	593	83.4%	84.7%	84.0%	84.6%	0.5%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	187	98.7%	98.8%	98.8%	97.6%	-0.4%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	36	87.5%	91.7%	84.0%	85.5%	-0.8%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	14,283	96.0%	96.1%	96.1%	96.4%	0.1%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	9,763	96.7%	96.9%	97.0%	97.3%	0.2%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	12,418	96.8%	97.2%	97.3%	97.7%	0.3%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	8,240	94.7%	94.7%	95.5%	96.0%	0.5%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	22	45.5%	44.3%	39.4%	43.9%	-1.1%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	540	94.5%	95.0%	95.9%	95.3%	0.3%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	381	97.6%	98.7%	96.6%	97.6%	0.0%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	610	92.3%	91.8%	92.6%	91.4%	-0.3%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	650	96.4%	97.4%	98.2%	98.3%	0.6%
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	565	97.5%	98.3%	98.0%	97.9%	0.2%
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	434	98.1%	99.0%	98.6%	96.1%	-0.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	6,599	79.1%	82.4%	84.7%	85.9%	2.8%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	75	98.1%	93.3%	93.6%	92.3%	-2.0%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	69	96.5%	99.8%	96.3%	94.4%	-0.7%
86	Hepatitis C: Antiviral Treatment Prescribed	53	64.2%	66.9%	64.9%	56.1%	-4.4%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	49	81.8%	94.1%	94.3%	82.2%	0.2%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	103	76.5%	76.7%	72.5%	67.5%	-4.1%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	17	50.0%	66.7%	57.1%	33.3%	-12.6%
91	Acute Otitis Externa (AOE): Topical Therapy	105	86.8%	91.6%	91.1%	85.6%	-0.4%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	85	86.8%	90.3%	89.2%	90.0%	1.2%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,422	97.8%	97.2%	97.6%	98.0%	0.0%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	1,929	98.3%	98.3%	97.9%	98.4%	0.0%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	115	88.9%	93.7%	91.4%	92.2%	1.2%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	129	96.1%	94.2%	95.2%	98.2%	0.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	65	89.8%	94.3%	97.5%	97.7%	2.9%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	130	94.7%	97.7%	98.0%	97.7%	1.1%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	284	94.8%	95.8%	95.8%	93.7%	-0.4%
109	Osteoarthritis (OA): Function and Pain Assessment	311	85.5%	88.0%	87.8%	89.7%	1.6%
110	Preventive Care and Screening: Influenza Immunization	2,229	65.2%	65.3%	64.4%	64.0%	-0.6%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	2,643	67.8%	72.1%	73.1%	70.0%	1.1%
112	Preventive Care and Screening: Breast Cancer Screening	1,595	64.9%	66.7%	69.6%	65.8%	0.4%
113	Preventive Care and Screening: Colorectal Cancer Screening	2,116	70.3%	71.9%	74.0%	72.5%	1.0%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	19	47.3%	31.1%	34.5%	27.3%	-16.8%
117	Diabetes Mellitus: Dilated Eye Exam	6,623	94.5%	94.5%	94.9%	95.2%	0.2%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	46	63.4%	73.1%	57.5%	46.9%	-9.6%
119	Diabetes Mellitus: Medical Attention for Nephropathy	1,168	82.3%	79.4%	83.1%	85.9%	1.5%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	148	88.9%	87.2%	73.8%	75.0%	-5.5%
122	Adult Kidney Disease: Blood Pressure Management	103	96.4%	96.2%	94.3%	96.0%	-0.1%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	118	93.2%	92.3%	22.5%	23.0%	-6.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	1,115	88.5%	90.7%	90.8%	91.3%	1.0%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	754	88.5%	91.1%	91.4%	91.7%	1.2%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	2,016	73.5%	76.0%	77.0%	76.4%	1.3%
130	Documentation of Current Medications in the Medical Record	6,981	83.1%	90.8%	91.3%	87.8%	1.9%
131	Pain Assessment and Follow-Up	2,636	98.0%	96.5%	92.3%	96.1%	-0.7%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	191	92.4%	92.2%	91.9%	84.2%	-3.0%
137	Melanoma: Continuity of Care - Recall System	682	92.6%	97.1%	98.3%	98.3%	2.0%
138	Melanoma: Coordination of Care	584	92.6%	96.5%	94.5%	93.9%	0.5%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	4,432	93.6%	93.6%	93.6%	94.0%	0.2%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	2,091	95.6%	96.4%	97.0%	97.2%	0.6%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	327	76.8%	78.5%	78.6%	78.4%	0.7%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	4	94.7%	83.1%	97.6%	99.9%	1.8%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	6,635	49.1%	54.3%	59.8%	66.6%	10.7%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	4,615	0.5%	0.8%	0.5%	0.4%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	3,831	56.1%	56.7%	59.4%	67.0%	6.1%
154	Falls: Risk Assessment	3,049	93.6%	93.7%	93.5%	93.8%	0.1%
155	Falls: Plan of Care	1,483	92.4%	92.4%	92.9%	92.6%	0.1%
156	Oncology: Radiation Dose Limits to Normal Tissues	164	98.0%	97.6%	97.5%	98.2%	0.1%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	2	87.5%	100.0%	100.0%	100.0%	4.6%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	27	93.7%	94.0%	96.0%	94.7%	0.4%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	17	95.6%	78.7%	90.3%	82.3%	-4.9%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	19	100.0%	99.6%	99.6%	98.5%	-0.5%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	26	96.5%	88.6%	96.3%	97.4%	0.3%
163	Diabetes Mellitus: Foot Exam	1,178	86.3%	86.9%	86.3%	84.9%	-0.5%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	79	94.7%	96.1%	97.2%	98.5%	1.3%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	863	84.3%	88.8%	90.0%	90.2%	2.3%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	112	85.4%	92.5%	90.1%	90.3%	1.9%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	116	90.8%	90.3%	90.6%	94.9%	1.5%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	125	85.3%	87.0%	86.3%	85.6%	0.1%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	89	90.8%	92.2%	90.8%	92.9%	0.8%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	94	99.2%	99.2%	99.8%	99.8%	0.2%
181	Elder Maltreatment Screen and Follow-Up Plan	2	100.0%	75.0%	83.3%	92.1%	-2.7%
182	Functional Outcome Assessment	154	74.6%	74.5%	76.1%	81.1%	2.8%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	72	61.3%	63.3%	61.3%	54.6%	-3.8%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	70	77.6%	76.7%	74.6%	65.7%	-5.4%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	391	97.1%	97.9%	98.3%	98.2%	0.4%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	100.0%	100.0%	100.0%	100.0%	0.0%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	18	95.9%	96.5%	97.6%	97.6%	0.6%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	11	0.6%	0.5%	2.4%	0.8%	0.0%
193	Perioperative Temperature Management	8,484	85.9%	88.4%	91.5%	92.5%	2.5%
194	Oncology: Cancer Stage Documented	493	93.6%	93.8%	94.0%	92.6%	-0.3%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	2	73.7%	68.6%	30.0%	0.0%	0.0%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	385	74.9%	69.9%	72.1%	69.3%	-2.6%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	516	90.7%	91.7%	91.5%	89.1%	-0.6%
211	Functional Communication Measure - Memory	1	100.0%	33.3%	66.7%	100.0%	0.0%
214	Functional Communication Measure - Spoken Language Expression	1	0.0%	100.0%	66.7%	33.3%	0.0%
216	Functional Communication Measure - Swallowing	1	100.0%	50.0%	33.3%	0.0%	-100.0%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

*Notes for Table A29: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals who participated as part of a Medicare ACO under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) Results included the claims, registry and EHR methods. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (5) The “Growth Rate” is the compound annual growth rate (i.e., CAGR). (6) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.*

**Table A30. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Three Years (2011 to 2013)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	8,372	22.7%	21.8%	23.1%	-0.3%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	7,403	57.0%	57.3%	56.6%	-0.4%
3	Diabetes Mellitus: High Blood Pressure Control	5,510	73.2%	73.6%	75.0%	1.2%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	267	94.9%	87.9%	93.5%	-0.8%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	3,182	90.4%	83.0%	90.0%	-0.2%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	146	94.4%	90.8%	90.0%	-2.4%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	127	91.9%	96.1%	89.6%	-1.3%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	382	89.7%	89.1%	88.0%	-1.0%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	8,612	96.4%	96.7%	96.6%	0.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	8,873	96.9%	96.9%	96.2%	-0.4%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	5,751	97.4%	97.6%	97.5%	0.0%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	2,958	92.9%	92.7%	93.1%	0.1%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	2,136	96.5%	96.6%	96.2%	-0.1%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	2,748	94.9%	95.0%	95.1%	0.1%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	2,109	95.9%	96.3%	96.0%	0.1%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2,473	96.0%	95.9%	95.4%	-0.3%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	246	64.8%	63.3%	57.6%	-5.7%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	7,024	85.8%	86.1%	87.9%	1.2%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	25,624	93.4%	94.2%	94.9%	0.8%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	1,262	83.1%	87.4%	93.0%	5.8%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	976	83.3%	85.2%	89.1%	3.4%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	68	68.8%	96.6%	96.8%	18.6%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	394	86.1%	84.5%	92.3%	3.5%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	824	73.5%	80.4%	87.0%	8.8%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	2,520	70.5%	69.6%	68.9%	-1.2%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	156	60.6%	54.5%	51.2%	-8.1%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	891	90.0%	88.5%	86.8%	-1.8%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	616	99.1%	99.2%	99.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	488	95.7%	96.3%	96.5%	0.4%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	353	99.7%	98.7%	99.7%	0.0%
46	Medication Reconciliation	173	97.9%	99.1%	99.0%	0.5%
47	Advance Care Plan	3,535	61.2%	59.8%	61.1%	0.0%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	2,396	90.8%	90.4%	91.3%	0.3%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	811	95.7%	96.4%	96.5%	0.4%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	848	97.2%	97.4%	97.5%	0.1%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	927	84.3%	84.1%	83.8%	-0.3%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	305	99.1%	99.0%	96.9%	-1.1%
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	172	89.6%	91.3%	92.7%	1.7%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	19,105	96.0%	96.0%	96.4%	0.2%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	12,604	96.9%	97.0%	97.3%	0.2%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	16,096	97.3%	97.4%	97.7%	0.2%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	10,869	94.7%	95.4%	96.0%	0.7%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	69	52.8%	50.5%	52.8%	0.1%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	1	83.3%	100.0%	100.0%	9.5%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	664	94.9%	95.4%	94.9%	0.0%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	465	98.8%	96.9%	97.9%	-0.5%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	773	92.2%	92.8%	91.5%	-0.4%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	835	97.3%	98.2%	98.1%	0.4%
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	739	97.9%	97.5%	97.0%	-0.4%
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	550	99.0%	98.8%	96.3%	-1.4%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	8,665	81.6%	84.0%	85.3%	2.2%
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	1	100.0%	100.0%	100.0%	0.0%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	108	90.3%	94.8%	94.2%	2.1%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	99	99.5%	96.3%	96.0%	-1.8%
86	Hepatitis C: Antiviral Treatment Prescribed	95	65.1%	63.0%	53.2%	-9.6%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	69	87.5%	93.6%	78.3%	-5.4%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	168	74.2%	71.5%	68.4%	-4.0%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	33	76.9%	71.4%	57.1%	-13.8%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
91	Acute Otitis Externa (AOE): Topical Therapy	228	90.4%	90.0%	88.3%	-1.2%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	183	82.8%	76.3%	77.2%	-3.4%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,737	97.0%	97.6%	97.8%	0.4%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,198	98.0%	97.6%	98.2%	0.1%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	183	95.4%	92.9%	90.6%	-2.5%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	193	95.1%	95.6%	97.9%	1.5%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	92	88.6%	90.3%	90.7%	1.2%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	180	96.2%	95.6%	94.7%	-0.8%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	397	95.7%	95.7%	94.4%	-0.7%
109	Osteoarthritis (OA): Function and Pain Assessment	502	87.0%	86.4%	89.0%	1.2%
110	Preventive Care and Screening: Influenza Immunization	5,599	57.5%	56.8%	57.2%	-0.3%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	6,312	63.3%	68.3%	63.5%	0.2%
112	Preventive Care and Screening: Breast Cancer Screening	3,854	63.6%	67.2%	60.5%	-2.5%
113	Preventive Care and Screening: Colorectal Cancer Screening	4,866	63.2%	64.5%	59.7%	-2.8%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	45	26.2%	41.4%	42.6%	27.4%
117	Diabetes Mellitus: Dilated Eye Exam	9,569	90.3%	93.9%	92.1%	1.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	98	75.7%	65.5%	62.4%	-9.2%
119	Diabetes Mellitus: Medical Attention for Nephropathy	2,403	81.3%	80.6%	87.6%	3.8%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	240	90.1%	75.8%	77.3%	-7.4%
122	Adult Kidney Disease: Blood Pressure Management	191	94.1%	91.5%	93.6%	-0.3%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	183	94.3%	19.8%	19.0%	-7.3%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	2,000	91.7%	92.2%	92.8%	0.6%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	1,388	91.2%	91.9%	92.5%	0.7%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	5,944	70.1%	70.6%	67.9%	-1.5%
130	Documentation of Current Medications in the Medical Record	16,230	89.5%	89.6%	89.1%	-0.2%
131	Pain Assessment and Follow-Up	4,409	96.1%	92.2%	95.5%	-0.3%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	311	86.5%	85.1%	79.0%	-4.4%
137	Melanoma: Continuity of Care - Recall System	1,004	97.0%	98.3%	98.4%	0.7%
138	Melanoma: Coordination of Care	943	96.3%	94.8%	94.1%	-1.1%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	6,330	93.2%	93.4%	93.9%	0.4%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	3,233	96.3%	97.1%	97.4%	0.6%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	677	82.7%	82.6%	82.0%	-0.5%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	18	90.9%	97.0%	89.7%	-0.7%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
144	Oncology: Medical and Radiation - Plan of Care for Pain	13	96.9%	98.2%	93.2%	-1.9%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	8,885	53.7%	59.9%	67.0%	11.7%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	6,280	1.1%	0.5%	0.4%	0.3%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	5,341	56.6%	59.9%	66.6%	8.4%
154	Falls: Risk Assessment	4,951	94.1%	93.8%	93.4%	-0.4%
155	Falls: Plan of Care	2,656	93.8%	93.9%	93.5%	-0.2%
156	Oncology: Radiation Dose Limits to Normal Tissues	244	98.4%	97.4%	98.4%	0.0%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	8	93.1%	95.7%	86.4%	-3.7%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	36	95.3%	95.6%	96.0%	0.4%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	19	78.3%	88.6%	78.7%	0.3%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	27	98.9%	99.7%	99.0%	0.0%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	33	91.2%	97.1%	96.4%	2.8%
163	Diabetes Mellitus: Foot Exam	2,800	79.6%	85.3%	75.5%	-2.6%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>	3	0.0%	4.5%	3.8%	-1.9%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	3	100.0%	100.0%	100.0%	0.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	96	95.5%	96.4%	98.0%	1.3%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	2,347	86.7%	88.9%	89.1%	1.4%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	157	87.8%	89.6%	89.1%	0.8%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	173	92.2%	93.0%	96.0%	2.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
178	Rheumatoid Arthritis (RA): Functional Status Assessment	183	89.4%	90.0%	88.9%	-0.3%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	127	93.2%	91.6%	93.2%	0.0%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	147	98.7%	99.8%	99.8%	0.5%
181	Elder Maltreatment Screen and Follow-Up Plan	5	90.0%	73.3%	76.8%	-7.6%
182	Functional Outcome Assessment	390	78.0%	80.8%	83.8%	3.7%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	128	62.7%	62.7%	59.3%	-2.8%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	115	77.6%	77.0%	70.5%	-4.7%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	573	97.1%	97.9%	98.3%	0.6%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	100.0%	100.0%	100.0%	0.0%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	54	96.8%	96.1%	94.2%	-1.4%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	26	0.7%	1.7%	1.0%	-0.2%
193	Perioperative Temperature Management	15,123	88.1%	90.9%	92.1%	2.2%
194	Oncology: Cancer Stage Documented	898	93.6%	94.7%	93.1%	-0.3%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	8,667	61.5%	67.0%	75.6%	10.9%
197	Coronary Artery Disease (CAD): Lipid Control	112	83.1%	40.1%	41.0%	-29.8%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	65	47.4%	54.2%	57.0%	9.6%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	3	71.1%	39.3%	0.0%	0.0%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	1,323	81.8%	73.5%	70.6%	-7.1%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	1,617	88.7%	79.0%	73.7%	-8.9%
209	Functional Communication Measure - Spoken Language Comprehension	3	100.0%	86.7%	16.7%	-59.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
210	Functional Communication Measure - Attention	1	66.7%	33.3%	0.0%	-100.0%
211	Functional Communication Measure - Memory	2	66.7%	53.3%	50.0%	-13.4%
212	Functional Communication Measure - Motor Speech	1	100.0%	100.0%	100.0%	0.0%
214	Functional Communication Measure - Spoken Language Expression	4	95.0%	66.3%	83.3%	-6.3%
216	Functional Communication Measure - Swallowing	4	65.0%	68.8%	54.2%	-8.7%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	95	69.1%	84.0%	86.2%	11.7%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	93	70.3%	76.9%	83.7%	9.1%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	107	69.5%	74.8%	77.0%	5.2%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	101	68.7%	78.2%	82.8%	9.8%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	39	71.3%	69.9%	75.7%	3.1%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	94	62.3%	73.2%	72.6%	7.9%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	1,039	94.9%	99.1%	99.6%	2.4%
225	Radiology: Reminder System for Mammograms	3,671	69.7%	75.1%	81.9%	8.4%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	12,515	87.8%	93.0%	94.5%	3.7%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	5	97.2%	98.0%	97.4%	0.1%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	28	96.8%	93.3%	93.8%	-1.5%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	13	100.0%	66.7%	100.0%	0.0%
237	Hypertension (HTN): Blood Pressure Measurement	22	0.0%	99.8%	100.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
238	Drugs to be Avoided in the Elderly <sup>a</sup>	92	12.5%	10.5%	6.5%	3.3%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A30: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) Results included the claims, registry and EHR methods. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (5) The “Growth Rate” is the compound annual growth rate (i.e., CAGR). (6) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.

**Table A31. PQRS Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Two Years (2012 to 2013)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	14,521	27.0%	26.9%	0.2%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	13,123	52.5%	52.5%	-0.1%
3	Diabetes Mellitus: High Blood Pressure Control	10,496	70.9%	73.7%	4.0%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	752	80.7%	86.5%	7.2%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	6,452	82.1%	87.3%	6.4%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	797	78.8%	76.0%	-3.6%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	245	79.7%	73.9%	-7.3%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	1,120	61.3%	65.4%	6.8%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	10,804	96.1%	96.2%	0.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	10,857	95.8%	95.4%	-0.4%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	7,219	96.9%	96.7%	-0.2%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	3,911	91.4%	92.0%	0.7%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	2,785	96.2%	95.7%	-0.5%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	3,380	94.7%	94.7%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	2,661	96.6%	96.1%	-0.5%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	3,043	95.3%	94.8%	-0.6%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	346	62.9%	60.0%	-4.7%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	11,900	85.8%	88.6%	3.2%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	33,168	93.9%	94.6%	0.7%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	3,196	82.9%	88.1%	6.3%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	2,039	82.0%	86.6%	5.6%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	165	93.3%	97.7%	4.7%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	3,317	72.8%	77.2%	6.0%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	1,875	80.3%	85.4%	6.3%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	8,392	42.9%	44.2%	2.9%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	352	48.2%	46.5%	-3.6%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	11,241	82.6%	84.4%	2.2%
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	1	100.0%	100.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	189	95.1%	95.4%	0.4%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	172	95.3%	95.9%	0.7%
86	Hepatitis C: Antiviral Treatment Prescribed	167	70.5%	60.7%	-13.9%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	120	95.2%	79.3%	-16.6%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	338	82.5%	78.9%	-4.4%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	46	75.0%	75.0%	0.0%
91	Acute Otitis Externa (AOE): Topical Therapy	904	84.5%	87.2%	3.2%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	705	78.9%	80.6%	2.2%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	3,280	97.6%	98.0%	0.4%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,640	97.6%	98.2%	0.6%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	265	92.5%	88.7%	-4.2%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	273	95.1%	97.2%	2.2%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	233	53.7%	51.5%	-4.1%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	390	78.0%	75.5%	-3.2%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	818	81.1%	80.1%	-1.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
109	Osteoarthritis (OA): Function and Pain Assessment	905	86.4%	88.7%	2.6%
110	Preventive Care and Screening: Influenza Immunization	15,724	45.8%	47.6%	3.9%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	18,238	57.4%	54.8%	-4.6%
112	Preventive Care and Screening: Breast Cancer Screening	12,581	53.8%	46.8%	-13.0%
113	Preventive Care and Screening: Colorectal Cancer Screening	14,086	51.8%	47.2%	-8.9%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	123	43.0%	41.8%	-2.8%
117	Diabetes Mellitus: Dilated Eye Exam	14,659	86.1%	83.2%	-3.4%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	323	60.2%	55.9%	-7.1%
119	Diabetes Mellitus: Medical Attention for Nephropathy	6,116	81.1%	85.7%	5.6%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	567	74.5%	76.4%	2.6%
122	Adult Kidney Disease: Blood Pressure Management	380	87.3%	89.7%	2.8%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	270	17.8%	15.7%	2.5%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	3,096	92.5%	93.3%	0.9%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	2,124	91.1%	92.1%	1.1%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	18,600	61.0%	56.5%	-7.4%
130	Documentation of Current Medications in the Medical Record	33,524	87.7%	87.3%	-0.4%
131	Pain Assessment and Follow-Up	9,661	87.7%	91.0%	3.8%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	1,519	63.2%	63.2%	0.1%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
137	Melanoma: Continuity of Care - Recall System	1,378	97.3%	98.1%	0.8%
138	Melanoma: Coordination of Care	1,315	94.0%	94.1%	0.0%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	8,268	92.8%	93.6%	0.8%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	4,389	97.0%	97.4%	0.4%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	1,586	65.4%	74.4%	13.9%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	26	97.6%	90.2%	-7.6%
144	Oncology: Medical and Radiation - Plan of Care for Pain	17	98.6%	93.5%	-5.1%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	11,647	57.9%	65.6%	13.3%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	7,785	0.6%	0.4%	0.2%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	6,805	59.4%	66.5%	12.0%
154	Falls: Risk Assessment	8,983	87.3%	87.9%	0.7%
155	Falls: Plan of Care	4,599	93.2%	93.4%	0.2%
156	Oncology: Radiation Dose Limits to Normal Tissues	325	96.9%	98.5%	1.6%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	14	97.6%	92.2%	-5.5%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	38	95.5%	95.8%	0.4%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	21	89.2%	80.8%	-9.4%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	28	99.7%	99.0%	-0.7%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	35	96.8%	96.6%	-0.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
163	Diabetes Mellitus: Foot Exam	6,520	68.6%	59.7%	-12.9%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a</sup>	2	23.7%	0.0%	31.1%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a</sup>	2	0.0%	0.0%	0.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>	4	3.4%	2.9%	0.6%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	4	100.0%	100.0%	0.0%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	1	100.0%	100.0%	0.0%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	1	100.0%	100.0%	0.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	133	95.8%	97.3%	1.6%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	5,680	86.4%	84.4%	-2.3%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	302	87.3%	85.8%	-1.7%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	336	94.0%	93.2%	-0.8%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	396	92.1%	90.2%	-2.1%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	260	91.5%	90.1%	-1.5%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	302	99.8%	99.5%	-0.3%
181	Elder Maltreatment Screen and Follow-Up Plan	115	90.7%	94.1%	3.8%
182	Functional Outcome Assessment	2,830	85.2%	92.6%	8.7%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	246	60.3%	61.0%	1.2%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	234	67.3%	66.4%	-1.3%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	746	97.8%	98.3%	0.4%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	100.0%	100.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	2	100.0%	100.0%	0.0%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	85	95.7%	94.4%	-1.4%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	39	3.9%	6.3%	-2.5%
193	Perioperative Temperature Management	22,415	90.4%	91.6%	1.3%
194	Oncology: Cancer Stage Documented	1,367	94.0%	91.9%	-2.2%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	11,448	66.4%	75.5%	13.8%
197	Coronary Artery Disease (CAD): Lipid Control	887	16.8%	25.5%	52.2%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	373	47.6%	51.1%	7.2%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	8	50.7%	100.0%	97.1%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	5,182	69.8%	63.0%	-9.8%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	6,476	71.7%	63.8%	-10.9%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	6	50.0%	59.4%	18.8%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	6	29.3%	62.9%	114.8%
209	Functional Communication Measure - Spoken Language Comprehension	3	86.7%	16.7%	-80.8%
210	Functional Communication Measure - Attention	3	61.1%	50.0%	-18.2%
211	Functional Communication Measure - Memory	2	53.3%	50.0%	-6.3%
212	Functional Communication Measure - Motor Speech	2	86.4%	100.0%	15.8%
213	Functional Communication Measure - Reading	1	100.0%	100.0%	0.0%
214	Functional Communication Measure - Spoken Language Expression	5	73.0%	86.7%	18.7%
216	Functional Communication Measure - Swallowing	5	55.0%	43.3%	-21.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	395	70.9%	84.1%	18.6%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	370	63.0%	80.4%	27.7%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	326	48.2%	76.2%	58.1%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	430	58.0%	75.5%	30.1%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	424	60.0%	79.4%	32.4%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	139	58.1%	72.5%	24.8%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	338	54.7%	73.8%	34.8%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	1,482	99.2%	99.6%	0.4%
225	Radiology: Reminder System for Mammograms	5,318	74.9%	81.2%	8.4%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	32,578	85.8%	91.6%	6.8%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	14	99.2%	98.8%	-0.5%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	91	94.2%	95.6%	1.5%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	36	78.6%	81.8%	4.1%
236	Hypertension (HTN): Controlling High Blood Pressure	3,000	66.3%	32.7%	-50.7%
237	Hypertension (HTN): Blood Pressure Measurement	1,592	96.7%	94.1%	-2.6%
238	Drugs to be Avoided in the Elderly <sup>a</sup>	1,609	13.9%	9.0%	5.7%
239	Weight Assessment and Counseling for Children and Adolescents	2	0.0%	0.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	2,819	51.7%	39.2%	-24.2%
242	Coronary Artery Disease (CAD): Symptom Management	1	0.7%	100.0%	13500.0%
244	Hypertension: Blood Pressure Management	2	90.1%	99.5%	10.5%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	183	96.1%	94.4%	-1.8%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	215	88.4%	89.6%	1.4%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	7	100.0%	100.0%	0.0%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	34	93.1%	87.7%	-5.8%
249	Barrett's Esophagus	2,768	98.8%	99.3%	0.5%
250	Radical Prostatectomy Pathology Reporting	1,313	99.3%	99.3%	0.0%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	1,979	97.6%	99.1%	1.6%
252	Anticoagulation for Acute Pulmonary Embolus Patients	973	87.1%	92.9%	6.7%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	12	68.2%	100.0%	46.7%
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	10	71.8%	90.8%	26.4%
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	6	38.9%	33.3%	-14.3%
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	8	71.9%	81.3%	13.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	15	74.9%	84.5%	12.7%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	67	83.7%	84.2%	0.5%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	102	96.9%	98.9%	2.1%
263	Preoperative Diagnosis of Breast Cancer	108	98.1%	99.0%	0.9%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	78	94.4%	94.7%	0.3%
265	Biopsy Follow-Up	194	91.4%	92.6%	1.3%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	168	93.9%	92.9%	-1.0%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	119	95.7%	95.4%	-0.3%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	36	92.2%	84.7%	-8.2%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	15	0.0%	0.0%	0.0%
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	2,042	4.5%	2.0%	-54.2%
309	Cervical Cancer Screening	1,723	35.4%	21.6%	-39.0%
310	Chlamydia Screening for Women	52	82.1%	80.9%	-1.5%
311	Use of Appropriate Medications for Asthma	180	85.8%	66.4%	-22.7%
312	Low Back Pain: Use of Imaging Studies	127	19.4%	54.6%	182.2%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	141	34.1%	54.0%	58.5%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2012	Average Performance Rate per EP in 2013	Growth Rate
316	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL.	2,047	48.7%	21.5%	-55.9%
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	7,906	96.1%	93.3%	-2.9%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A31: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) Results included the claims, registry and EHR methods. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (5) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.

**Table A32. Percent of Eligible Professionals who Participated and had at Least a 90% Performance Rate by PQRS Individual Measure (2013)**

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	40.4%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	13.2%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	33.7%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	64.9%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	59.3%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	35.1%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	63.1%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	44.7%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	89.3%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	88.1%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	91.2%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	81.9%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	87.7%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	83.2%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	87.3%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	87.6%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	37.6%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	73.0%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	84.7%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	71.9%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	75.7%



Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	86.7%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	25.7%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	73.0%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	19.9%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	30.1%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	47.9%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	96.0%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	87.2%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	98.9%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	91.4%
47	Advance Care Plan	31.1%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	66.4%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	85.7%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	89.5%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	47.2%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	29.2%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	38.7%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	89.4%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	91.7%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	93.8%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	85.3%
64	Asthma: Assessment of Asthma Control	17.6%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	65.9%
66	Appropriate Testing for Children with Pharyngitis	19.2%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	81.8%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	61.0%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	71.9%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	90.5%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	63.7%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	41.6%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	73.8%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	100.0%
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	100.0%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	93.5%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	21.9%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	24.6%
86	Hepatitis C: Antiviral Treatment Prescribed	43.9%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	17.2%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	62.5%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	19.0%
91	Acute Otitis Externa (AOE): Topical Therapy	77.8%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	71.1%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	92.3%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	94.8%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	48.0%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	71.5%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	67.7%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	69.6%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	60.6%
109	Osteoarthritis (OA): Function and Pain Assessment	76.0%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
110	Preventive Care and Screening: Influenza Immunization	24.0%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	20.0%
112	Preventive Care and Screening: Screening Mammography	16.4%
113	Preventive Care and Screening: Colorectal Cancer Screening	17.9%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	33.0%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	65.9%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	36.1%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	52.7%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	42.2%
122	Adult Kidney Disease: Blood Pressure Management	67.4%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>a</sup>	87.8%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	71.1%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	63.8%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	33.1%
130	Documentation of Current Medications in the Medical Record	76.3%
131	Pain Assessment and Follow-Up	80.5%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	65.3%
137	Melanoma: Continuity of Care – Recall System	93.7%
138	Melanoma: Coordination of Care	82.0%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	84.5%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	95.1%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	54.3%
143	Oncology: Medical and Radiation – Pain Intensity Quantified	62.9%
144	Oncology: Medical and Radiation – Plan of Care for Pain	75.0%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	42.7%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>a</sup>	99.0%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	38.2%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
154	Falls: Risk Assessment	45.9%
155	Falls: Plan of Care	83.1%
156	Oncology: Radiation Dose Limits to Normal Tissues	95.6%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	88.5%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	87.1%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	65.6%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	96.2%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	70.4%
163	Diabetes Mellitus: Foot Exam	47.5%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a</sup>	100.0%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a</sup>	100.0%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a</sup>	100.0%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a</sup>	100.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a</sup>	100.0%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	100.0%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	100.0%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	30.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	84.1%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	54.0%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	21.4%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	83.0%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	80.8%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	77.0%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	99.4%
181	Elder Maltreatment Screen and Follow-Up Plan	34.4%
182	Functional Outcome Assessment	90.7%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	32.9%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	34.5%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	90.7%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	93.9%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	42.3%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	84.5%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a</sup>	76.7%
193	Perioperative Temperature Management	69.2%
194	Oncology: Cancer Stage Documented	66.2%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	53.0%
197	Coronary Artery Disease (CAD): Lipid Control	4.9%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	22.2%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	52.6%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	28.8%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	38.3%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	12.5%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	61.5%
209	Functional Communication Measure - Spoken Language Comprehension	20.0%
210	Functional Communication Measure - Attention	16.7%
211	Functional Communication Measure - Memory	41.7%
212	Functional Communication Measure - Motor Speech	63.6%
213	Functional Communication Measure - Reading	100.0%
214	Functional Communication Measure - Spoken Language Expression	57.1%
215	Functional Communication Measure - Writing	0.0%
216	Functional Communication Measure - Swallowing	36.8%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	50.8%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	47.4%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	49.4%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	33.2%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	45.1%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	49.3%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	41.3%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	97.6%
225	Radiology: Reminder System for Mammograms	71.7%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	69.1%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	51.4%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	86.5%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	29.0%
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	0.0%
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	100.0%
236	Hypertension (HTN): Controlling High Blood Pressure	28.9%
237	Hypertension (HTN): Blood Pressure Measurement	86.4%
238	Drugs to be Avoided in the Elderly <sup>a</sup>	73.5%
239	Weight Assessment and Counseling for Children and Adolescents	0.0%
240	Childhood Immunization Status	0.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	11.0%
242	Coronary Artery Disease (CAD): Symptom Management	100.0%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	0.0%
244	Hypertension: Blood Pressure Management	24.8%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	83.6%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	78.1%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	92.3%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	79.6%
249	Barrett's Esophagus	95.9%
250	Radical Prostatectomy Pathology Reporting	95.9%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	82.8%
252	Anticoagulation for Acute Pulmonary Embolus Patients	84.9%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	64.0%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	0.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	100.0%
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	41.4%
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	31.3%



Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	57.4%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	50.0%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	42.5%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	92.9%
263	Preoperative Diagnosis of Breast Cancer	94.1%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	75.9%
265	Biopsy Follow-Up	85.6%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	91.1%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	86.1%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	75.6%
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	100.0%
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	66.7%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	0.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	0.0%
307	Prenatal Care: Anti-D Immune Globulin	0.0%
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	0.0%
309	Cervical Cancer Screening	1.5%
310	Chlamydia Screening for Women	16.7%
311	Use of Appropriate Medications for Asthma	45.9%
312	Low Back Pain: Use of Imaging Studies	5.5%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	0.9%
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	1.1%
317	Preventive Care and Screening: Screening for High Blood Pressure	32.8%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A32: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the PQRS GPRO, eligible professionals participating as part of a Medicare ACO participating under the Shared Savings Program or the Pioneer ACO Model, or eligible professionals participating through the CPC initiative. (2) Results included the claims, registry and EHR methods. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an

*eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (5) For information on which reporting mechanisms were available for each measure in a given program year, please refer to Table A51 of the Appendix.*



**Table A33. Performance Information for PQRS Measures Reported by Practices Participating in the Small Group Practice Reporting Option (2013)**

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	27	0	1,938	6,825	8,763	325	8,763	24.2%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	22	0	3,314	4,392	7,706	350	7,706	37.8%
3	Diabetes Mellitus: High Blood Pressure Control	36	0	8,037	3,699	11,736	326	11,736	70.5%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	4	4	253	61	318	80	314	86.7%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	15	386	5,733	1,145	7,264	484	6,878	78.5%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	9	9	358	90	457	51	448	81.7%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	2	2	189	2	193	97	191	95.8%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	2	0	7	37	44	22	44	12.1%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	8	17	4,618	220	4,855	607	4,838	96.9%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	2	233	335	1,952	2,520	1,260	2,287	17.5%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	3	12	122	195	329	110	317	56.3%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	2	0	67	243	310	155	310	18.3%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	13	38	2,991	171	3,200	246	3,162	95.8%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	8	64	1,622	132	1,818	227	1,754	87.6%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	10	71	1,762	112	1,945	195	1,874	89.2%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	8	2	1,317	58	1,377	172	1,375	93.1%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	2	0	3	117	120	60	120	1.3%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	1	0	17	1	18	18	18	94.4%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	3	20	129	8	157	52	137	96.4%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	4	7	54	0	61	15	54	100.0%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	3	3	13	1	17	6	14	88.9%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	3	74	87	21	182	61	108	75.2%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	6	39	170	6	215	36	176	89.3%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	7	32	3,312	5,297	8,641	1,234	8,609	39.5%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	1	0	2	118	120	120	120	1.7%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	5	2	63	50	115	23	113	46.7%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	1	1	27	0	28	28	27	100.0%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	1	0	29	0	29	29	29	100.0%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	2	0	126	7	133	67	133	94.8%
46	Medication Reconciliation	5	0	10	4	14	3	14	88.9%
47	Advance Care Plan	6	0	8,006	5,176	13,182	2,197	13,182	48.1%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	3	10	986	5,321	6,317	2,106	6,307	58.0%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	2	0	14	0	14	7	14	100.0%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	2	0	13	1	14	7	14	94.4%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	2	0	1,765	160	1,925	963	1,925	95.7%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	1	0	1	0	1	1	1	100.0%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	1	6	577	8	591	591	585	98.6%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	1	0	123	2	125	125	125	98.4%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	2	0	291	14	305	153	305	91.3%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	1	2	195	17	214	214	212	92.0%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	2	0	0	7	7	4	7	0.0%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	1	3	38	14	55	55	52	73.1%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	2	74	119	19	212	106	138	76.2%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	2	11	36	15	62	31	51	74.0%
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	1	440	632	36	1,108	1,108	668	94.6%
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	2	100	54	3	157	79	57	94.0%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	2	0	351	8	359	180	359	97.8%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	1	0	11	21	32	32	32	34.4%
91	Acute Otitis Externa (AOE): Topical Therapy	9	16	705	82	803	89	787	92.9%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	7	16	571	22	609	87	593	98.3%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	9	28	342	7	377	42	349	97.7%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	11	1	243	1	245	22	244	99.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	1	1	9	0	10	10	9	100.0%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	1	3	19	0	22	22	19	100.0%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	1	0	0	4	4	4	4	0.0%



GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	2	0	4	592	596	298	596	0.3%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	1	0	2	10	12	12	12	16.7%
110	Preventive Care and Screening: Influenza Immunization	29	675	24,031	27,788	52,494	1,810	51,819	46.9%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	33	597	17,313	27,808	45,718	1,385	45,121	38.7%
112	Preventive Care and Screening: Breast Cancer Screening	23	5	5,198	6,837	12,040	523	12,035	44.5%
113	Preventive Care and Screening: Colorectal Cancer Screening	19	389	12,105	8,106	20,600	1,084	20,211	52.0%
117	Diabetes Mellitus: Dilated Eye Exam	13	0	2,850	2,391	5,241	403	5,241	49.2%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	6	3	56	17	76	13	73	79.8%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
119	Diabetes Mellitus: Medical Attention for Nephropathy	11	0	2,836	937	3,773	343	3,773	71.7%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	2	1	14	12	27	14	26	54.8%
122	Adult Kidney Disease: Blood Pressure Management	1	0	92	59	151	151	151	60.9%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	4	0	92	164	256	64	256	43.1%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	2	0	0	150	150	75	150	0.0%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	31	91	33,767	32,873	66,731	2,153	66,640	52.8%
130	Documentation of Current Medications in the Medical Record	42	48	146,781	27,949	174,778	4,161	174,730	83.9%
131	Pain Assessment and Follow-Up	11	64	3,743	1,800	5,607	510	5,543	80.4%
137	Melanoma: Continuity of Care - Recall System	8	6	801	25	832	104	826	91.9%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
138	Melanoma: Coordination of Care	8	45	169	12	226	28	181	93.9%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	2	0	978	1,542	2,520	1,260	2,520	31.7%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	2	2	723	54	779	390	777	95.2%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	2	0	11	15	26	13	26	42.3%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	3	0	226	77	303	101	303	35.8%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	7	0	107	25,647	25,754	3,679	25,754	0.7%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	8	283	1,332	505	2,120	265	1,837	69.8%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
154	Falls: Risk Assessment	5	502	313	647	1,462	292	960	73.6%
155	Falls: Plan of Care	4	4	319	7	330	83	326	95.2%
163	Diabetes Mellitus: Foot Exam	13	0	1,496	2,285	3,781	291	3,781	45.6%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	7	0	28,289	10,362	38,651	5,522	38,651	69.7%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	1	0	0	2	2	2	2	0.0%
182	Functional Outcome Assessment	8	22	3,414	64	3,500	438	3,478	98.6%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1	1	8	23	32	32	31	25.8%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	2	3	8	22	33	17	30	62.1%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	1	13	21	1	35	35	22	95.5%
194	Oncology: Cancer Stage Documented	1	0	1,393	0	1,393	1,393	1,393	100.0%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	6	0	1,360	229	1,589	265	1,589	89.5%
197	Coronary Artery Disease (CAD): Lipid Control	8	0	247	1,506	1,753	219	1,753	13.2%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	2	0	302	159	461	231	461	35.2%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	15	0	2,017	822	2,839	189	2,839	77.8%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	13	0	3,014	2,301	5,315	409	5,315	65.8%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	8	10	552	7	569	71	559	95.1%
225	Radiology: Reminder System for Mammograms	10	0	32,761	1,432	34,193	3,419	34,193	92.2%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	42	6	115,089	18,822	133,917	3,189	133,911	86.1%
236	Hypertension (HTN): Controlling High Blood Pressure	26	0	21,180	6,419	27,599	1,062	27,599	73.1%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) + (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	5	0	24	111	135	27	135	20.9%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	2	0	5,328	0	5,328	2,664	5,328	100.0%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	1	0	11	0	11	11	11	100.0%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	1	0	3	25	28	28	28	10.7%
249	Barrett's Esophagus	4	5	335	0	340	85	335	100.0%
250	Radical Prostatectomy Pathology Reporting	4	1	30	0	31	8	30	100.0%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	9	13	254	0	267	30	254	100.0%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	1	0	5	1	6	6	6	83.3%
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	1	0	7	2	9	9	9	77.8%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	1	0	31	0	31	31	31	100.0%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	1	0	7	0	7	7	7	100.0%
263	Preoperative Diagnosis of Breast Cancer	2	1	10	2	13	7	12	87.5%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	2	1	12	1	14	7	13	93.8%
265	Biopsy Follow-Up	3	399	233	22	654	218	255	83.0%

GPRO Measure	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	10	4,119	5,753	3,297	13,169	1,317	9,050	51.7%
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	1	0	66	0	66	66	66	100.0%
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients <sup>a</sup>	1	0	1	31	32	32	32	3.1%
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) <sup>a</sup>	1	0	0	32	32	32	32	0.0%
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients <sup>a</sup>	1	0	1	31	32	32	32	3.1%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 123, 146, 164, 165, 166, 167, 168, 192, 238, 322, 323, 324, 328).



*Notes for Table A33: Performance rate is the performance met as a percent of (performance met + performance not met); the final column is the average performance rate across practices, and therefore cannot be recreated from the other columns in the table.*

**Table A34. Performance Information for PQRS Measures Reported by Practices Participating in the Medium Group Practice Web Interface Reporting Option (2013)**

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance not met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Care Coordination/ Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	27	0	1,946	747	2,693	100	2,693	78.8%
Care-2	Falls: Screening for Future Fall Risk	27	29	1,942	2,760	4,731	175	4,702	42.2%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
CAD-2	Lipid Control	27	25	2,769	519	3,313	123	3,288	79.0%
CAD-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	27	47	1,171	362	1,580	59	1,533	77.4%
CAD-Composite	CAD Composite (All or Nothing Scoring), CAD-2 and CAD-7	27	0	2,503	810	3,313	123	3,313	73.1%
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	27	0	734	2,982	3,716	138	3,716	31.4%
DM-13	High Blood Pressure Control in Diabetes Mellitus	27	0	2,633	1,083	3,716	138	3,716	68.3%
DM-14	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	27	0	2,060	1,656	3,716	138	3,716	46.2%

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance not met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
DM-15	Hemoglobin A1c Control (<8%)	27	0	2,651	1,065	3,716	138	3,716	61.1%
DM-16	Daily Aspirin or Antiplatelet Medication Use for Patients with Diabetes and Ischemic Vascular Disease	27	20	884	191	1,095	41	1,075	82.1%
DM-17	Tobacco Non-Use	27	0	3,035	681	3,716	138	3,716	76.9%
DM-Composite	Diabetes Composite: Optimal Diabetes Care (All of Nothing Scoring) DM-13, DM-14, DM-15, DM-16, and DM-17	27	0	987	2,729	3,716	138	3,716	22.3%
Heart Failure (HF)	--	--	--	--	--	--	--	--	--
HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	27	14	456	55	525	19	511	90.9%
Hypertension (HTN)	--	--	--	--	--	--	--	--	--
HTN-2	Controlling High Blood Pressure	27	6	2,913	1,315	4,234	157	4,228	57.7%
Ischemic Vascular Disease (IVD)	--	--	--	--	--	--	--	--	--
IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	27	0	1,759	1,262	3,021	112	3,021	53.9%
IVD-2	Use of Aspirin or Another Antithrombotic	27	0	2,537	484	3,021	112	3,021	81.2%
Preventive Care	--	--	--	--	--	--	--	--	--
Prev-5	Screening Mammography	27	15	2,649	1,333	3,997	148	3,982	57.6%
Prev-6	Colorectal Cancer Screening	27	17	2,736	1,722	4,475	166	4,458	54.8%
Prev-7	Influenza Immunization	27	238	3,003	1,397	4,638	172	4,400	58.3%

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance not met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	27	8	2,734	1,791	4,533	168	4,525	51.1%
Prev-9	Body Mass Index (BMI) Screening and Follow-Up	27	26	3,147	1,728	4,901	182	4,875	56.5%
Prev-10	Tobacco Use: Screening and Cessation Intervention	27	8	4,625	294	4,927	182	4,919	85.4%
Prev-11	Screening for High Blood Pressure	27	503	2,358	1,322	4,183	155	3,680	59.8%
Prev-12	Screening for Clinical depression and Follow-Up Plan	27	558	548	3,483	4,589	170	4,031	12.7%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

Notes for Table A34: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).

**Table A35. Performance Information for PQRS Measures Reported by Practices Participating in the Medium Group Practice Registry Reporting Option (2013)**

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	36	0	7,591	14,954	22,545	626	22,545	37.9%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	33	0	10,225	12,293	22,518	682	22,518	39.6%
3	Diabetes Mellitus: High Blood Pressure Control	40	0	21,001	7,067	28,068	702	28,068	77.4%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	13	120	483	69	672	52	552	87.6%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	19	591	5,321	939	6,851	361	6,260	82.6%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	13	35	323	591	949	73	914	66.3%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	4	35	925	22	982	246	947	92.3%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	5	0	120	479	599	120	599	17.0%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	2	0	55	4	59	30	59	47.4%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	3	0	0	38	38	13	38	0.0%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	2	0	0	5	5	3	5	0.0%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	3	0	849	104	953	318	953	85.6%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	2	0	584	304	888	444	888	80.3%
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	3	0	615	185	800	267	800	61.8%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	4	4	984	57	1,045	261	1,041	85.0%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	6	0	11	111	122	20	122	5.7%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	1	0	2	0	2	2	2	100.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	3	66	259	40	365	122	299	91.2%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	11	61	1,385	85	1,531	139	1,470	91.9%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	10	42	175	20	237	24	195	91.9%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	11	262	740	188	1,190	108	928	76.5%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	11	10	14,890	32,882	47,782	4,344	47,772	24.7%



GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	1	0	4	29	33	33	33	12.1%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	6	5	254	251	510	85	505	57.4%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	4	1	460	34	495	124	494	96.6%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	4	4	481	12	497	124	493	94.9%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	4	1	783	0	784	196	783	100.0%
46	Medication Reconciliation	7	0	2,837	377	3,214	459	3,214	86.8%
47	Advance Care Plan	10	1	43,477	23,867	67,345	6,735	67,344	45.7%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	3	6	6,141	5,027	11,174	3,725	11,168	51.5%
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	4	10	74	20	104	26	94	90.4%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	1	0	313	22	335	335	335	93.4%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	2	0	9	4	13	7	13	83.3%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	1	0	54	3	57	57	57	94.7%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	1	0	50	7	57	57	57	87.7%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	4	0	0	168	168	42	168	0.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	2	0	30	58	88	44	88	66.7%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	2	0	0	11	11	6	11	0.0%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	3	2	487	3	492	164	490	99.3%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	1	0	19	9	28	28	28	67.9%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	1	3	16	5	24	24	21	76.2%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	4	3	348	0	351	88	348	100.0%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	3	3	202	0	205	68	202	100.0%
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	6	0	29	263	292	49	292	5.1%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	6	0	235	57	292	49	292	51.9%
110	Preventive Care and Screening: Influenza Immunization	22	3,270	51,482	81,713	136,465	6,203	133,195	36.8%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	20	745	31,643	77,843	110,231	5,512	109,486	26.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
112	Preventive Care and Screening: Breast Cancer Screening	18	19	10,128	21,582	31,729	1,763	31,710	33.7%
113	Preventive Care and Screening: Colorectal Cancer Screening	20	588	26,279	61,207	88,074	4,404	87,486	33.4%
117	Diabetes Mellitus: Dilated Eye Exam	6	0	293	2,695	2,988	498	2,988	6.2%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	16	802	7,953	3,583	12,338	771	11,536	59.1%
119	Diabetes Mellitus: Medical Attention for Nephropathy	11	5	5,215	952	6,172	561	6,167	81.0%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	1	0	308	60	368	368	368	83.7%
122	Adult Kidney Disease: Blood Pressure Management	3	0	2,047	2,076	4,123	1,374	4,123	47.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	8	8	181	3,940	4,129	516	4,121	10.3%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	5	0	0	3,218	3,218	644	3,218	0.0%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	20	398	80,609	96,117	177,124	8,856	176,726	45.8%
130	Documentation of Current Medications in the Medical Record	16	262	69,175	46,250	115,687	7,230	115,425	55.6%
131	Pain Assessment and Follow-Up	6	0	0	56,936	56,936	9,489	56,936	0.0%
138	Melanoma: Coordination of Care	1	0	1	0	1	1	1	100.0%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	3	0	6	32	38	13	38	6.5%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	5	0	531	584	1,115	223	1,115	39.1%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	5	0	12,819	6,873	19,692	3,938	19,692	81.6%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	6	136	43	73,975	74,154	12,359	74,018	0.2%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	7	674	3,049	245	3,968	567	3,294	86.8%
154	Falls: Risk Assessment	7	114	158	22,986	23,258	3,323	23,144	13.8%
155	Falls: Plan of Care	3	1	182	6	189	63	188	66.2%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	1	0	8	0	8	8	8	100.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	2	0	5	12	17	9	17	50.0%
163	Diabetes Mellitus: Foot Exam	6	4	483	2,411	2,898	483	2,894	15.7%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	3	0	20,104	9,505	29,609	9,870	29,609	68.8%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	2	0	0	11	11	6	11	0.0%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	1	0	1	7	8	8	8	12.5%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	1	0	1	7	8	8	8	12.5%
182	Functional Outcome Assessment	3	0	2,084	170	2,254	751	2,254	95.4%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	4	0	11,414	1,161	12,575	3,144	12,575	89.1%
197	Coronary Artery Disease (CAD): Lipid Control	10	2	3,277	6,416	9,695	970	9,693	21.8%



GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	4	0	143	294	437	109	437	26.6%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	13	0	4,949	558	5,507	424	5,507	88.2%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	18	0	33,764	8,608	42,372	2,354	42,372	64.8%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	2	0	0	28	28	14	28	0.0%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	1	0	83	0	83	83	83	100.0%
225	Radiology: Reminder System for Mammograms	6	0	29,557	6,738	36,295	6,049	36,295	65.4%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	24	0	148,420	78,502	226,922	9,455	226,922	64.2%
236	Hypertension (HTN): Controlling High Blood Pressure	25	0	56,193	25,673	81,866	3,275	81,866	74.8%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	10	0	3,972	7,152	11,124	1,112	11,124	22.4%
242	Coronary Artery Disease (CAD): Symptom Management	1	0	1	1	2	2	2	50.0%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	1	1	15	0	16	16	15	100.0%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	1	0	106	16	122	122	122	86.9%
249	Barrett's Esophagus	2	0	81	0	81	41	81	100.0%
250	Radical Prostatectomy Pathology Reporting	2	0	70	0	70	35	70	100.0%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	2	0	126	0	126	63	126	100.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	1	5	1	11	17	17	12	8.3%
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	1	0	6	4	10	10	10	60.0%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	2	0	43	0	43	22	43	100.0%
263	Preoperative Diagnosis of Breast Cancer	2	3	65	0	68	34	65	100.0%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	2	11	38	7	56	28	45	86.5%
265	Biopsy Follow-Up	1	0	67	0	67	67	67	100.0%
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	15	37,427	25,124	41,436	103,987	6,932	66,560	37.7%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	3	0	298	0	298	99	298	100.0%
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients <sup>a</sup>	1	0	0	16	16	16	16	0.0%
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) <sup>a</sup>	1	0	0	16	16	16	16	0.0%
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients <sup>a</sup>	1	0	2	14	16	16	16	12.5%
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	1	0	24	8	32	32	32	75.0%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 123, 146, 164, 165, 166, 167, 168, 192, 238, 322, 323, 324, 328).

Notes for Table A35: Performance rate is the performance met as a percent of (performance met + performance not met); the final column is the average performance rate across practices, and therefore cannot be recreated from the other columns in the table.

**Table A36. Performance Information for PQRS Measures Reported by Practices Participating in the Large Group Practice Web Interface Reporting Option (2013)**

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Care Coordination/ Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	142	0	39,091	7,180	46,271	326	46,271	85.4%
Care-2	Falls: Screening for Future Fall Risk	142	339	26,341	31,464	58,144	409	57,805	45.1%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
CAD-2	Lipid Control	142	848	39,954	8,622	49,424	348	48,576	81.3%
CAD-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	142	1,268	18,291	4,603	24,162	170	22,894	78.9%
CAD-Composite	CAD Composite (All or Nothing Scoring), CAD-2 and CAD-7	142	0	37,110	12,314	49,424	348	49,424	73.8%

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	142	0	9,380	42,726	52,106	367	52,106	19.0%
DM-13	High Blood Pressure Control in Diabetes Mellitus	142	0	36,803	15,303	52,106	367	52,106	70.5%
DM-14	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	142	0	31,194	20,912	52,106	367	52,106	58.2%
DM-15	Hemoglobin A1c Control (<8%)	142	0	37,723	14,383	52,106	367	52,106	71.1%
DM-16	Daily Aspirin or Antiplatelet Medication Use for Patients with Diabetes and Ischemic Vascular Disease	142	784	13,709	2,228	16,721	118	15,937	85.3%
DM-17	Tobacco Non-Use	142	0	42,038	10,068	52,106	367	52,106	80.0%
DM-Composite	Diabetes Composite: Optimal Diabetes Care (All of Nothing Scoring) DM-13, DM-14, DM-15, DM-16, and DM-17	142	0	15,099	37,007	52,106	367	52,106	27.7%
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	142	588	9,992	1,182	11,762	83	11,174	89.8%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
HTN-2	Controlling High Blood Pressure	142	264	41,292	19,446	61,002	430	60,738	67.6%

GPRO Web-Interface Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	142	0	28,556	18,006	46,562	328	46,562	60.5%
IVD-2	Use of Aspirin or Another Antithrombotic	142	0	40,732	5,830	46,562	328	46,562	87.5%
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
Prev-5	Screening Mammography	142	442	38,752	17,442	56,636	399	56,194	68.6%
Prev-6	Colorectal Cancer Screening	142	381	39,547	19,496	59,424	418	59,043	66.3%
Prev-7	Influenza Immunization	142	1,862	38,522	20,769	61,153	431	59,291	64.9%
Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	142	230	41,969	20,393	62,592	441	62,362	65.9%
Prev-9	Body Mass Index (BMI) Screening and Follow-Up	142	283	37,384	22,428	60,095	423	59,812	62.2%
Prev-10	Tobacco Use: Screening and Cessation Intervention	142	8	56,099	5,265	61,372	432	61,364	91.1%
Prev-11	Screening for High Blood Pressure	142	10,364	32,499	15,360	58,223	410	47,859	68.9%
Prev-12	Screening for Clinical depression and Follow-Up Plan	142	8,169	12,211	39,122	59,502	419	51,333	22.9%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

Notes for Table A36: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).



**Table A37. Performance Information for PQRS Measures Reported by Practices Participating in the Large Group Practice Registry Reporting Option (2013)**

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control <sup>a</sup>	80	0	59,890	153,324	213,214	2,665	213,214	26.9%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	73	0	97,505	106,190	203,695	2,790	203,695	45.0%
3	Diabetes Mellitus: High Blood Pressure Control	91	0	159,229	82,786	242,015	2,660	242,015	68.7%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	12	1,676	2,262	916	4,854	405	3,178	79.7%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	23	7,486	55,492	11,332	74,310	3,231	66,824	83.6%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	16	125	14,622	8,573	23,320	1,458	23,195	66.4%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	2	0	51	0	51	26	51	100.0%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	6	0	1,743	2,615	4,358	726	4,358	26.0%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	5	18	4,967	858	5,843	1,169	5,825	84.3%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	3	57	48	91	196	65	139	15.4%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+ (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	5	129	1,766	549	2,444	489	2,315	40.6%
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	3	12	856	1,554	2,422	807	2,410	36.3%
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	2	0	817	1,141	1,958	979	1,958	59.1%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	4	77	892	1,321	2,290	573	2,213	47.3%
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	2	0	433	20	453	227	453	73.7%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2	0	573	1,074	1,647	824	1,647	61.2%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	2	0	0	94	94	47	94	0.0%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	2	75	3,672	540	4,287	2,144	4,212	89.5%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	1	0	7	0	7	7	7	100.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	6	337	1,451	483	2,271	379	1,934	71.2%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	6	205	3,477	236	3,918	653	3,713	93.3%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	5	65	290	37	392	78	327	89.2%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	1	117	185	131	433	433	316	58.5%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	6	578	1,696	470	2,744	457	2,166	77.3%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	11	2,900	57,465	117,511	177,876	16,171	174,976	37.5%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	5	0	1,074	1,345	2,419	484	2,419	40.3%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	10	20	637	2	659	66	639	99.5%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	10	25	646	12	683	68	658	92.4%
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	10	15	1,215	2	1,232	123	1,217	99.1%
46	Medication Reconciliation	13	0	35,534	6,473	42,007	3,231	42,007	87.9%
47	Advance Care Plan	15	0	66,681	114,808	181,489	12,099	181,489	56.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	1	0	18,442	377	18,819	18,819	18,819	98.0%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	1	6	3,644	0	3,650	3,650	3,644	100.0%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	1	6	3,644	0	3,650	3,650	3,644	100.0%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	4	0	11,995	8,156	20,151	5,038	20,151	54.7%
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	2	3	32	1	36	18	33	87.5%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	9	607	55,951	3,097	59,655	6,628	59,048	87.4%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	11	45	16,417	1,194	17,656	1,605	17,611	77.0%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	5	0	24,384	1,686	26,070	5,214	26,070	69.1%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	4	70	24,659	1,107	25,836	6,459	25,766	86.4%
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	4	0	13	276	289	72	289	10.2%
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	2	0	459	276	735	368	735	59.2%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	4	0	6	75	81	20	81	14.2%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	1	0	2	0	2	2	2	100.0%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	1	0	66	3	69	69	69	95.7%
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	1	0	39	0	39	39	39	100.0%
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	1	0	1	0	1	1	1	100.0%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	4	9	596	20	625	156	616	72.8%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	1	0	29	0	29	29	29	100.0%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	2	0	54	18	72	36	72	65.5%
86	Hepatitis C: Antiviral Treatment Prescribed	1	21	27	2	50	50	29	93.1%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	4	0	660	378	1,038	260	1,038	61.7%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	1	0	2	0	2	2	2	100.0%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+ (D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	4	0	151	110	261	65	261	30.6%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	4	0	170	91	261	65	261	44.2%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	5	0	2,103	1,823	3,926	785	3,926	50.6%
109	Osteoarthritis (OA): Function and Pain Assessment	2	0	1,124	3,216	4,340	2,170	4,340	18.8%
110	Preventive Care and Screening: Influenza Immunization	49	5,110	284,289	600,926	890,325	18,170	885,215	38.6%
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	39	2,373	198,878	380,862	582,113	14,926	579,740	41.3%
112	Preventive Care and Screening: Breast Cancer Screening	29	216	42,814	87,758	130,788	4,510	130,572	35.4%
113	Preventive Care and Screening: Colorectal Cancer Screening	38	1,079	131,069	258,407	390,555	10,278	389,476	40.3%
117	Diabetes Mellitus: Dilated Eye Exam	17	0	13,964	26,192	40,156	2,362	40,156	34.3%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	23	2,712	15,157	5,980	23,849	1,037	21,137	71.5%
119	Diabetes Mellitus: Medical Attention for Nephropathy	26	78	53,949	20,517	74,544	2,867	74,466	77.3%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	8	0	12,331	7,453	19,784	2,473	19,784	60.4%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
122	Adult Kidney Disease: Blood Pressure Management	4	0	35,953	45,745	81,698	20,425	81,698	45.2%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	5	48	448	4,397	4,893	979	4,845	9.0%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	4	0	0	7,264	7,264	1,816	7,264	0.0%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	49	1,910	381,915	588,529	972,354	19,844	970,444	47.0%
130	Documentation of Current Medications in the Medical Record	26	670	798,572	338,797	1,138,039	43,771	1,137,369	70.9%
131	Pain Assessment and Follow-Up	3	31	582	69,886	70,499	23,500	70,468	33.3%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	1	3,942	0	14,262	18,204	18,204	14,262	0.0%
137	Melanoma: Continuity of Care - Recall System	1	0	0	0	0	0	0	0.0%
138	Melanoma: Coordination of Care	1	0	0	0	0	0	0	0.0%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	4	0	96	190	286	72	286	21.9%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	3	0	3,216	2,305	5,521	1,840	5,521	58.4%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	1	0	0	4	4	4	4	0.0%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	1	0	13	917	930	930	930	1.4%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening <sup>a</sup>	1	0	9	2,713	2,722	2,722	2,722	0.3%
154	Falls: Risk Assessment	3	19	107	19,391	19,517	6,506	19,498	32.7%
155	Falls: Plan of Care	3	12	220	294	526	175	514	74.9%
156	Oncology: Radiation Dose Limits to Normal Tissues	1	0	2	4	6	6	6	33.3%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	1	0	987	110	1,097	1,097	1,097	90.0%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	1	86	148	2	236	236	150	98.7%
163	Diabetes Mellitus: Foot Exam	11	53	9,759	16,319	26,131	2,376	26,078	31.7%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	9	1,410	71,365	152,812	225,587	25,065	224,177	44.5%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	2	0	0	5	5	3	5	0.0%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	2	0	7	29	36	18	36	21.4%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	2	0	7	32	39	20	39	20.8%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	2	23	166	14	203	102	180	92.2%
194	Oncology: Cancer Stage Documented	2	724	5,721	1,810	8,255	4,128	7,531	51.1%
197	Coronary Artery Disease (CAD): Lipid Control	18	2	32,014	48,151	80,167	4,454	80,165	27.9%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	3	0	26	1,650	1,676	559	1,676	1.8%



GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	24	0	31,541	23,152	54,693	2,279	54,693	69.3%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	37	0	113,605	37,455	151,060	4,083	151,060	70.6%
225	Radiology: Reminder System for Mammograms	1	0	37	2,683	2,720	2,720	2,720	1.4%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	58	426	788,973	310,124	1,099,523	18,957	1,099,097	71.7%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	1	0	720	3,535	4,255	4,255	4,255	16.9%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	2	0	1,544	39	1,583	792	1,583	57.4%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	1	0	3	28	31	31	31	9.7%
236	Hypertension (HTN): Controlling High Blood Pressure	53	0	311,010	157,266	468,276	8,835	468,276	67.5%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	12	0	8,656	12,646	21,302	1,775	21,302	35.4%
244	Hypertension: Blood Pressure Management	2	0	16,867	12,396	29,263	14,632	29,263	59.2%
249	Barrett's Esophagus	1	0	9	0	9	9	9	100.0%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	15	5	218	1	224	15	219	99.7%
263	Preoperative Diagnosis of Breast Cancer	15	12	416	77	505	34	493	94.0%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	14	87	203	17	307	22	220	94.1%

GPRO Registry Measures	Measure Description	(A) GPRO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met Count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	1	0	51	37	88	88	88	58.0%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	1	0	54	34	88	88	88	61.4%
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	17	89,941	81,519	110,677	282,137	16,596	192,196	44.6%
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	1	28	31	98	157	157	129	24.0%
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	10	0	1,272	0	1,272	127	1,272	100.0%

<sup>a</sup> Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 123, 146, 164, 165, 166, 167, 168, 192, 238, 322, 323, 324, 328).

Notes for Table A37: Performance rate is the performance met as a percent of (performance met + performance not met); the final column is the average performance rate across practices, and therefore cannot be recreated from the other columns in the table.

**Table A38. CAHPS Results for Practices Participating via the PQRS Web Interface for the Large Group Practice Reporting Option (2013).**

Measure type	National Program Year 2013 PQRS Mean
<b>Scored Measures</b>	--
How Well Providers Communicate	93.31%
Patient's Rating of Provider	92.32%
Access to Specialists	85.07%
Making Decisions about Medication	85.02%
Cognitive Functioning	84.88%
Getting Timely Care, Appointments, and Information	81.92%
Making Decisions about Surgery	79.04%
Beneficiaries' Functional Status	77.00%
Shared Decision Making	74.71%
Health Status and Functional Status	70.91%
General Health Promotion and Education	66.70%
Self-Rated Mental Health	64.02%
Health Promotion and Education	58.36%
Percent of Beneficiaries without a Chronic Condition	58.14%
Sharing Your Health Information	52.85%
Self-Rated Health	52.23%
Mental Health Promotion and Education	41.68%
<b>Unscored Measures</b>	--
Courteous and Helpful Office Staff	92.95%
Care Coordination	88.13%
Helping You to Take Medications as Directed	75.69%
Between Visit Communication	58.94%
Stewardship of Patient Resources	25.91%

**Table A39. Performance Information for PQRS Measures Reported by Eligible Professionals Participating in Medicare ACOs participating under the Pioneer ACO Model (2013)**

ACO measures	Measure Description	(A) ACO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met count	(E)=(B)+(C) +(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per ACO	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Care Coordination/ Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
ACO-Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	23	0	8,622	3,713	12,335	536	12,335	70.4%
ACO-Care-2	Falls: Screening for Future Fall Risk	23	37	7,146	4,758	11,941	519	11,904	59.5%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
ACO-CAD-2	Lipid Control	23	232	8,247	2,520	10,999	478	10,767	76.5%
ACO-CAD-7	Diabetes/LVSD and ACE-I/ARB	23	368	3,678	1,216	5,262	229	4,894	74.9%
ACO-CAD-COMP		23	0	7,573	3,426	10,999	478	10,999	68.7%
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
ACO-DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	23	0	1,659	8,617	10,276	447	10,276	16.1%
ACO-DM-13	High Blood Pressure Control in Diabetes Mellitus	23	0	7,972	2,304	10,276	447	10,276	77.2%
ACO-DM-14	Low Density Lipoprotein (LDL- C) Control in Diabetes Mellitus	23	0	6,606	3,670	10,276	447	10,276	63.8%
ACO-DM-15	Hemoglobin A1c Control (< 8%)	23	0	7,743	2,533	10,276	447	10,276	75.4%
ACO-DM-16	Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	23	226	2,818	552	3,596	156	3,370	83.9%
ACO-DM-17	Tobacco Non Use	23	0	7,774	2,502	10,276	447	10,276	75.4%
ACO-DM-COMP	Diabetes Composite (All or Nothing Scoring)	23	0	3,485	6,791	10,276	447	10,276	33.3%

ACO measures	Measure Description	(A) ACO Count	(B) Performance Exclusion Count	(C) Performance Met Count	(D) Performance Not Met count	(E)=(B)+(C) +(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per ACO	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
ACO-HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	23	282	2,279	439	3,000	130	2,718	85.1%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
ACO-HTN-2	Controlling High Blood Pressure	23	32	8,340	2,827	11,199	487	11,167	74.2%
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
ACO-IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	23	0	6,718	3,883	10,601	461	10,601	62.5%
ACO-IVD-2	Use of Aspirin or Another Antithrombotic	23	0	9,013	1,588	10,601	461	10,601	84.3%
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
ACO-Prev-5	Screening Mammography	23	90	8,221	3,242	11,553	502	11,463	71.7%
ACO-Prev-6	Colorectal Cancer Screening	23	67	8,405	3,254	11,726	510	11,659	72.0%
ACO-Prev-7	Influenza Immunization	23	449	7,442	3,539	11,430	497	10,981	69.0%
ACO-Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	23	47	8,662	3,313	12,022	523	11,975	72.1%
ACO-Prev-9	Body Mass Index (BMI) Screening and Follow-Up	23	152	7,755	4,181	12,088	526	11,936	65.1%
ACO-Prev-10	Tobacco Use: Screening and Cessation Intervention	23	0	10,587	1,168	11,755	511	11,755	90.1%
ACO-Prev-11	Screening for High Blood Pressure	23	2,008	6,114	3,610	11,732	510	9,724	61.8%
ACO-Prev-12	Depression Screening	23	1,725	4,895	4,957	11,577	503	9,852	49.8%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

Notes for Table A39: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).

**Table A40. Performance Information for PQRS Measures Reported by Eligible Professionals Participating in Medicare ACOs participating under the Shared Savings Program (2013)**

ACO Measures	Measure Description	(A) ACO Count	(B) Performance Exclusion count	(C) Performance Met count	(D) Performance not met count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
<b>Care Coordination/ Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
ACO-Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	220	0	66,316	17,965	84,281	383	84,281	75.6%
ACO-Care-2	Falls: Screening for Future Fall Risk	220	821	42,693	68,661	112,175	510	111,354	37.8%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
ACO-CAD-2	Lipid Control	220	1,567	69,171	25,670	96,408	438	94,841	71.7%
ACO-CAD-7	Diabetes/LVSD and ACE-I/ARB	220	2,383	32,218	13,142	47,743	217	45,360	69.1%
ACO-CAD- COMPOSITE	CAD Composite (All or Nothing Scoring)	220	0	61,995	34,413	96,408	438	96,408	62.7%
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
ACO-DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	220	0	21,729	76,187	97,916	445	97,916	22.9%
ACO-DM-13	High Blood Pressure Control in Diabetes Mellitus	220	0	68,460	29,456	97,916	445	97,916	69.4%
ACO-DM-14	Low Density Lipoprotein (LDL- C) Control in Diabetes Mellitus	220	0	53,882	44,034	97,916	445	97,916	54.3%
ACO-DM-15	Hemoglobin A1c Control (< 8%)	220	0	67,597	30,319	97,916	445	97,916	68.5%
ACO-DM-16	Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	220	1,080	24,135	7,417	32,632	148	31,552	75.2%
ACO-DM-17	Tobacco Non Use	220	0	63,742	34,174	97,916	445	97,916	62.6%

ACO Measures	Measure Description	(A) ACO Count	(B) Performance Exclusion count	(C) Performance Met count	(D) Performance not met count	(E)=(B)+(C)+(D) Total Reported Instances	(F)=(E)/(A) Average Reported Instances per Practice	(G)=(C)+(D) Total Performance Denominator Instances	Average Performance Rate
ACO-DM-COMP	Diabetes Composite (All or Nothing Scoring)	220	0	21,740	76,176	97,916	445	97,916	21.2%
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
ACO-HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	220	1,179	16,974	3,380	21,533	98	20,354	82.3%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
ACO-HTN-2	Controlling High Blood Pressure	220	347	72,043	33,286	105,676	480	105,329	68.0%
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
ACO-IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	220	0	52,291	40,535	92,826	422	92,826	55.5%
ACO-IVD-2	Use of Aspirin or Another Antithrombotic	220	0	72,707	20,119	92,826	422	92,826	76.6%
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
ACO-Prev-5	Screening Mammography	220	888	66,951	41,041	108,880	495	107,992	61.6%
ACO-Prev-6	Colorectal Cancer Screening	220	771	65,441	45,112	111,324	506	110,553	58.8%
ACO-Prev-7	Influenza Immunization	220	4,312	61,030	47,973	113,315	515	109,003	56.2%
ACO-Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	220	835	61,194	51,537	113,566	516	112,731	53.7%
ACO-Prev-9	Body Mass Index (BMI) Screening and Follow-Up	220	1,111	69,237	42,344	112,692	512	111,581	62.1%
ACO-Prev-10	Tobacco Use: Screening and Cessation Intervention	220	91	95,430	17,482	113,003	514	112,912	84.5%
ACO-Prev-11	Screening for High Blood Pressure	220	14,846	72,754	22,366	109,966	500	95,120	76.2%
ACO-Prev-12	Depression Screening	220	11,649	30,886	68,910	111,445	507	99,796	29.6%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

*Notes for Table A40: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).*



**Table A41. PQRS Incentive Eligibility and Incentives Earned by Reporting Mechanism or Alternative Program (2013)**

Reporting Mechanism or Alternative Program	Number of TINs Participating	Number of TINs Qualifying For Incentive	Percent of Participating TINs who Qualify for Incentive	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount
Pioneer ACO	23	22	95.7%	\$3,103	\$221,558	\$305,415	\$1,125,232	\$6,719,135
CPC	67	56	83.6%	\$25	\$1,495	\$2,785	\$23,949	\$155,945
Claims	69,320	32,832	47.4%	\$0.05	\$651	\$2,635	\$513,417	\$86,510,039
Registry	15,353	12,863	83.8%	\$0.06	\$1,496	\$3,832	\$105,770	\$49,289,458
EHR	4,200	3,785	90.1%	\$0.35	\$910	\$3,568	\$204,045	\$13,503,846
Small GPRO	161	155	96.3%	\$13	\$4,034	\$7,902	\$63,663	\$1,224,829
Medium GPRO	114	108	94.7%	\$161	\$20,412	\$24,663	\$104,016	\$2,663,582
Large GPRO	275	253	92.0%	\$872	\$87,887	\$126,916	\$716,096	\$32,109,808
SSP ACO	220	214	97.3%	\$691	\$90,402	\$154,287	\$1,219,023	\$33,017,405
<b>Unduplicated Total</b>	<b>84,832</b>	<b>48,313</b>	<b>57.0%</b>	<b>\$0.05</b>	<b>\$902</b>	<b>\$4,531</b>	<b>\$1,219,023</b>	<b>\$218,930,348</b>

*Notes for Table A41: The unduplicated total will not match the sum of the incentives for each mechanism since some eligible professionals were incentive eligible under more than one reporting mechanism.*

## 2013 ERX INCENTIVE PROGRAM APPENDIX TABLES

**Table A42. Distribution of Incentive Amounts by Specialty for the eRx Incentive Program (2013)**

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
<b>MD/DO</b>	<b>201,878</b>	<b>71.6%</b>	<b>38.3%</b>	<b>\$0.04</b>	<b>\$458</b>	<b>\$753</b>	<b>\$41,771</b>	<b>\$151,955,299</b>	<b>88.5%</b>
Allergy/Immunology	1,324	67.2%	35.3%	\$0.24	\$283	\$398	\$5,707	\$526,981	0.3%
Anesthesiology	3,741	83.8%	37.7%	\$0.05	\$209	\$397	\$7,147	\$1,486,993	0.9%
Cardiology	13,979	76.9%	56.3%	\$0.08	\$1,148	\$1,456	\$17,513	\$20,349,553	11.8%
Colon/Rectal Surgery	321	49.0%	24.6%	\$0.60	\$569	\$643	\$2,520	\$206,435	0.1%
Critical Care	642	75.2%	44.3%	\$0.24	\$519	\$750	\$5,934	\$481,695	0.3%
Dermatology	5,426	69.8%	46.2%	\$0.13	\$997	\$1,440	\$41,771	\$7,811,959	4.5%
Emergency Medicine	3,493	77.5%	33.4%	\$0.04	\$186	\$268	\$9,440	\$936,312	0.5%
Endocrinology	3,178	77.4%	53.3%	\$0.19	\$366	\$495	\$4,259	\$1,573,263	0.9%
Family Practice	43,369	78.2%	47.1%	\$0.04	\$281	\$406	\$17,877	\$17,609,465	10.3%
Gastroenterology	6,329	69.2%	48.1%	\$0.12	\$716	\$819	\$8,683	\$5,182,935	3.0%
General Practice	1,000	65.5%	19.3%	\$0.04	\$333	\$550	\$7,492	\$550,007	0.3%
General Surgery	3,314	45.6%	15.1%	\$0.05	\$400	\$510	\$6,658	\$1,689,745	1.0%
Geriatrics	1,758	76.0%	41.7%	\$0.05	\$490	\$699	\$9,502	\$1,229,403	0.7%
Hand Surgery	316	38.3%	16.8%	\$0.40	\$737	\$869	\$6,678	\$274,682	0.2%
Infectious Disease	1,594	55.6%	28.7%	\$0.37	\$303	\$538	\$5,873	\$856,779	0.5%
Internal Medicine	38,137	78.3%	45.4%	\$0.04	\$456	\$654	\$11,093	\$24,945,250	14.5%
Interventional Radiology	201	79.1%	17.8%	\$0.14	\$401	\$436	\$1,512	\$87,636	0.1%
Nephrology	3,725	65.0%	43.3%	\$0.13	\$1,212	\$1,276	\$7,016	\$4,751,486	2.8%
Neurology	6,312	73.6%	45.1%	\$0.13	\$433	\$618	\$8,834	\$3,900,514	2.3%
Neurosurgery	893	49.2%	18.4%	\$0.05	\$560	\$721	\$6,724	\$643,568	0.4%
Nuclear Medicine	144	88.9%	46.0%	\$0.24	\$575	\$936	\$7,492	\$134,809	0.1%
Obstetrics/Gynecology	5,774	42.2%	17.6%	\$0.10	\$85	\$177	\$3,647	\$1,023,180	0.6%
Oncology/Hematology	5,860	73.9%	46.5%	\$0.13	\$718	\$1,064	\$13,632	\$6,236,104	3.6%
Ophthalmology	9,748	71.9%	48.0%	\$0.17	\$1,581	\$1,952	\$21,692	\$19,030,935	11.1%

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
Oral/Maxillofacial Surgery	29	53.7%	7.6%	\$4.61	\$83	\$123	\$548	\$3,559	0.0%
Orthopaedic Surgery	5,461	49.6%	24.3%	\$0.12	\$934	\$1,106	\$13,796	\$6,041,085	3.5%
Other MD/DO	1,978	70.9%	23.6%	\$0.04	\$404	\$750	\$10,441	\$1,483,474	0.9%
Otolaryngology	4,120	71.8%	43.8%	\$0.12	\$601	\$730	\$8,399	\$3,006,698	1.8%
Pathology	1,455	96.9%	77.8%	\$0.09	\$193	\$246	\$4,488	\$358,004	0.2%
Pediatrics	2,084	73.0%	26.9%	\$0.04	\$3	\$54	\$2,580	\$111,621	0.1%
Physical Medicine	1,999	61.0%	24.8%	\$0.33	\$545	\$772	\$9,865	\$1,542,640	0.9%
Plastic Surgery	435	47.1%	9.4%	\$0.53	\$307	\$479	\$6,315	\$208,415	0.1%
Psychiatry	5,212	70.0%	17.8%	\$0.04	\$167	\$289	\$4,657	\$1,503,811	0.9%
Pulmonary Disease	4,908	74.6%	50.5%	\$0.06	\$853	\$1,054	\$8,889	\$5,173,511	3.0%
Radiation Oncology	527	50.8%	10.8%	\$0.25	\$542	\$739	\$9,460	\$389,497	0.2%
Radiology	3,443	97.4%	49.5%	\$0.04	\$232	\$342	\$5,387	\$1,178,610	0.7%
Rheumatology	2,902	82.2%	60.4%	\$0.23	\$481	\$706	\$11,980	\$2,048,949	1.2%
Thoracic/Cardiac Surgery	598	54.5%	15.9%	\$0.30	\$583	\$748	\$7,076	\$447,030	0.3%
Urology	5,590	79.7%	57.0%	\$0.08	\$995	\$1,119	\$12,052	\$6,257,893	3.6%
Vascular Surgery	559	41.5%	17.1%	\$0.17	\$943	\$1,218	\$10,176	\$680,813	0.4%
<b>Other Eligible Professionals</b>	<b>57,388</b>	<b>60.6%</b>	<b>20.5%</b>	<b>\$0.03</b>	<b>\$123</b>	<b>\$344</b>	<b>\$25,433</b>	<b>\$19,741,843</b>	<b>11.5%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	288	69.2%	21.5%	\$0.09	\$249	\$447	\$4,776	\$128,828	0.1%
Audiologist	386	98.5%	62.6%	\$0.06	\$22	\$35	\$284	\$13,472	0.0%
Certified Nurse Midwives	285	41.0%	15.2%	\$0.08	\$2	\$10	\$300	\$2,801	0.0%
Chiropractor	35	81.4%	25.4%	\$1.69	\$41	\$76	\$562	\$2,662	0.0%
Clinical Nurse Specialists	498	61.7%	20.7%	\$0.09	\$106	\$146	\$1,251	\$72,937	0.0%
Counselor/Psychologist	990	84.8%	3.0%	\$0.10	\$45	\$80	\$1,017	\$79,494	0.0%
Dentist	139	81.8%	4.6%	\$0.09	\$28	\$96	\$2,490	\$13,393	0.0%
Dietitian/Nutritionist	313	89.2%	36.4%	\$0.12	\$12	\$28	\$1,223	\$8,766	0.0%
Nurse Anesthetist	2,712	97.4%	92.1%	\$0.13	\$55	\$70	\$1,760	\$189,912	0.1%
Nurse Practitioner	20,148	60.1%	29.2%	\$0.03	\$91	\$152	\$3,033	\$3,062,692	1.8%

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
Optometry	2,754	37.2%	7.9%	\$0.45	\$377	\$505	\$5,475	\$1,390,638	0.8%
Other Eligible Professional	9,302	66.8%	30.1%	\$0.09	\$596	\$957	\$25,433	\$8,905,797	5.2%
Physical/Occupational Therapy	807	95.4%	78.0%	\$0.18	\$72	\$117	\$3,177	\$94,548	0.1%
Physician Assistant	13,454	60.8%	30.4%	\$0.03	\$87	\$160	\$5,155	\$2,146,912	1.3%
Podiatrist	4,387	50.4%	24.4%	\$0.39	\$700	\$809	\$7,176	\$3,549,458	2.1%
Registered Nurse	424	59.8%	20.8%	\$0.05	\$94	\$142	\$2,131	\$60,066	0.0%
Social Worker	466	72.0%	1.4%	\$0.29	\$28	\$42	\$277	\$19,467	0.0%
Unknown/Missing	135	49.6%	16.6%	\$0.17	\$119	\$263	\$5,917	\$35,530	0.0%
<b>Total (Unduplicated)</b>	<b>259,401</b>	<b>68.8%</b>	<b>32.1%</b>	<b>\$0.03</b>	<b>\$364</b>	<b>\$662</b>	<b>\$41,771</b>	<b>\$171,732,673</b>	<b>100.0%</b>

*Notes for Table A42: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A43. Potential Incentives and Participation Information by Specialty for the eRx Incentive Program (2013)**

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
<b>MD/DO</b>	<b>\$555</b>	<b>53.4%</b>
Allergy/Immunology	\$285	52.5%
Anesthesiology	\$400	44.9%
Cardiology	\$1,165	73.1%
Colon/Rectal Surgery	\$521	50.2%
Critical Care	\$634	59.0%
Dermatology	\$1,249	66.2%
Emergency Medicine	\$198	43.1%
Endocrinology	\$391	68.9%
Family Practice	\$309	60.2%
Gastroenterology	\$664	69.4%
General Practice	\$279	29.5%
General Surgery	\$456	33.1%
Geriatrics	\$552	54.9%
Hand Surgery	\$590	43.7%
Infectious Disease	\$559	51.7%
Internal Medicine	\$517	57.9%
Interventional Radiology	\$1,195	22.5%
Nephrology	\$1,237	66.7%
Neurology	\$456	61.3%
Neurosurgery	\$694	37.3%
Nuclear Medicine	\$887	51.8%
Obstetrics/Gynecology	\$93	41.7%
Oncology/Hematology	\$711	63.0%
Ophthalmology	\$1,310	66.8%
Oral/Maxillofacial Surgery	\$95	14.1%
Orthopaedic Surgery	\$756	49.0%
Other MD/DO	\$521	33.2%
Otolaryngology	\$556	61.1%
Pathology	\$306	80.3%
Pediatrics	\$35	36.8%
Physical Medicine	\$573	40.7%
Plastic Surgery	\$333	20.0%
Psychiatry	\$190	25.4%
Pulmonary Disease	\$863	67.7%
Radiation Oncology	\$1,730	21.3%
Radiology	\$653	50.8%
Rheumatology	\$564	73.5%
Thoracic/Cardiac Surgery	\$790	29.2%
Urology	\$852	71.5%
Vascular Surgery	\$1,356	41.3%

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
<b>Other Eligible Professionals</b>	<b>\$200</b>	<b>33.8%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	\$304	31.1%
Audiologist	\$85	63.5%
Certified Nurse Midwives	\$8	37.0%
Chiropractor	\$110	31.2%
Clinical Nurse Specialists	\$117	33.5%
Counselor/Psychologist	\$105	3.5%
Dentist	\$56	5.6%
Dietitian/Nutritionist	\$37	40.8%
Nurse Anesthetist	\$77	94.5%
Nurse Practitioner	\$112	48.5%
Optometry	\$159	21.4%
Other Eligible Professional	\$675	45.0%
Physical/Occupational Therapy	\$265	81.7%
Physician Assistant	\$113	50.1%
Podiatrist	\$557	48.5%
Registered Nurse	\$112	34.8%
Social Worker	\$49	1.9%
Unknown/Missing	\$197	33.4%
<b>Total (Unduplicated)</b>	<b>\$432</b>	<b>46.6%</b>

*Notes for Table A43: Results include eligible professionals who are part of a practice that participated under the GPRO.*

**Table A44. Eligible Professional Information by Specialty for the eRx Incentive Program (2012 to 2013)**

Specialty	Eligible Professionals in 2012	Eligible Professionals in 2013	Eligible Professionals who Participated in 2012	Eligible Professionals who Participated in 2013	Participation Percent in 2012	Participation Percent in 2013
<b>MD/DO</b>	<b>515,904</b>	<b>527,701</b>	<b>264,114</b>	<b>282,026</b>	<b>51.2%</b>	<b>53.4%</b>
Allergy/Immunology	3,732	3,749	1,881	1,970	50.4%	52.5%
Anesthesiology	8,676	9,936	3,164	4,466	36.5%	44.9%
Cardiology	24,382	24,845	17,856	18,168	73.2%	73.1%
Colon/Rectal Surgery	1,222	1,305	563	655	46.1%	50.2%
Critical Care	1,362	1,448	772	854	56.7%	59.0%
Dermatology	11,428	11,735	7,326	7,769	64.1%	66.2%
Emergency Medicine	9,324	10,470	3,331	4,510	35.7%	43.1%
Endocrinology	5,757	5,959	3,909	4,104	67.9%	68.9%
Family Practice	91,318	92,146	54,596	55,451	59.8%	60.2%
Gastroenterology	12,965	13,171	8,748	9,142	67.5%	69.4%
General Practice	5,305	5,173	1,423	1,527	26.8%	29.5%
General Surgery	21,818	22,009	6,240	7,275	28.6%	33.1%
Geriatrics	4,104	4,213	2,151	2,314	52.4%	54.9%
Hand Surgery	1,780	1,884	813	824	45.7%	43.7%
Infectious Disease	5,226	5,549	2,580	2,869	49.4%	51.7%
Internal Medicine	82,948	84,026	47,454	48,693	57.2%	57.9%
Interventional Radiology	1,025	1,128	181	254	17.7%	22.5%
Nephrology	8,339	8,594	5,679	5,728	68.1%	66.7%
Neurology	13,508	13,992	8,028	8,578	59.4%	61.3%
Neurosurgery	4,727	4,860	1,633	1,814	34.5%	37.3%
Nuclear Medicine	312	313	143	162	45.8%	51.8%
Obstetrics/Gynecology	32,375	32,816	12,025	13,670	37.1%	41.7%
Oncology/Hematology	12,256	12,597	7,462	7,934	60.9%	63.0%
Ophthalmology	20,159	20,293	13,393	13,551	66.4%	66.8%
Oral/Maxillofacial Surgery	403	384	44	54	10.9%	14.1%
Orthopaedic Surgery	22,131	22,464	10,587	11,009	47.8%	49.0%

Specialty	Eligible Professionals in 2012	Eligible Professionals in 2013	Eligible Professionals who Participated in 2012	Eligible Professionals who Participated in 2013	Participation Percent in 2012	Participation Percent in 2013
Other MD/DO	7,894	8,391	2,204	2,790	27.9%	33.2%
Otolaryngology	9,274	9,398	5,527	5,740	59.6%	61.1%
Pathology	1,266	1,870	882	1,501	69.7%	80.3%
Pediatrics	7,272	7,756	1,984	2,856	27.3%	36.8%
Physical Medicine	7,790	8,056	3,019	3,276	38.8%	40.7%
Plastic Surgery	4,631	4,620	769	923	16.6%	20.0%
Psychiatry	29,821	29,359	6,158	7,450	20.6%	25.4%
Pulmonary Disease	9,327	9,712	6,187	6,579	66.3%	67.7%
Radiation Oncology	4,849	4,877	841	1,037	17.3%	21.3%
Radiology	5,808	6,961	2,233	3,536	38.4%	50.8%
Rheumatology	4,684	4,803	3,448	3,531	73.6%	73.5%
Thoracic/Cardiac Surgery	3,705	3,764	823	1,098	22.2%	29.2%
Urology	9,790	9,810	6,850	7,016	70.0%	71.5%
Vascular Surgery	3,211	3,265	1,207	1,348	37.6%	41.3%
<b>Other Eligible Professionals</b>	<b>262,215</b>	<b>280,181</b>	<b>80,379</b>	<b>94,706</b>	<b>30.7%</b>	<b>33.8%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	1,316	1,339	348	416	26.4%	31.1%
Audiologist	427	617	218	392	51.1%	63.5%
Certified Nurse Midwives	1,738	1,879	523	695	30.1%	37.0%
Chiropractor	100	138	34	43	34.0%	31.2%
Clinical Nurse Specialists	2,255	2,406	651	807	28.9%	33.5%
Counselor/Psychologist	32,724	33,124	780	1,168	2.4%	3.5%
Dentist	3,101	3,017	132	170	4.3%	5.6%
Dietitian/Nutritionist	776	861	264	351	34.0%	40.8%
Nurse Anesthetist	1,638	2,944	1,505	2,783	91.9%	94.5%
Nurse Practitioner	59,913	69,064	27,057	33,523	45.2%	48.5%
Optometry	33,936	34,717	7,054	7,413	20.8%	21.4%
Other Eligible Professional	31,567	30,931	13,413	13,916	42.5%	45.0%



Specialty	Eligible Professionals in 2012	Eligible Professionals in 2013	Eligible Professionals who Participated in 2012	Eligible Professionals who Participated in 2013	Participation Percent in 2012	Participation Percent in 2013
Physical/Occupational Therapy	818	1,035	629	846	76.9%	81.7%
Physician Assistant	39,048	44,187	18,107	22,117	46.4%	50.1%
Podiatrist	18,026	17,964	8,609	8,710	47.8%	48.5%
Registered Nurse	2,037	2,035	586	709	28.8%	34.8%
Social Worker	32,795	33,923	469	647	1.4%	1.9%
Unknown/Missing	785	815	183	272	23.3%	33.4%
<b>Total (Unduplicated)</b>	<b>778,904</b>	<b>808,697</b>	<b>344,676</b>	<b>377,004</b>	<b>44.3%</b>	<b>46.6%</b>

*Note for Table A44: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A45. Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program (2012 to 2013)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligible EPs as a Percent of EPs who Participated in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligible EPs as a Percent of EPs who Participated in 2013
<b>MD/DO</b>	<b>182,217</b>	<b>69.0%</b>	<b>201,878</b>	<b>71.6%</b>
Allergy/Immunology	1,188	63.2%	1,324	67.2%
Anesthesiology	2,484	78.5%	3,741	83.8%
Cardiology	13,378	74.9%	13,979	76.9%
Colon/Rectal Surgery	273	48.5%	321	49.0%
Critical Care	527	68.3%	642	75.2%
Dermatology	4,795	65.5%	5,426	69.8%
Emergency Medicine	2,545	76.4%	3,493	77.5%
Endocrinology	2,883	73.8%	3,178	77.4%
Family Practice	41,571	76.1%	43,369	78.2%
Gastroenterology	5,692	65.1%	6,329	69.2%
General Practice	930	65.4%	1,000	65.5%
General Surgery	2,450	39.3%	3,314	45.6%
Geriatrics	1,596	74.2%	1,758	76.0%
Hand Surgery	296	36.4%	316	38.3%
Infectious Disease	1,295	50.2%	1,594	55.6%
Internal Medicine	36,518	77.0%	38,137	78.3%
Interventional Radiology	131	72.4%	201	79.1%
Nephrology	3,514	61.9%	3,725	65.0%
Neurology	5,563	69.3%	6,312	73.6%
Neurosurgery	702	43.0%	893	49.2%
Nuclear Medicine	118	82.5%	144	88.9%
Obstetrics/Gynecology	4,476	37.2%	5,774	42.2%
Oncology/Hematology	5,359	71.8%	5,860	73.9%
Ophthalmology	9,650	72.1%	9,748	71.9%
Oral/Maxillofacial Surgery	21	47.7%	29	53.7%
Orthopaedic Surgery	5,002	47.2%	5,461	49.6%
Other MD/DO	1,425	64.7%	1,978	70.9%
Otolaryngology	3,734	67.6%	4,120	71.8%
Pathology	859	97.4%	1,455	96.9%
Pediatrics	1,366	68.9%	2,084	73.0%
Physical Medicine	1,722	57.0%	1,999	61.0%
Plastic Surgery	332	43.2%	435	47.1%
Psychiatry	4,144	67.3%	5,212	70.0%
Pulmonary Disease	4,391	71.0%	4,908	74.6%
Radiation Oncology	327	38.9%	527	50.8%
Radiology	2,140	95.8%	3,443	97.4%
Rheumatology	2,708	78.5%	2,902	82.2%
Thoracic/Cardiac Surgery	369	44.8%	598	54.5%

Specialty	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligible EPs as a Percent of EPs who Participated in 2012	Eligible Professionals who Qualified for an Incentive in 2013	Incentive Eligible EPs as a Percent of EPs who Participated in 2013
Urology	5,327	77.8%	5,590	79.7%
Vascular Surgery	416	34.5%	559	41.5%
<b>Other Eligible Professionals</b>	<b>45,145</b>	<b>56.2%</b>	<b>57,388</b>	<b>60.6%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	220	63.2%	288	69.2%
Audiologist	211	96.8%	386	98.5%
Certified Nurse Midwives	181	34.6%	285	41.0%
Chiropractor	27	79.4%	35	81.4%
Clinical Nurse Specialists	389	59.8%	498	61.7%
Counselor/Psychologist	632	81.0%	990	84.8%
Dentist	105	79.5%	139	81.8%
Dietitian/Nutritionist	226	85.6%	313	89.2%
Nurse Anesthetist	1,499	99.6%	2,712	97.4%
Nurse Practitioner	15,098	55.8%	20,148	60.1%
Optometry	2,577	36.5%	2,754	37.2%
Other Eligible Professional	8,216	61.3%	9,302	66.8%
Physical/Occupational Therapy	571	90.8%	807	95.4%
Physician Assistant	10,280	56.8%	13,454	60.8%
Podiatrist	4,239	49.2%	4,387	50.4%
Registered Nurse	337	57.5%	424	59.8%
Social Worker	337	71.9%	466	72.0%
Unknown/Missing	85	46.4%	135	49.6%
<b>Total (Unduplicated)</b>	<b>227,447</b>	<b>66.0%</b>	<b>259,401</b>	<b>68.8%</b>

Notes for Table A45: Results include eligible professionals who are part of a practice that participated under the GPRO.

**Table A46. Eligible Professional Characteristics for the eRx Incentive Program (2013)**

Eligible Professional (EP) Characteristics	Number of EPs	Number of EPs Participating	Participation Rate	Number of EPs who were Incentive Eligible	Incentive Eligibility Rate
Participation Mechanism/Option	--	--	--	--	--
Claims	728,059	292,388	40.2%	177,529	60.7%
Registry	728,059	7,934	1.1%	6,096	76.8%
EHR	728,059	3,292	0.5%	2,791	84.8%
Small GPRO	1,029	837	81.3%	799	95.5%
Medium GPRO	2,132	1,839	86.3%	1,790	97.3%
Large GPRO	77,477	77,333	99.8%	75,213	97.3%
Geography (Regions)	--	--	--	--	--
1 - Boston	57,999	25,475	43.9%	16,472	64.7%
2 - New York	92,659	34,469	37.2%	21,769	63.2%
3 - Philadelphia	82,631	39,344	47.6%	26,443	67.2%
4 - Atlanta	140,718	67,722	48.1%	45,015	66.5%
5 - Chicago	147,392	74,417	50.5%	52,721	70.8%
6 - Dallas	76,208	36,631	48.1%	24,875	67.9%
7 - Kansas City	35,358	18,049	51.0%	12,841	71.1%
8 - Denver	27,298	11,256	41.2%	7,825	69.5%
9 - San Francisco	89,960	32,242	35.8%	20,071	62.3%
10 - Seattle	33,058	13,861	41.9%	8,882	64.1%
Unknown	25,415	25,186	99.1%	23,822	94.6%
Practice Size (# of NPIs)	--	--	--	--	--
Individual Participants	--	--	--	--	--
1	155,811	42,958	27.6%	27,754	64.6%
2-4	104,484	44,878	43.0%	27,663	61.6%
5-10	88,245	38,984	44.2%	24,265	62.2%
11-24	79,424	33,224	41.8%	20,403	61.4%
25-50	62,858	27,082	43.1%	16,336	60.3%
51-99	58,187	27,307	46.9%	17,195	63.0%
100-199	59,010	29,188	49.5%	18,065	61.9%
200+	120,040	53,374	44.5%	29,918	56.1%
GPRO	--	--	--	--	--
1-24	768	590	253.4%	532	349.0%
25-50	690	537	77.8%	488	90.9%
51-99	1,457	1,303	89.4%	1,251	96.0%
100-199	2,777	2,633	94.8%	2,497	94.8%
200+	74,946	74,946	100.0%	73,034	97.4%
Total PFS charges per Practice	--	--	--	--	--
Individual Participants	--	--	--	--	--
less than or equal to \$10,000	162,652	24,002	14.8%	2,073	8.6%
\$10,001 - \$40,000	144,496	40,319	27.9%	17,757	44.0%
\$40,001 - \$100,000	121,813	51,181	42.0%	31,649	61.8%
\$100,001 - \$300,000	163,042	87,976	54.0%	60,593	68.9%

Eligible Professional (EP) Characteristics	Number of EPs	Number of EPs Participating	Participation Rate	Number of EPs who were Incentive Eligible	Incentive Eligibility Rate
over \$300,000	135,461	92,933	68.6%	69,527	74.8%
Unknown	595	584	98.2%	0	0.0%
GPRO	--	--	--	--	--
less than or equal to \$10,000	19,294	19,106	99.0%	18,644	97.6%
\$10,001 - \$40,000	18,038	17,907	99.3%	17,288	96.5%
\$40,001 - \$100,000	17,187	17,084	99.4%	16,586	97.1%
\$100,001 - \$300,000	19,959	19,832	99.4%	19,285	97.2%
over \$300,000	6,160	6,080	98.7%	5,999	98.7%
Unknown	0	0	0.0%	0	0.0%
Beneficiary Volume	--	--	--	--	--
Individual Participants	--	--	--	--	--
1 – 25	228,110	22,186	9.7%	759	3.4%
26 – 100	164,645	56,896	34.6%	21,935	38.6%
101 – 200	119,810	64,524	53.9%	40,764	63.2%
> 200	214,786	152,695	71.1%	118,141	77.4%
Unknown	708	694	98.0%	0	0.0%
GPRO	--	--	--	--	--
1 – 25	16,201	16,082	99.3%	15,677	97.5%
26 – 100	14,644	14,548	99.3%	14,058	96.6%
101 – 200	11,199	11,133	99.4%	10,792	96.9%
> 200	13,887	13,754	99.0%	13,453	97.8%
Unknown	24,707	24,492	99.1%	23,822	97.3%
Specialty	--	--	--	--	--
<b>MD/DO</b>	--	--	--	--	--
Primary Care	189,101	108,527	57.4%	84,590	77.9%
Surgery	64,555	25,000	38.7%	11,926	47.7%
Other Specialties	274,045	148,499	54.2%	105,362	71.0%
<b>Other eligible professionals</b>	--	--	--	--	--
Physicians	37,872	7,626	20.1%	2,928	38.4%
Physician Assistant	44,187	22,117	50.1%	13,454	60.8%
Nurse Practitioner	69,064	33,523	48.5%	20,148	60.1%
Podiatrists	17,964	8,710	48.5%	4,387	50.4%
Other Eligible Professionals	111,909	23,002	20.6%	16,606	72.2%
<b>Total (Unduplicated)</b>	<b>808,697</b>	<b>377,004</b>	<b>46.6%</b>	<b>259,401</b>	<b>68.8%</b>

Notes for Table A46: (1) Eligible professional-level results in this table include eligible professionals who belong to a practice that participated under the GPRO. (2) Sums across participation methods do not equal totals due to participation in multiple methods. (3) Eligible Professionals in the Unknown categories include Registry and EHR data where a match in claims was not found.

**Table A47. Eligible Professional Information by State for the eRx Incentive Program (2013)**

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received Incentive	Incentive Eligibility Rate
Alaska	1,848	483	26.1%	272	56.3%
Alabama	9,439	5,223	55.3%	3,913	74.9%
Arkansas	6,029	3,426	56.8%	2,629	76.7%
Arizona	14,159	6,007	42.4%	3,776	62.9%
California	68,520	24,162	35.3%	15,297	63.3%
Colorado	12,205	3,922	32.1%	2,150	54.8%
Connecticut	12,688	6,093	48.0%	4,443	72.9%
District of Columbia	2,897	1,243	42.9%	910	73.2%
Delaware	2,568	1,137	44.3%	757	66.6%
Florida	45,589	21,257	46.6%	13,605	64.0%
Georgia	19,682	9,956	50.6%	7,239	72.7%
Hawaii	2,830	935	33.0%	522	55.8%
Iowa	8,235	4,809	58.4%	4,029	83.8%
Idaho	3,707	1,524	41.1%	890	58.4%
Illinois	34,223	17,020	49.7%	12,476	73.3%
Indiana	16,043	7,811	48.7%	5,194	66.5%
Kansas	7,631	3,380	44.3%	2,131	63.0%
Kentucky	11,336	5,171	45.6%	3,491	67.5%
Louisiana	10,115	3,937	38.9%	2,462	62.5%
Massachusetts	31,597	15,572	49.3%	9,563	61.4%
Maryland	16,590	6,781	40.9%	4,090	60.3%
Maine	5,797	1,766	30.5%	1,068	60.5%
Michigan	32,104	16,320	50.8%	12,080	74.0%
Minnesota	20,368	10,265	50.4%	7,287	71.0%
Missouri	15,823	8,729	55.2%	6,378	73.1%
Mississippi	5,793	2,763	47.7%	1,891	68.4%
Montana	2,765	1,169	42.3%	844	72.2%
North Carolina	25,039	13,571	54.2%	9,046	66.7%
North Dakota	2,893	1,931	66.7%	1,728	89.5%
Nebraska	5,231	2,635	50.4%	1,833	69.6%
New Hampshire	5,466	2,874	52.6%	2,315	80.5%
New Jersey	24,441	9,966	40.8%	6,553	65.8%
New Mexico	4,979	2,583	51.9%	1,889	73.1%
Nevada	4,665	1,931	41.4%	1,234	63.9%
New York	64,600	25,422	39.4%	16,553	65.1%
Ohio	33,686	18,736	55.6%	14,290	76.3%
Oklahoma	8,590	4,438	51.7%	3,165	71.3%
Oregon	10,405	4,763	45.8%	3,160	66.3%
Pennsylvania	40,829	21,408	52.4%	15,647	73.1%
Puerto Rico	5,610	640	11.4%	252	39.4%
Rhode Island	3,762	1,380	36.7%	792	57.4%

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received Incentive	Incentive Eligibility Rate
South Carolina	9,743	4,911	50.4%	3,329	67.8%
South Dakota	3,145	2,025	64.4%	1,577	77.9%
Tennessee	16,725	6,981	41.7%	4,435	63.5%
Texas	47,204	24,088	51.0%	16,889	70.1%
Utah	6,089	2,911	47.8%	2,350	80.7%
Virginia	18,701	9,815	52.5%	6,856	69.9%
Virgin Islands	137	51	37.2%	29	56.9%
Vermont	2,406	1,191	49.5%	1,021	85.7%
Washington	18,044	7,763	43.0%	5,234	67.4%
Wisconsin	18,788	11,208	59.7%	8,124	72.5%
West Virginia	4,541	2,083	45.9%	1,251	60.1%
Wyoming	1,330	464	34.9%	273	58.8%
Other	252	102	40.5%	54	52.9%
Unknown/Missing	815	272	33.4%	135	49.6%
<b>Total (Unduplicated)</b>	<b>808,697</b>	<b>377,004</b>	<b>46.6%</b>	<b>259,401</b>	<b>68.8%</b>

*Notes for Table A47: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A48. Eligible Professionals who Successfully met Reporting Criteria but did not Receive an Incentive Because they did not have at Least 10% of their MPFS Charges from Instances for the eRx Measure (i.e., 10% Limitation Threshold) for the eRx Incentive Program (2012 to 2013)**

Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013
<b>MD/DO</b>	<b>2,228</b>	<b>0.4%</b>	<b>2,006</b>	<b>0.4%</b>
Allergy/Immunology	3	0.1%	2	0.1%
Anesthesiology	7	0.1%	15	0.2%
Cardiology	188	0.8%	162	0.7%
Colon/Rectal Surgery	3	0.2%	5	0.4%
Critical Care	17	1.2%	18	1.2%
Dermatology	315	2.8%	296	2.5%
Emergency Medicine	17	0.2%	5	0.0%
Endocrinology	3	0.1%	1	0.0%
Family Practice	168	0.2%	93	0.1%
Gastroenterology	131	1.0%	125	0.9%
General Practice	3	0.1%	6	0.1%
General Surgery	64	0.3%	50	0.2%
Geriatrics	6	0.1%	5	0.1%
Hand Surgery	0	0.0%	0	0.0%
Infectious Disease	89	1.7%	98	1.8%
Internal Medicine	256	0.3%	203	0.2%
Interventional Radiologist	1	0.1%	2	0.2%
Nephrology	498	6.0%	475	5.5%
Neurology	26	0.2%	20	0.1%
Neurosurgery	24	0.5%	20	0.4%
Nuclear Medicine	3	1.0%	0	0.0%
Obstetrics/Gynecology	9	0.0%	9	0.0%
Oncology/Hematology	7	0.1%	6	0.0%
Ophthalmology	27	0.1%	23	0.1%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%



Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013
Orthopaedic Surgery	42	0.2%	28	0.1%
Other MD/DO	24	0.3%	26	0.3%
Otolaryngology	7	0.1%	5	0.1%
Pathology	0	0.0%	1	0.1%
Pediatrics	0	0.0%	10	0.1%
Physical Medicine	33	0.4%	27	0.3%
Plastic Surgery	9	0.2%	8	0.2%
Psychiatry	22	0.1%	34	0.1%
Pulmonary Disease	98	1.1%	89	0.9%
Radiation Oncology	46	0.9%	45	0.9%
Radiologist	5	0.1%	0	0.0%
Rheumatology	2	0.0%	1	0.0%
Thoracic/Cardiac Surgery	32	0.9%	39	1.0%
Urology	6	0.1%	11	0.1%
Vascular Surgery	37	1.2%	43	1.3%
<b>Other Eligible Professionals</b>	<b>392</b>	<b>0.1%</b>	<b>408</b>	<b>0.1%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	2	0.2%	4	0.3%
Audiologist	1	0.2%	0	0.0%
Certified Nurse Midwives	0	0.0%	0	0.0%
Chiropractor	0	0.0%	0	0.0%
Clinical Nurse Specialists	1	0.0%	1	0.0%
Counselor/Psychologist	2	0.0%	0	0.0%
Dentist	0	0.0%	0	0.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%
Nurse Anesthetist	0	0.0%	0	0.0%
Nurse Practitioner	118	0.2%	141	0.2%
Optometry	0	0.0%	3	0.0%
Other Eligible Professional	149	0.5%	120	0.4%

Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2013
Physical/Occupational Therapy	0	0.0%	1	0.1%
Physician Assistant	89	0.2%	106	0.2%
Podiatrist	26	0.1%	31	0.2%
Registered Nurse	4	0.2%	1	0.0%
Social Worker	0	0.0%	0	0.0%
Unknown/Missing	4	0.5%	12	1.5%
<b>Total (Unduplicated)</b>	<b>2,624</b>	<b>0.3%</b>	<b>2,426</b>	<b>0.3%</b>

*Notes for Table A48: (1) Eligible professional-level results in this table include eligible professionals who were part of a practice that participated under the GPRO*

**Table A49. Eligible Professionals by Specialty Subject to the eRx Payment Adjustment (2012–2014)**

Specialty	Number of EPs Subject to Payment Adjustment in 2012	Percent of EPs Subject to Payment Adjustment in 2012	Number of EPs Subject to Payment Adjustment in 2013	Percent of EPs Subject to Payment Adjustment in 2013	Number of EPs Subject to Payment Adjustment in 2014	Percent of EPs Subject to Payment Adjustment in 2014
<b>MD/DO</b>	<b>115,182</b>	<b>85.1%</b>	<b>48,165</b>	<b>80.3%</b>	<b>37,828</b>	<b>76.3%</b>
Allergy/Immunology	800	0.6%	426	0.7%	350	0.7%
Anesthesiology	1,313	1.0%	650	1.1%	604	1.2%
Cardiology	5,855	4.3%	1,833	3.1%	1,324	2.7%
Colon/Rectal Surgery	241	0.2%	100	0.2%	78	0.2%
Critical Care	218	0.2%	84	0.1%	69	0.1%
Dermatology	3,142	2.3%	1,627	2.7%	1,357	2.7%
Emergency Medicine	1,332	1.0%	815	1.4%	746	1.5%
Endocrinology	1,500	1.1%	557	0.9%	395	0.8%
Family Practice	24,534	18.1%	9,218	15.4%	6,915	13.9%
Gastroenterology	3,330	2.5%	1,156	1.9%	802	1.6%
General Practice	1,747	1.3%	997	1.7%	755	1.5%
General Surgery	3,274	2.4%	1,401	2.3%	1,239	2.5%
Geriatrics	1,348	1.0%	590	1.0%	462	0.9%
Hand Surgery	400	0.3%	159	0.3%	157	0.3%
Infectious Disease	597	0.4%	267	0.4%	215	0.4%
Internal Medicine	20,905	15.4%	7,980	13.3%	6,097	12.3%
Interventional Radiologist	5	0.0%	5	0.0%	6	0.0%
Nephrology	1,540	1.1%	494	0.8%	354	0.7%
Neurology	2,920	2.2%	1,140	1.9%	904	1.8%
Neurosurgery	796	0.6%	368	0.6%	294	0.6%
Nuclear Medicine	34	0.0%	9	0.0%	8	0.0%
Obstetrics/Gynecology	2,852	2.1%	1,410	2.4%	1,036	2.1%
Oncology/Hematology	3,258	2.4%	1,325	2.2%	946	1.9%
Ophthalmology	5,046	3.7%	1,879	3.1%	1,610	3.2%

Specialty	Number of EPs Subject to Payment Adjustment in 2012	Percent of EPs Subject to Payment Adjustment in 2012	Number of EPs Subject to Payment Adjustment in 2013	Percent of EPs Subject to Payment Adjustment in 2013	Number of EPs Subject to Payment Adjustment in 2014	Percent of EPs Subject to Payment Adjustment in 2014
Oral/Maxillofacial Surgery	19	0.0%	8	0.0%	6	0.0%
Orthopaedic Surgery	5,764	4.3%	2,428	4.0%	2,095	4.2%
Other MD/DO	1,231	0.9%	605	1.0%	653	1.3%
Otolaryngology	2,975	2.2%	1,214	2.0%	968	2.0%
Pathology	45	0.0%	7	0.0%	16	0.0%
Pediatrics	274	0.2%	103	0.2%	86	0.2%
Physical Medicine	1,821	1.3%	880	1.5%	805	1.6%
Plastic Surgery	405	0.3%	205	0.3%	211	0.4%
Psychiatry	8,431	6.2%	5,559	9.3%	4,208	8.5%
Pulmonary Disease	2,282	1.7%	812	1.4%	609	1.2%
Radiation Oncology	280	0.2%	170	0.3%	142	0.3%
Radiologist	104	0.1%	41	0.1%	61	0.1%
Rheumatology	1,081	0.8%	400	0.7%	298	0.6%
Thoracic/Cardiac Surgery	218	0.2%	94	0.2%	86	0.2%
Urology	2,637	1.9%	911	1.5%	661	1.3%
Vascular Surgery	628	0.5%	238	0.4%	200	0.4%
<b>Other Eligible Professionals <sup>a</sup></b>	<b>19,899</b>	<b>14.7%</b>	<b>11,665</b>	<b>19.5%</b>	<b>11,444</b>	<b>23.1%</b>
Nurse Practitioner	9,042	6.7%	5,818	9.7%	5,596	11.3%
Physician Assistant	4,548	3.4%	3,181	5.3%	3,498	7.1%
Podiatrist	6,309	4.7%	2,666	4.4%	2,350	4.7%
Other <sup>b</sup>	249	0.2%	125	0.2%	304	0.6%
<b>Total (Unduplicated)</b>	<b>135,330</b>	<b>100.0%</b>	<b>59,955</b>	<b>100.0%</b>	<b>49,576</b>	<b>100.0%</b>

<sup>a</sup> Table does not show the "Other Eligible Professionals" specialties that are not subject to the payment adjustment.

<sup>b</sup> "Other" includes eligible professionals who belong to a practice that participated under the GPRO. For these practices, there are no exemptions based on specialty, so these are the eligible professionals within those practices whose specialty is not MD/DO, Nurse Practitioner, Physician Assistant, or Podiatrist.

*Notes for Table A49: Eligible professional-level results in this table include EPs who were part of a practice that participated under the GPRO. The April 2013, April 2012, and September 2011 NPPES files were used to determine specialty, to be consistent with file used for payment adjustment.*

**Table A50. Incentive Eligibility and Incentives Earned by Reporting Mechanism for the eRx Incentive Program (2013)**

GPRO	Number of TINs Participating	Number of TINs Qualifying For Incentive	Percent of Participating TINs who Qualify for Incentive	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount
Claims	77,238	54,331	70.3%	\$8	\$1,118	\$2,757	\$453,472	\$149,770,325
Registry	946	854	90.3%	\$1	\$1,737	\$5,309	\$151,005	\$4,533,725
EHR	373	327	87.7%	\$1	\$2,377	\$6,725	\$98,915	\$2,199,223
Small GPRO	70	60	85.7%	\$270	\$4,760	\$8,933	\$77,672	\$536,002
Medium GPRO	27	26	96.3%	\$2,027	\$27,796	\$30,584	\$100,905	\$795,175
Large GPRO	111	106	95.5%	\$9,464	\$143,844	\$174,942	\$716,096	\$18,543,892
<b>Total Unduplicated</b>	<b>77,708</b>	<b>54,854</b>	<b>70.6%</b>	<b>\$5</b>	<b>\$1,124</b>	<b>\$3,131</b>	<b>\$716,096</b>	<b>\$171,732,673</b>

*Notes for Table A50: the unduplicated total will not match the sum of the incentives for each mechanism since some EPs were incentive eligible under more than one reporting mechanism.*

**Table A51. History of Available Reporting Mechanisms for each PQRS Measure, by Program Year (2007–2013)**

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
1	Diabetes Mellitus: Hemoglobin A1c Poor Control	C	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E, G, A
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control	C	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E
3	Diabetes Mellitus: High Blood Pressure Control	C	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E
4	Screening for Future Fall Risk	C	C, R	RETIRED	N/A	N/A	N/A	N/A
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	C	C, R	C, R	R, E	R, E, G1, G2	R, E, G, A	R, E
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	C	C, R	C, R	C, R	C, R, E, G1, G2	C, R, E, G, A	C, R, E
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	C	C, R	RETIRED	R, E	R, E, G1, G2	R, E	R, E
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	C	C, R	C, R	R	R, G1, G2	R, E, G, A	R, E, G, A
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance imaging (MRI) Reports	C	C, R	C, R	C, R	C, R, G2	C, R	RETIRED
11	Stroke and Stroke Rehabilitation: Carotid Imaging Reports	C	C, R	C, R	RETIRED	N/A	N/A	N/A

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
13	Age-Related Macular Degeneration: Age-Related Eye Disease Study (AREDS) Prescribed/Recommended	C	RETIRED	N/A	N/A	N/A	N/A	N/A
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
15	Cataracts: Assessment of Visual Functional Status	C	RETIRED	N/A	N/A	N/A	N/A	N/A
16	Cataracts: Documentation of Pre-Surgical Axial Length, Corneal Power Measurement and Method of Intraocular Lens Power Calculation	C	RETIRED	N/A	N/A	N/A	N/A	N/A
17	Cataracts: Pre-Surgical Dilated Fundus Evaluation	C	RETIRED	N/A	N/A	N/A	N/A	N/A
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic - Ordering Physician	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	C	C, R	C, R	C, R	C, R, G2	C, R	C, R



Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
25	Melanoma: Patient Medical History	C	RETIRED	N/A	N/A	N/A	N/A	N/A
26	Melanoma: Complete Physical Skin Examination	C	RETIRED	N/A	N/A	N/A	N/A	N/A
27	Melanoma: Counseling on Self-Examination	C	RETIRED	N/A	N/A	N/A	N/A	N/A
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
29	Beta-Blocker at Time of Arrival for Acute Myocardial Infarction (AMI)	C	RETIRED	N/A	N/A	N/A	N/A	N/A
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	C	C, R	R	R	R, G2	R	R
34	Stroke and Stroke Rehabilitation: Tissue Plasminogen Activator (t-PA) Considered	C	C, R	C, R	RETIRED	N/A	N/A	N/A
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	C	C, R	C, R	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
37	Dialysis Dose in End Stage Renal Disease (ESRD) Patients	C	RETIRED	N/A	N/A	N/A	N/A	N/A
38	Hematocrit Level in End Stage Renal Disease (ESRD) Patients	C	RETIRED	N/A	N/A	N/A	N/A	N/A
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	C	C, R	C, R	C, R	C, R, E, G2	C, R, E	C, R, E
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
42	Osteoporosis: Counseling for Vitamin D, Calcium Intake, and Exercise	C	RETIRED	N/A	N/A	N/A	N/A	N/A
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
46	Medication Reconciliation	C	C, R	R	C, R	C, R, G2	C, R, G, A	C, R, G, A
47	Advance Care Plan	C	C, R	C, R	C, R	C, R, E, G2	C, R, E	C, R, E
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	C	C, R	C, R	C, R	C, R, E, G2	C, R, E	C, R, E

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	C	C, R	C, R	C, R	C, R, G2	C, R, G, A	C, R
53	Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
57	Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	C	C, R	C, R	C, R	C, R, G2	C, R	RETIRED
58	Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	C	C, R	C, R	C, R	C, R, G2	C, R	RETIRED
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
60	Gastroesophageal Reflux Disease (GERD): Assessment for Alarm Symptoms	C	RETIRED	N/A	N/A	N/A	N/A	N/A

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
61	Gastroesophageal Reflux Disease (GERD): Upper Endoscopy for Patients with Alarm Symptoms	C	RETIRED	N/A	N/A	N/A	N/A	N/A
62	Gastroesophageal Reflux Disease (GERD): Biopsy for Barrett's Esophagus	C	RETIRED	N/A	N/A	N/A	N/A	N/A
63	Gastroesophageal Reflux Disease (GERD): Barium Swallow- Inappropriate Use	C	RETIRED	N/A	N/A	N/A	N/A	N/A
64	Asthma: Assessment of Asthma Control - Ambulatory Care Setting	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
66	Appropriate Testing for Children with Pharyngitis	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	C	C, R	C, R	C, R	C, R, G2	C, R	C, R
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	C	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
73	Plan for Chemotherapy Documented Before Chemotherapy Administered	C	C, R	RETIRED	N/A	N/A	N/A	N/A
74	Radiation Therapy Recommended for Invasive Breast Cancer Patients who have Undergone Breast Conserving Surgery	C	C, R	RETIRED	N/A	N/A	N/A	N/A
75	Prevention of Ventilator-Associated Pneumonia – Head Elevation	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
77	Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
78	Vascular Access for Patients Undergoing Hemodialysis	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
79	Influenza Vaccination in Patients with End Stage Renal Disease (ESRD)	N/A	C, R	C, R	C, R	C, R, G2	RETIRED	N/A
80	Plan of Care for ESRD Patients with Anemia	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	N/A	C, R	R	R	R, G2	R	R
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	N/A	C, R	R	R	R, G2	R	R
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	N/A	C, R	C, R	R	R, G2	R	R
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
86	Hepatitis C: Antiviral Treatment Prescribed	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
88	Hepatitis A and B Vaccination in Patients with HCV	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
91	Acute Otitis Externa (AOE): Topical Therapy	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
92	Acute Otitis Externa (AOE): Pain Assessment	N/A	C, R	C, R	C, R	C, R, G2	C, R	RETIRED
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
94	Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	N/A	C, R	C, R	C, R	C, R, G2	RETIRED	N/A
95	Otitis Media with Effusion (OME): Hearing Testing	N/A	C, R	C, R	RETIRED	N/A	N/A	N/A
96	Otitis Media with Effusion (OME): Antihistamines or Decongestants – Avoidance of Inappropriate Use	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
97	Otitis Media with Effusion (OME): Systemic Antimicrobials – Avoidance of Inappropriate Use	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
98	Otitis Media with Effusion (OME): Systemic Corticosteroids – Avoidance of Inappropriate Use	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
101	Appropriate Initial Evaluation of Patients with Prostate Cancer	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	N/A	C, R	C, R	C, R	C, R, G2	C, R, E	C, R, E
103	Review of Treatment Options in Patients with Clinically Localized Prostate Cancer	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
105	Three-dimensional Radiotherapy for Patients with Prostate Cancer	N/A	C, R	C, R	C, R	C, R, G2	C, R	RETIRED
106	Adult Major Depressive Disorder (MDD): Comprehensive Diagnostic Evaluation: Diagnosis and Severity	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
109	Osteoarthritis (OA): Function and Pain Assessment	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
110	Preventive Care and Screening: Influenza Immunization	N/A	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E, G, A

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	N/A	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E, G, A
112	Preventive Care and Screening: Breast Cancer Screening	N/A	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E, G, A
113	Preventive Care and Screening: Colorectal Cancer Screening	N/A	C, R	C, R	C, R, E	C, R, E, G1, G2	C, R, E, G, A	C, R, E, G, A
114	Inquiry Regarding Tobacco Use	N/A	C, R	C, R	C, R	RETIRED	N/A	N/A
115	Advising Smokers to Quit	N/A	C, R	C, R	C, R	RETIRED	N/A	N/A
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
117	Diabetes Mellitus: Dilated Eye Exam	N/A	C, R	C, R	C, R	C, R, G1, G2	C, R, E, G, A	C, R, E
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	N/A	C, R	C, R	R	R, G1, G2	R, G, A	R, G, A
119	Diabetes Mellitus: Medical Attention for Nephropathy	N/A	C, R	C, R	C, R	C, R, G1, G2	C, R, E	C, R, E
120	ACE Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy in Patients with CKD	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
122	Adult Kidney Disease: Blood Pressure Management	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
124	HIT- Adoption/Use of Health Information Technology (Electronic Health Records)	N/A	C, R	C, R	C, R, E	C, R, E, G2	C, R	RETIRED



Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
125	HIT- Adoption/Use of e-Prescribing	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	N/A	C, R	C, R	C, R	C, R, E, G2	C, R, E, G, A	C, R, E, G, A
129	Universal Influenza Vaccine Screening and Counseling	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
130	Documentation of Current Medications in the Medical Record	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
131	Pain Assessment and Follow-Up	N/A	C, R	C, R	C, R	C, R, G2	C, R	C, R
132	Patient Co-Development of Treatment Plan/Plan of Care	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
133	Screening for Cognitive Impairment	N/A	C, R	RETIRED	N/A	N/A	N/A	N/A
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	N/A	C, R	C, R	C, R	C, R, G2	C, R, A	C, R, G, A
135	Chronic Kidney Disease (CKD): Influenza Immunization	N/A	N/A	C, R	C, R	C, R, G2	RETIRED	N/A
136	Melanoma: Follow-Up Aspects of Care	N/A	N/A	C, R	R	RETIRED	N/A	N/A
137	Melanoma: Continuity of Care - Recall System	N/A	N/A	C, R	R	R, G2	R	R
138	Melanoma: Coordination of Care	N/A	N/A	C, R	R	R, G2	R	R
139	Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	N/A	N/A	C, R	C, R	RETIRED	N/A	N/A
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
143	Oncology: Medical and Radiation - Pain Intensity Quantified	N/A	N/A	C, R	R	R, G2	R	R
144	Oncology: Medical and Radiation - Plan of Care for Pain	N/A	N/A	C, R	R	R, G2	R	R
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
148	Back Pain: Initial Visit	N/A	N/A	C, R	C, R	G2	C, R	C, R
149	Back Pain: Physical Exam	N/A	N/A	C, R	C, R	G2	C, R	C, R
150	Back Pain: Advice for Normal Activities	N/A	N/A	C, R	C, R	G2	C, R	C, R
151	Back Pain: Advice Against Bed Rest	N/A	N/A	C, R	C, R	G2	C, R	C, R
152	Coronary Artery Disease (CAD): Lipid profile in Patients with CAD	N/A	N/A	C, R	RETIRED	N/A	N/A	N/A
153	Chronic Kidney Disease (CKD): Referral for Antiriovenous (AV) Fistula	N/A	N/A	C, R	C, R	C, R, G2	RETIRED	N/A
154	Falls: Risk Assessment	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
155	Falls: Plan of Care	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
156	Oncology: Radiation Dose Limits to Normal Tissues	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
158	Endarterectomy: Use of Patch During Conventional Endarterectomy	N/A	N/A	C, R	C, R	C, R, G2	C, R	RETIRED
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	N/A	N/A	R	R	R, G2	R	R
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	N/A	N/A	R	R	R, G2	R	R
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	N/A	N/A	R	R	R, G2	R	R
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	N/A	N/A	R	R	R, G2	R	R
163	Diabetes Mellitus: Foot Exam	N/A	N/A	C, R	C, R	C, R, G1, G2	C, R, E, G, A	C, R, E
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	N/A	N/A	R	R	R, G2	R	R
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	N/A	N/A	R	R	R, G2	R	R
166	Coronary Artery Bypass Graft (CABG): Stroke	N/A	N/A	R	R	R, G2	R	R
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	N/A	N/A	R	R	R, G2	R	R
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	N/A	N/A	R	R	R, G2	R	R
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	N/A	N/A	R	R	R, G2	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	N/A	N/A	R	R	R, G2	R	R
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	N/A	N/A	R	R	R, G2	R	R
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	N/A	N/A	C, R	C, R	C, R, E, G2	C, R, E	C, R, E
174	Pediatric End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis	N/A	N/A	R	R	RETIRED	N/A	N/A
175	Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	N/A	N/A	C, R	C, R	C, R, G2	RETIRED	N/A
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
178	Rheumatoid Arthritis (RA): Functional Status Assessment	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
181	Elder Maltreatment Screen and Follow-Up Plan	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
182	Functional Outcome Assessment	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	N/A	N/A	C, R	C, R	C, R, G2	C, R	C, R
186	Wound Care: use of Compression System in Patients with Venous Ulcers	N/A	N/A	C, R	C, R	C, R, G2	C, R	RETIRED
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	N/A	N/A	N/A	R	R, G2	R	R
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	N/A	N/A	C, R	C, R, G2	C, R	C, R
189	Referral for Otologic Evaluation for Patients with History of Active Drainage From Ear Within the Previous 90 Days	N/A	N/A	N/A	C, R	C, R, G2	C, R	RETIRED
190	Referral for Otologic Evaluation for Patients with a history of Sudden or Rapidly Progressing Hearing Loss	N/A	N/A	N/A	C, R	C, R, G2	C, R	RETIRED
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	N/A	N/A	N/A	R	R, G2	R	R
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	N/A	N/A	N/A	R	R, G2	R	R
193	Perioperative Temperature Management	N/A	N/A	N/A	C, R	C, R, G2	C, R	C, R
194	Oncology: Cancer Stage Documented	N/A	N/A	N/A	C, R	C, R, G2	C, R	C, R
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	N/A	N/A	N/A	C, R	C, R, G2	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	N/A	N/A	N/A	R	R, G2	R	RETIRED
197	Coronary Artery Disease (CAD): Lipid Control	N/A	N/A	N/A	R	R, G1, G2	R, E, G, A	R, E, G, A
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	N/A	N/A	N/A	R	R, G1, G2	R, G, A	R
199	Heart Failure: Patient Education	N/A	N/A	N/A	R	R, G1, G2	G, A	RETIRED
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	N/A	N/A	N/A	R	R, G1, G2	E	E
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	N/A	N/A	N/A	C, R	C, R, G2	C, R, E	C, R, E
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile	N/A	N/A	N/A	C, R	C, R, G2	RETIRED	N/A
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	C, R	C, R, G2	RETIRED	N/A
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	N/A	N/A	C, R	C, R, G2	C, R, E, G, A	C, R, E, G, A
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	N/A	N/A	N/A	R	R, G2	R	R
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	N/A	N/A	N/A	R	R, G2	R	RETIRED
207	HIV/AIDS: Screening for Injection Drug Use	N/A	N/A	N/A	R	R, G2	R	RETIRED
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	N/A	N/A	N/A	R	R, G2	R	R
209	Functional Communication Measure - Spoken Language Comprehension	N/A	N/A	N/A	R	R, G2	R	R
210	Functional Communication Measure - Attention	N/A	N/A	N/A	R	R, G2	R	R
211	Functional Communication Measure - Memory	N/A	N/A	N/A	R	R, G2	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
212	Functional Communication Measure - Motor Speech	N/A	N/A	N/A	R	R, G2	R	R
213	Functional Communication Measure - Reading	N/A	N/A	N/A	R	R, G2	R	R
214	Functional Communication Measure - Spoken Language Expression	N/A	N/A	N/A	R	R, G2	R	R
215	Functional Communication Measure - Writing	N/A	N/A	N/A	R	R, G2	R	R
216	Functional Communication Measure - Swallowing	N/A	N/A	N/A	R	R, G2	R	R
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	N/A	N/A	N/A	N/A	R, G2	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	N/A	N/A	N/A	N/A	R, G2	R	R
224	Melanoma: Overutilization of Imaging Studies in Melanoma	N/A	N/A	N/A	N/A	R, G2	R	R
225	Radiology: Reminder System for Mammograms	N/A	N/A	N/A	N/A	C, R, G2	C, R	C, R
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	N/A	N/A	N/A	C, R, E, G2	C, R, E, G, A	C, R, E, G, A
227	Heart Failure: Weight Management	N/A	N/A	N/A	N/A	G1	RETIRED	N/A
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	N/A	N/A	N/A	N/A	R, G1, G2	R, G, A	R
229	Diabetes mellitus: Hemoglobin A1c Testing	N/A	N/A	N/A	N/A	G1	RETIRED	N/A
230	Diabetes Mellitus: Lipid Profile	N/A	N/A	N/A	N/A	G1	RETIRED	N/A
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	N/A	N/A	N/A	C, R, G2	C, R	C, R
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	N/A	N/A	N/A	C, R, G2	C, R	C, R
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	N/A	N/A	N/A	N/A	R, G2	R	R
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	N/A	N/A	N/A	N/A	R, G2	R	R
235	Hypertension (HTN): Plan of Care	N/A	N/A	N/A	N/A	C, R, G1, G2	C, R	RETIRED
236	Hypertension (HTN): Controlling High Blood Pressure	N/A	N/A	N/A	N/A	G1	E, G, A	C, R, E, G, A



Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
237	Hypertension (HTN): Blood Pressure Measurement	N/A	N/A	N/A	N/A	E, G1	E	E
238	Drugs to be Avoided in the Elderly	N/A	N/A	N/A	N/A	E	E	E
239	Weight Assessment and Counseling for Children and Adolescents	N/A	N/A	N/A	N/A	E	E	E
240	Childhood Immunization Status	N/A	N/A	N/A	N/A	E	E	E
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	N/A	N/A	C, R, E, G, A	C, R, E, G, A
242	Coronary Artery Disease (CAD): Symptom Management	N/A	N/A	N/A	N/A	N/A	R	R
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	N/A	N/A	N/A	N/A	N/A	R	R
244	Hypertension: Blood Pressure Management	N/A	N/A	N/A	N/A	N/A	R	R
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	N/A	N/A	N/A	N/A	N/A	C, R	C, R
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	N/A	N/A	N/A	N/A	N/A	C, R	C, R
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	N/A	N/A	N/A	C, R	C, R
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	N/A	N/A	N/A	C, R	C, R
249	Barrett's Esophagus	N/A	N/A	N/A	N/A	N/A	C, R	C, R
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	N/A	N/A	N/A	C, R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	N/A	N/A	N/A	C, R	C, R
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	N/A	N/A	N/A	C, R	C, R
253	Pregnancy Test for Female Abdominal Pain Patients	N/A	N/A	N/A	N/A	N/A	C, R	RETIRED
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	N/A	N/A	N/A	C, R	C, R
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	N/A	N/A	N/A	C, R	C, R
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	N/A	N/A	N/A	N/A	N/A	R	R
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	N/A	N/A	N/A	N/A	N/A	R	R
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	N/A	N/A	N/A	N/A	N/A	R	R
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	N/A	N/A	N/A	N/A	N/A	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	N/A	N/A	N/A	N/A	N/A	R	R
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	N/A	N/A	N/A	C, R	C, R
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	N/A	N/A	N/A	N/A	N/A	C, R	C, R
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	N/A	N/A	N/A	C, R	C, R
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	N/A	N/A	N/A	N/A	N/A	R	R
265	Biopsy Follow-Up	N/A	N/A	N/A	N/A	N/A	R	R
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	N/A	N/A	N/A	C, R	C, R
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	N/A	N/A	N/A	C, R	C, R
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	N/A	N/A	N/A	C, R	C, R
269	Inflammatory Bowel Disease (IBD): Type, Anatomical Location and Activity All Documented	N/A	N/A	N/A	N/A	N/A	R	R
270	Inflammatory Bowel Disease (IBD): Preventive Care: Colocosteroid Sparing Therapy	N/A	N/A	N/A	N/A	N/A	R	R
271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment	N/A	N/A	N/A	N/A	N/A	R	R
272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization	N/A	N/A	N/A	N/A	N/A	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization	N/A	N/A	N/A	N/A	N/A	R	R
274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	N/A	N/A	N/A	N/A	N/A	R	R
275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor)	N/A	N/A	N/A	N/A	N/A	R	R
276	Sleep Apnea: Assessment of Sleep Symptoms	N/A	N/A	N/A	N/A	N/A	R	R
277	Sleep Apnea: Severity Assessment at Initial Diagnosis	N/A	N/A	N/A	N/A	N/A	R	R
278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed	N/A	N/A	N/A	N/A	N/A	R	R
279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy	N/A	N/A	N/A	N/A	N/A	R	R
280	Dementia: Staging of Dementia	N/A	N/A	N/A	N/A	N/A	R	C, R
281	Dementia: Cognitive Assessment	N/A	N/A	N/A	N/A	N/A	R	C, R
282	Dementia: Functional Status Assessment	N/A	N/A	N/A	N/A	N/A	R	C, R
283	Dementia: Neuropsychiatric Symptom Assessment	N/A	N/A	N/A	N/A	N/A	R	C, R
284	Dementia: Management of Neuropsychiatric Symptoms	N/A	N/A	N/A	N/A	N/A	R	C, R
285	Dementia: Screening for Depressive Symptoms	N/A	N/A	N/A	N/A	N/A	R	C, R
286	Dementia: Counseling Regarding Safety Concerns	N/A	N/A	N/A	N/A	N/A	R	C, R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
287	Dementia: Counseling Regarding Risks of Driving	N/A	N/A	N/A	N/A	N/A	R	C, R
288	Dementia: Caregiver Education and Support	N/A	N/A	N/A	N/A	N/A	R	C, R
289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review	N/A	N/A	N/A	N/A	N/A	R	R
290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment	N/A	N/A	N/A	N/A	N/A	R	R
291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment	N/A	N/A	N/A	N/A	N/A	R	R
292	Parkinson's Disease: Querying about Sleep Disturbances	N/A	N/A	N/A	N/A	N/A	R	R
293	Parkinson's Disease: Rehabilitative Therapy Options	N/A	N/A	N/A	N/A	N/A	R	R
294	Parkinson's Disease: Parkinson's Disease medical and Surgical Treatment Options Reviewed	N/A	N/A	N/A	N/A	N/A	R	R
295	Hypertension: Appropriate use of Aspirin or Other Antithrombotic Therapy	N/A	N/A	N/A	N/A	N/A	R	R
296	Hypertension: Complete Lipid Profile	N/A	N/A	N/A	N/A	N/A	R	R
297	Hypertension: Urine Protein Test	N/A	N/A	N/A	N/A	N/A	R	R
298	Hypertension: Annual Serum Creatinine Test	N/A	N/A	N/A	N/A	N/A	R	R
299	Hypertension: Diabetes Mellitus Screening Test	N/A	N/A	N/A	N/A	N/A	R	R
300	Hypertension: Blood Pressure Control	N/A	N/A	N/A	N/A	N/A	R	R
301	Hypertension: Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	N/A	N/A	R	R
302	Hypertension: Dietary and Physical Activity Modifications Appropriately Prescribed	N/A	N/A	N/A	N/A	N/A	R	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	N/A	N/A	N/A	N/A	N/A	R	R
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	N/A	N/A	N/A	N/A	N/A	R	R
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	N/A	N/A	N/A	N/A	N/A	E	E
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	N/A	N/A	N/A	N/A	N/A	E	E
307	Prenatal Care: Anti-D Immune Globulin	N/A	N/A	N/A	N/A	N/A	E	E
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	N/A	N/A	N/A	N/A	N/A	E	E
309	Cervical Cancer Screening	N/A	N/A	N/A	N/A	N/A	E	E
310	Chlamydia Screening for Women	N/A	N/A	N/A	N/A	N/A	E	E
311	Use of Appropriate Medications for Asthma	N/A	N/A	N/A	N/A	N/A	E	E
312	Low Back Pain: Use of Imaging Studies	N/A	N/A	N/A	N/A	N/A	E	E
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	N/A	N/A	N/A	N/A	N/A	E, G, A	E
314	Diabetes Mellitus: Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	N/A	N/A	N/A	N/A	N/A	G, A	RETIRED
315	Diabetes Mellitus: Tobacco Non Use	N/A	N/A	N/A	N/A	N/A	G, A	RETIRED

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
316	Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL.	N/A	N/A	N/A	N/A	N/A	E	E
317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	N/A	N/A	N/A	N/A	N/A	C, R, E, G, A	C, R, E, G, A
318	Falls: Screening for Future Fall Risk	N/A	N/A	N/A	N/A	N/A	G, A	G, A
319	Diabetes Composite: Optimal Diabetes Care	N/A	N/A	N/A	N/A	N/A	N/A	G, A
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	N/A	N/A	N/A	N/A	N/A	N/A	C, R
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	N/A	N/A	N/A	N/A	N/A	N/A	C, R
322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	N/A	N/A	N/A	N/A	N/A	N/A	R
323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	N/A	N/A	N/A	N/A	N/A	N/A	R
324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients	N/A	N/A	N/A	N/A	N/A	N/A	R
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	N/A	N/A	N/A	N/A	N/A	N/A	R

Measure Number	Measure Description	Available Reporting Mechanisms in 2007	Available Reporting Mechanisms in 2008	Available Reporting Mechanisms in 2009	Available Reporting Mechanisms in 2010	Available Reporting Mechanisms in 2011	Available Reporting Mechanisms in 2012	Available Reporting Mechanisms in 2013
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	N/A	N/A	N/A	N/A	N/A	N/A	C, R
327	Pediatric Kidney Disease: Adequacy of Volume Management	N/A	N/A	N/A	N/A	N/A	N/A	C, R
328	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL	N/A	N/A	N/A	N/A	N/A	N/A	C, R

*Notes for Table A51: (1) C=Claims Reporting Mechanism, R=Registry Reporting Mechanism, E=EHR Reporting Mechanism, G=GPRO, G1=GPRO I (2011 only), G2=GPRO II (2011 only), A=ACO. (2) For Program Year 2013, practices participating under the GPRO who elected registry reporting could report on any of the individual measures available to registry reporters.*



## ABBREVIATIONS

**Table A52. Abbreviations**

Abbreviation	Meaning
ACO	Accountable Care Organization
CMS	Centers for Medicare & Medicaid Services
CPC	Comprehensive Primary Care
CSP	Communication Support Page
EHR	Electronic Health Record
eRx	Electronic Prescribing Program
EP	Eligible Professional
FFS	Fee for Service
GPRO	Group Practice Reporting Option
HCPCS	Healthcare Common Procedure Coding System
HCV	Hepatitis C Virus
HIC	Health Insurance Claim Number
HIV/AIDS	Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome
MAV	Measure Applicability Validation
MD/DO	Doctor of Medicine or Doctor of Osteopathy
MOCP	Maintenance of Certification Program Incentive
MPFS	Medicare Physician Fee Schedule
NPPES	National Plan and Provider Enumeration System
NPI	National Provider Identifier
PQRS	Physician Quality Reporting System
QDC	Quality Data Code
QRUR	Quality Resource Use Reports
RRB	Railroad Retirement Board
TIN	Taxpayer Identification Number